RNA-targeted compositions and methods for treating myotonic dystrophy type 1

JP2023551874A5Inactive Publication Date: 2024-12-09LOCANABIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023533279
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-12
Filing Date
2021-12-01
Publication Date
2024-12-09
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for myotonic dystrophy type 1 (DM1) do not effectively target the underlying etiology of the disease, as they address symptoms but not the toxic RNA repeats causing the disorder, and existing RNA-targeting systems suffer from toxicity, off-target effects, and immune responses.

Method used

Development of non-Cas9 RNA-binding systems, such as those using PUF or PUMBY proteins and ZC3H12A zinc finger endonucleases, to specifically target and degrade or block toxic CUG repeat RNAs, reducing their expression and correcting alternative splicing abnormalities.

Benefits of technology

These systems achieve a dose-dependent reduction in toxic RNA levels, ameliorating DM1 symptoms by preserving MBNL function and restoring normal splicing and muscle function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Disclosed are RNA-targeted gene therapy compositions and methods for disrupting or blocking toxic target CUG repeat RNAs and for treating DM1. The present disclosure provides compositions and methods for treating myotonic dystrophy type 1 (DM1). The compositions and methods disclosed herein disrupt or block toxic target CUG repeat RNAs. exp (CUG repeat expansion) resulting in a dose-dependent reduction of RNA, a reduction in DMPK and subsequent correction of alternative splicing and myotonia.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Field of Disclosure The present disclosure is directed to molecular biology, gene therapy, and compositions and methods for altering the expression and activity of RNA molecules.

[0002] Related Applications This application claims the benefit of and priority to U.S. Patent Application No. 63 / 119,977, filed December 1, 2020, U.S. Patent Application No. 63 / 130,092, filed December 23, 2020, and U.S. Patent Application No. 63 / 278,746, filed November 12, 2021, the contents of each of which are incorporated herein by reference in their entirety.

[0003] Incorporation by reference to sequence listing The contents of the text file named "LOCN_007_001WO_SeqList_ST25", created on December 1, 2021, and sized at 1.81 MB, are hereby incorporated by reference in their entirety into this specification. [Background technology]

[0004] background There is a long-standing but unmet need in the art for an effective RNA targeting system that provides effective gene therapy. In particular, the present disclosure provides compositions and methods for specifically targeting and degrading toxic RNAs expressed from repeat tracts in microsatellite repeat expansion (MRE) disease, also known as myotonic dystrophy type 1 (DM1). DM1 is a multisystemic autosomal dominant disorder caused by a CTG MRE in the 3' untranslated region of the DMPK gene. As with all MRE diseases, available treatments address the symptoms of DM1 but do not target its underlying pathology. While eliminating the MRE in DNA through genome editing could eliminate the pathogenic MRE that causes DM1, the occurrence of a DNA break near the repeat may activate repair mechanisms whose activity is linked to the growth of the expansion, leading to further mutations in the repeat and / or failing to distinguish the pathogenic repeat from normal repeats that play a role in regulating transcription. Other potential DM1 treatments, such as antisense oligonucleotides, shRNAs, and small molecules, have been evaluated, but they suffer from issues related to frequent re-administration, poor penetration into affected tissues, lack of direct engagement with the repeat, toxicity, and off-target effects. In an effort to overcome these issues, a Cas9-based RNA targeting system (RCas9) was shown to be able to specifically target toxic CUG repeat RNAs in mice, resulting in long-term reversal of the disease phenotype associated with adult-onset myotonic dystrophy (DM1). However, details of other non-Cas9 RNA-binding systems remain to be defined, and these systems must be developed to provide effective, sustained, and scalable gene therapy for the treatment of DM1. Such non-Cas9 RNA-binding systems targeting CUG MREs are important for manufacturing scale because the system components are small enough to rely on unitary vectors. These non-RCas9 systems are also important for avoiding any adverse immune responses elicited by immunogenic Cas9 components.Thus, provided herein are new and improved RNA-targeted non-RCas9 gene therapy compositions and systems that can eliminate toxic CUG repeats, and methods of using same to treat DM1. Summary of the Invention [Means for solving the problem]

[0005] Abstract The present disclosure provides compositions and methods for treating myotonic dystrophy type 1 (DM1). The compositions and methods disclosed herein inhibit CUG by either degradation or blocking. exp (CUG repeat expansion) resulting in a dose-dependent reduction of RNA, a reduction in DMPK and subsequent correction of alternative splicing and myotonia.

[0006] Disclosed herein are compositions comprising a nucleic acid encoding an unguided RNA-binding protein, including a PUF or PUMBY protein, capable of binding to a toxic target CUG repeat RNA sequence, wherein the RNA-binding protein is unable to cleave the toxic target CUG repeat RNA sequence.

[0007] Disclosed herein is a composition comprising a nucleic acid sequence encoding an unguided RNA-binding fusion protein, wherein the fusion protein comprises: a) a PUF or PUMBY protein capable of binding to a toxic target CUG repeat RNA sequence; and b) an endonuclease capable of cleaving the toxic target RNA sequence, wherein the endonuclease is the nuclease domain of ZC3H12A zinc finger endonuclease.

[0008] The present disclosure provides compositions comprising nucleic acid sequences encoding RNA-binding polypeptides, including unguided or guided RNA-binding polypeptides, capable of binding to a toxic target CUG repeat RNA sequence.

[0009] In some embodiments, the RNA-binding polypeptide is a fusion protein.

[0010] In some embodiments, the fusion protein comprises an RNA-binding polypeptide fused to an endonuclease capable of cleaving a toxic CUG repeat RNA sequence.

[0011] In some embodiments, the unguided RNA-binding polypeptide is a PUF or PUMBY protein.

[0012] In some embodiments, the guided RNA-binding polypeptide. In some embodiments, the cas13d protein is catalytically inactive. In some embodiments, the cas13d protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 583, or 586-589.

[0013] In some embodiments, the endonuclease is the nuclease domain of a ZC3H12A zinc finger endonuclease.

[0014] In some embodiments, the PUF RNA-binding protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 444 to 451, 461, 570, or 638 to 649. In some embodiments, the PUF RNA-binding protein comprises the amino acid sequence set forth in SEQ ID NO: 444.

[0015] In some embodiments, the toxic target CUG RNA repeat sequence comprises any one of the nucleic acid sequences set forth in SEQ ID NOs: 453-456.

[0016] In some embodiments, the toxic target CUG RNA repeat sequence comprises the nucleic acid sequence set forth in SEQ ID NO:454.

[0017] In some embodiments, the CUG-targeting PUF protein is encoded by the nucleic acid sequence set forth in SEQ ID NO: 452. In some embodiments, the PUF or PUMBY protein is a human PUF or PUMBY protein.

[0018] In some embodiments, the PUF or PUMBY protein is linked to the ZC3H12A endonuclease by a linker sequence.

[0019] In some embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO:411.

[0020] The fusion protein comprises one or more signal sequences selected from the group consisting of a nuclear localization sequence (NLS) and a nuclear export sequence (NES).

[0021] In some embodiments, the ZC3H12A zinc finger nuclease comprises the amino acid sequence set forth in SEQ ID NO:358 or SEQ ID NO:359.

[0022] In some embodiments, the fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 559-567. In some embodiments, the fusion protein is encoded by a nucleic acid sequence comprising SEQ ID NO: 460, SEQ ID NO: 516, or SEQ ID NO: 517.

[0023] In some embodiments, the nucleic acid molecule encoding the fusion protein comprises a promoter. In some embodiments, the promoter is a tCAG promoter, an EFS / UBB promoter, a desmin promoter, a CK8e promoter, or an EFS promoter.

[0024] The present disclosure provides a vector comprising the composition of any of the embodiments of the present disclosure.

[0025] In some embodiments, the vector is selected from the group consisting of an adeno-associated virus (AAV), a retrovirus, a lentivirus, an adenovirus, a nanoparticle, a micelle, a liposome, a lipoplex, a polymersome, a polyplex, and a dendrimer. The present disclosure provides an AAV vector of any embodiment of the present disclosure, comprising a first AAV ITR sequence, a first promoter sequence, a polynucleotide sequence encoding at least one CUG repeat RNA-binding polypeptide, and a second AAV ITR sequence.

[0026] In some embodiments, the CUG repeat RNA-binding polypeptide comprises a PUF or PUMBY protein. In some embodiments, the polynucleotide sequence encoding the PUF or PUMBY sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 452.

[0027] In some embodiments, the CUG repeat RNA-binding polypeptide comprises a Cas13d protein. In some embodiments, the polynucleotide sequence encoding the Cas13d sequence comprises the nucleic acid sequence set forth in SEQ ID NOs: 601, 612, or 615-618.

[0028] In some embodiments, the first promoter sequence comprises a nucleic acid sequence set forth in SEQ ID NOs: 568, 569, 608, 609, 634-637.

[0029] In some embodiments, the first AAV ITR sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 599 or 600. In some embodiments, the second AAV ITR sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 599 or 600.

[0030] In some embodiments, the second promoter further comprises a second promoter sequence. In some embodiments, the second promoter controls the expression of guide RNA (gRNA), and the gRNA comprises (i) a DR sequence and (ii) a spacer sequence. In some embodiments, the second promoter comprises the nucleic acid sequence shown in SEQ ID NO: 519.

[0031] In some embodiments, the vector further comprises a polyA sequence. In some embodiments, the vector comprises at least one linker sequence. In some embodiments, the vector comprises at least one nuclear localization sequence.

[0032] In some embodiments, the vector is encoded by a nucleic acid set forth in any of SEQ ID NOs: 574-582, 584-585, and 590-597.

[0033] The present disclosure provides a pharmaceutical composition comprising: a) an AAV viral vector of any embodiment of the present disclosure; and b) at least one pharmaceutically acceptable excipient and / or additive.

[0034] The present disclosure provides an AAV virus vector, comprising: a) the AAV vector of any embodiment of the present disclosure; and b) an AAV capsid protein.In some embodiments, the AAV capsid protein is AAV1 capsid protein, AAV2 capsid protein, AAV4 capsid protein, AAV5 capsid protein, AAV6 capsid protein, AAV7 capsid protein, AAV8 capsid protein, AAV9 capsid protein, AAV10 capsid protein, AAV11 capsid protein, AAV12 capsid protein, AAV13 capsid protein, AAVPHP.B capsid protein, AAVrh74 capsid protein or AAVrh.10 capsid protein.In some embodiments, the AAV capsid protein is AAV9 capsid protein.

[0035] A cell comprising the vector of any one of the embodiments of the present disclosure.

[0036] The present disclosure provides a method for treating myotonic dystrophy type 1 (DM1) in a mammal, comprising administering a composition or AAV vector of any embodiment of the present disclosure to a toxic target CUG microsatellite repeat expansion (MRE) RNA sequence in a tissue of the mammal, thereby reducing the expression level of the toxic target RNA.

[0037] In some embodiments, the composition or AAV vector is administered to a subject intravenously, intrathecally, intracerebrally, intraventricularly, intranasally, intratracheally, intraaurally, intraocularly or periocularly, orally, rectally, transmucosally, by inhalation, transdermally, parenterally, subcutaneously, intradermally, intramuscularly, intracisternally, intraneurally, intrapleurally, topically, intralymphatically, intracisternally, or intraneurally.

[0038] In some embodiments, the composition or AAV vector is administered to the subject intravenously.

[0039] In some embodiments, a reduction in the expression level of a toxic target RNA ameliorates DM1 symptoms in a mammal. In some embodiments, the expression level of the toxic target RNA is reduced compared to the reduction in the expression level of an untreated toxic target CUG RNA. In some embodiments, the level of reduction is between 1-fold and 20-fold.

[0040] In some embodiments, the PUF RNA-binding protein comprises an amino acid sequence set forth in any one of SEQ ID NOs: 444-451, 461, 570, or 638-649.

[0041] In some embodiments, the PUF RNA-binding protein comprises the amino acid sequence set forth in SEQ ID NO:444.

[0042] In some embodiments, the toxic target CUG RNA repeat sequence comprises any one of SEQ ID NOs: 453-456.

[0043] In some embodiments, the toxic target CUG RNA repeat sequence comprises SEQ ID NO:454.

[0044] In some embodiments, the CUG-targeting PUF protein is encoded by the nucleic acid sequence set forth in SEQ ID NO:452.

[0045] In some embodiments, the PUF or PUMBY protein is a human PUF or PUMBY protein.

[0046] In some embodiments, the PUF or PUMBY protein is linked to ZC3H12A by a linker sequence.

[0047] In some embodiments, the linker comprises the amino acid sequence set forth in SEQ ID NO:411.

[0048] In some embodiments, the fusion protein comprises one or more signal sequences selected from the group consisting of a nuclear localization sequence (NLS) and a nuclear export sequence (NES).

[0049] In some embodiments, the ZC3H12A zinc finger nuclease comprises the amino acid sequence set forth in SEQ ID NO:358 or SEQ ID NO:359.

[0050] In some embodiments, the fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 559-567.

[0051] In some embodiments, the fusion protein is encoded by a nucleic acid sequence comprising SEQ ID NO:460, SEQ ID NO:516, or SEQ ID NO:517.

[0052] In some embodiments, the nucleic acid molecule encoding the fusion protein comprises a promoter.

[0053] In some embodiments, the promoter is a tCAG promoter.

[0054] The present disclosure provides a vector comprising any of the aforementioned compositions.

[0055] In some embodiments, the vector is selected from the group consisting of adeno-associated virus (AAV), retrovirus, lentivirus, adenovirus, nanoparticle, micelle, liposome, lipoplex, polymersome, polyplex and dendrimer.In some embodiments, the vector is an AAV vector.In some embodiments, the AAV vector is AAV9 or AAVrh74.

[0056] The present disclosure provides a cell comprising a vector of the present disclosure.

[0057] Disclosed herein is a method of treating myotonic dystrophy type 1 (DM1) in a mammal, comprising the step of administering a composition to a toxic target CUG microsatellite repeat expansion (MRE) RNA sequence in a tissue of the mammal, wherein the composition comprises a nucleic acid sequence encoding an unguided RNA-binding fusion protein comprising: a) a PUF RNA-binding protein capable of binding to the toxic target CUG RNA repeat sequence; and b) an endonuclease capable of cleaving the toxic target CUG RNA repeat sequence, thereby reducing the expression level of the toxic target RNA.

[0058] In some embodiments, the PUF RNA binding protein comprises any one of SEQ ID NOs: 444-451, 461, 570, or 638-649.

[0059] In some embodiments, the PUF RNA binding protein comprises SEQ ID NO:444.

[0060] In some embodiments, the toxic target CUG RNA repeat sequence comprises any one of SEQ ID NOs: 453-456.

[0061] In some embodiments, the toxic target CUG RNA repeat sequence comprises SEQ ID NO:453.

[0062] In some embodiments, the composition is administered to the mammalian tissue by intravenous administration.

[0063] In some embodiments, reducing the expression level of the toxic target RNA ameliorates symptoms of DM1 in a mammal.

[0064] In some embodiments, the expression level of the toxic target RNA is reduced compared to the reduction in the expression level of the untreated toxic target CUG RNA.

[0065] In some embodiments, the level of reduction is between 1-fold and 20-fold.

[0066] In some embodiments, the endonuclease is a domain of the ZC3H12A zinc finger endonuclease.

[0067] In some embodiments, the ZC3H12A zinc finger nuclease comprises the amino acid sequence set forth in SEQ ID NO:358 or SEQ ID NO:359.

[0068] In some embodiments, the nucleic acid sequence encoding the fusion protein comprises a promoter.

[0069] In some embodiments, the promoter is a tCAG promoter.

[0070] In some embodiments, the promoter is a muscle-specific promoter.

[0071] In some embodiments, the muscle-specific promoter is the desmin promoter (full length or truncated).

[0072] In some embodiments, the fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs: 559-567.

[0073] In some embodiments, the fusion protein is encoded by a nucleic acid sequence comprising SEQ ID NO:460, SEQ ID NO:516, or SEQ ID NO:517.

[0074] 1. A composition comprising a nucleic acid sequence encoding a non-naturally occurring or engineered clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) system, wherein the nucleic acid sequence comprises (a) at least one RNA-guided RNase Cas protein; and (b) at least one cognate CRISPR-Cas system guide RNA (gRNA) capable of forming a complex with one of the at least one Cas protein, wherein the gRNA comprises (i) a DR sequence and (ii) a spacer sequence, wherein the spacer sequence is capable of binding to a target CUG. 1. A composition that hybridizes to an MRE molecule, wherein the spacer sequence comprises a spacer sequence selected from the group consisting of agcagcagcagcagcagcagcagcag (SEQ ID NO: 457), gcagcagcagcagcagcagcagcagc (SEQ ID NO: 458), and cagcagcagcagcagcagcagcagca (SEQ ID NO: 459), or a portion thereof, wherein the CRISPR-Cas system is catalytically inactive, and wherein the CRISPR-Cas can bind to and cleave the target CUG MRE.

[0075] 1. A composition comprising a nucleic acid sequence encoding a non-naturally occurring or engineered clustered regularly interspaced short palindromic repeats (CRISPR) associated (Cas) system, wherein the nucleic acid sequence comprises (a) at least one RNA-guided RNase Cas protein; and (b) at least one cognate CRISPR-Cas system guide RNA (gRNA) capable of forming a complex with one of the at least one Cas protein, wherein the gRNA comprises (i) a DR sequence and (ii) a spacer sequence, wherein the spacer sequence hybridizes to a target CUG MRE molecule, the spacer sequence comprising a spacer sequence selected from the group consisting of agcagcagcagcagcagcagcagcag (SEQ ID NO: 457), gcagcagcagcagcagcagcagc (SEQ ID NO: 458), and cagcagcagcagcagcagcagcagca (SEQ ID NO: 459), or a portion thereof; and wherein the CRISPR-Cas system is capable of hybridizing to a target CUG MRE molecule. A composition capable of binding to and cleaving the MRE, wherein the CRISPR-Cas system is catalytically inactive, and wherein the CRISPR-Cas is capable of binding to but not cleaving the target CUG MRE.

[0076] In some embodiments, the Cas protein is Cas13a, Cas13b, Cas13c, or Cas13d. In some embodiments, the Cas protein is Cas13d.

[0077] In some embodiments, the RNA-guided RNase Cas protein or the unguided RNA-binding polypeptide is a first RNA-binding polypeptide fused with a second RNA-binding polypeptide. In one embodiment, the second RNA-binding polypeptide can bind to RNA in a manner that associates with RNA. In some embodiments, the second RNA-binding polypeptide can associate with RNA in a manner that cleaves RNA. In one embodiment, the second RNA-binding polypeptide is the nuclease domain of ZC3H12A zinc finger endonuclease.

[0078] In some embodiments, the nucleic acid encoding the Cas or dCas system comprises a promoter. In some embodiments, the promoter is an EFS promoter. In some embodiments, the promoter is a muscle-specific promoter. In some embodiments, the muscle-specific promoter is a desmin promoter (full-length or truncated).

[0079] Disclosed herein are vectors comprising any of the foregoing compositions.

[0080] In another embodiment, the vector is selected from the group consisting of an adeno-associated virus (AAV), a retrovirus, a lentivirus, an adenovirus, a nanoparticle, a micelle, a liposome, a lipoplex, a polymersome, a polyplex, and a dendrimer.

[0081] In another embodiment, the vector is an AAV vector.

[0082] In another embodiment, the AAV vector is AAV9 or AAVrh74.

[0083] Disclosed herein are cells containing the vectors.

[0084] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief explanation of the drawings]

[0085] [Figure 1]Figure 1 shows the results of a CUG960 qPCR assay demonstrating that exemplary embodiments of the CUG-targeting Cas13d and PUF compositions disclosed herein disrupt DM1 toxic CUG repeats. Reduction of toxic repeats in a Cas13d-based system (labeled Cas13d-L1) is shown using three different guides, CUG-g1, CUG-g2, and CUG-g3. Reduction of toxic repeats in a PUF-based system is shown using exemplary nucleic acid molecules encoding a PUF(CUG)-E17 fusion protein (labeled CUG-f1) and an E17-PUF(CUG) fusion protein (labeled CUG-f2). E17 is a domain of the ZC3H12A endonuclease. Results are normalized to a non-targeting control and are shown as the mean + / - sd of two biological replicates (n = 2).

[0086] [Figure 2] FIG. 2 shows the results of an RNA fluorescence in situ hybridization (FISH) assay with exemplary CUG-targeting Cas13d and PUF compositions disclosed herein compared to non-targeting controls.

[0087] [Figure 3] Figure 3 shows the results of a CUG960 qPCR assay demonstrating degradation of DM1 toxic CUG repeat RNA using the Cas13d and PUF compositions disclosed herein compared to the RCas9 system. Results are normalized to a non-targeting control and are shown as the mean + / - sd of two biological replicates.

[0088] [Figure 4]Figures 4A-C show exemplary vector configurations of the DM1 gene therapy compositions disclosed herein. Figure 4A illustrates the configuration of a DM1 gene therapy construct comprising a CUG-targeting PUF-E17 operably linked to a truncated CAG promoter (tCAG). Figure 4B illustrates the configuration of a DM1 gene therapy construct comprising a catalytically inactive Cas13d targeting CUG fused to E17 and a corresponding guide operably linked to an EFS promoter. Figure 4C illustrates the configuration of a DM1 gene therapy construct comprising a CUG-targeting Cas13d and a corresponding guide operably linked to an EFS promoter.

[0089] [Figure 5] FIG. 5 depicts the alignment of CUG-targeting PUFs with human PUM1, highlighting mismatches.

[0090] [Figure 6] Figures 6A-B show the results of the CUG960 assay. Figure 6A shows knockdown of DMPK-CUG960 reporter mRNA. Specifically, Cas13d-CUG (A01215) reduces CUG960 repeat mRNA expression in CosM6 cells. CUG960 repeat mRNA levels (relative to human DMPK exons 11-15) are normalized to the reference gene GAPDH and transfection control GFP (expressed from the same plasmid as CUG960). Data are presented as fold change in cells transfected with Cas13d-CUG compared to cells transfected with the Cas13d non-targeting (NT) negative control (n = 3 separate experiments). Figure 6B shows that endogenous DMPK mRNA is preserved. Specifically, Cas13d-CUG did not reduce normal DMPK mRNA levels in HEK293 cells, whereas the Cas13d-DMPK positive control targeting the repeat flanking region knocked down total DMPK mRNA by 58%.

[0091] [Figure 7]FIG. 7 depicts the two mechanisms of action of DM1 gene therapy: 1) repeat resolution, and 2) repeat blocking.

[0092] [Figure 8] Figure 8 shows three different embodiments of the DM1 AAV-based gene therapy compositions disclosed herein packaged in AAV9 vectors. Specifically, Figure 8 depicts 1) a therapeutic construct A01215 for degradation of repetitive CUGs based on a CRISPR / Cas13d system with a cognate CUG-targeting gRNA, 2) a therapeutic construct A01344 for degradation of repetitive CUGs based on a PUF (human PUM1-derived) protein fused with a human endonuclease domain (E17) engineered to target and cleave repetitive CUG RNA, and 3) a therapeutic construct A01686 based on a PUF (human PUM1-derived) protein engineered to target and bind to (but not cleave) repetitive CUG RNA.

[0093] [Figure 9] Figures 9A-B show the reduction of nuclear CUGexp foci in patient muscle cells. Figure 9A shows RNA-FISH to assess nuclear CUGexp RNA aggregates in DM1 patient muscle cells (2600 CUG repeats) treated with modified AAVrh74 (eAAV) encoding GFP (A01475-control), Cas13d-CUG (A01215), or PUF(CUG)-E17 (A01344). Figure 9B shows RNA FISH quantification of the number of nuclear CUGexp RNA aggregates normalized to eAAV-GFP (A01475-control), demonstrating a dose-dependent reduction of toxic CUG RNA aggregates with A01215 (Cas13d-CUG) and A01344 (PUF(CUG)-E17).

[0094] [Figure 10-1]Figures 10A-G show degradation of CUGexpRNA and correction of DM1-associated missplicing and myotonia in HSALR DM1 mice. Figure 10A depicts the mechanism of action for AAV-based A01215 (Cas13d-CUG) and A01344 (PUF(CUG)-E17)-mediated CUGexp degradation and subsequent correction of alternative splicing and myotonia. Figure 10B depicts the injection scheme showing injection of vehicle and treatment in the contralateral tibialis anterior (TA) muscle. Figure 10C shows reduction of nuclear CUGexpRNA aggregates in treated TA muscle using RNA-FISH with a CAG10 probe. Figure 10D shows dose-dependent reduction of HSA-CUGexpRNA with AAV9-based A01344 (PUF(CUG)-E17) using RT-ddPCR. Figures 10E-F show the correction of DM1-associated Atp2a1 exon 22 and ClCn1 exon 7a alternative splicing using semi-quantitative RT-PCR followed by capillary electrophoresis, respectively. Figure 10G shows the reduction in myotonia expressed as the % of needle insertions resulting in tetanic movements using needle electromyography (EMG). [Figure 10-2] Same as above. [Figure 10-3] Same as above.

[0095] [Figure 11-1]Figures 11A-G show the blockade of CUGexpRNA and the correction of DM1-associated mis-splicing and myotonia in HSALR DM1 mice. Figure 11A depicts the mechanism of action for AAV-based A01686(PUF(CUG))-mediated CUGexp blockade and the subsequent correction of alternative splicing and myotonia. Figure 11B depicts the injection scheme showing injection of vehicle and treatment in the contralateral tibialis anterior (TA) muscle. Figure 11C shows the reduction of nuclear CUGexpRNA aggregates in treated TA muscle using RNA-FISH with a CAG10 probe. Figure 11D shows the dose-dependent reduction of HSA-CUGexpRNA with AAV9-based A01686(PUF(CUG)) using RT-ddPCR. Figures 11E-F show the correction of DM1-associated Atp2a1 exon 22 and ClCn1 exon 7a alternative splicing using semi-quantitative RT-PCR followed by capillary electrophoresis, respectively. Figure 11G shows the reduction in myotonia expressed as the % of needle insertions resulting in tetanic movements using needle electromyography (EMG). [Figure 11-2] Same as above. [Figure 11-3] Same as above.

[0096] [Figure 12] Figures 12A-B depict exemplary vector configurations for the DM1-blocking (non-cleavage) gene therapy compositions disclosed herein. Figure 12A shows several PUF(CUG) embodiments, and Figure 12B shows several dCas13d(CUG) embodiments. DETAILED DESCRIPTION OF THE INVENTION

[0097] Detailed Description The present disclosure provides RNA-targeted gene therapy compositions and methods for treating myotonic dystrophy type 1 (DM1).

[0098] DM1 is a multisystemic autosomal dominant disorder caused by a CTG microsatellite repeat expansion (MRE) in the 3' untranslated region of the DMPK gene. RNA transcripts containing the CUG repeat expansion sequester the muscleblind-like (MBNL) protein, a regulator of the alternative splicing switch from fetal to adult isoforms. Adult DM1 patients experience debilitating myotonia and progressive weakness of skeletal muscles, while infants born with DM1 (congenital DM or CDM) are hypotonic and exhibit respiratory failure. The DMPK gene encodes a protein called myotonic dystrophy protein kinase, which is thought to be involved in muscle, heart, and brain cells. This protein may be involved in intracellular communication. This protein also appears to regulate the production and function of key structures within muscle cells by interacting with other proteins. For example, myotonic dystrophy protein kinase has been shown to inhibit a portion of a muscle protein called myosin phosphatase. Myosin phosphatase is an enzyme involved in muscle contraction and relaxation. One region of the DMPK gene contains a segment consisting of three DNA basic units (nucleotides) repeated multiple times. This sequence is written as CTG and is called a triplet or trinucleotide repeat. In most unaffected individuals, the number of CTG repeats in this gene ranges from 5 to 34. DM1 patients have CTG repeat expansions that increase the size of the CTG repeats in the DMPK gene. DM1 is classified as either adult-onset or congenital, and these are distinguished by the size of the expanded CTG tract. The number of repeats in such CTG repeat expansions can range from approximately 50 to approximately 1,000 CTG repeats in most cells, with certain cell types, such as muscle cells, typically having higher repeat numbers. Indeed, the size of the trinucleotide repeat expansion is associated with the severity of DM1 signs and symptoms. Classical features such as muscle weakness and wasting occur in adulthood and correlate with approximately 100 to 1,000 CTG repeats per cell. The more severe congenital form of DM1 tends to correlate with more than 1,000 CTG repeats per cell.Mild forms of DM1 typically range from approximately 50 to approximately 150 CTG repeats per cell. DM1 is classified as either adult-onset or congenital, distinguished by the size of the expanded CTG tract. Repetitive RNAs produced by the DMPK locus form intranuclear RNA aggregates, which sequester RNA-binding proteins such as MBNL1 (muscleblind-like splicing regulator 1) and divert them from their homeostatic RNA processing activities. Loss of MBNL1 function is associated with hundreds of alternative splicing defects and respiratory failure, which contribute to varying degrees of patient mortality. Targeting and eliminating (or blocking) CUG repeats is a therapeutic strategy for DM1.

[0099] The gene therapy compositions disclosed herein provide effective cleavage or blocking of toxic CUG repeats in methods for treating DM1. Building on previous studies using the RCas9 system, several RNA-binding systems are disclosed herein that do not rely on RCas9 system components. While the Cas9-based RNA targeting system (RCas9) can specifically target toxic CUG repeat RNAs and provide long-term correction of the disease phenotype associated with adult-onset myotonic dystrophy (DM1) in mice, the non-Cas9 RNA-binding systems disclosed herein provide efficient cleavage or blocking of toxic CUG repeat RNAs. Such non-Cas9 RNA-binding systems targeting CUG MREs are important for scaling the therapeutic systems for manufacturing. Notably, the non-Cas9 system components are small enough to rely on unitary (single) vectors. The non-RCas9 systems disclosed herein can achieve more effective knockdown or blockage of toxic CUG repeats than RCas9 systems, which is also important for avoiding any adverse immune responses elicited by the immunogenic and recalcitrant Cas9 components.

[0100] Disclosed herein is a composition for treating DM1, comprising a nucleic acid molecule encoding a non-Cas9 RNA-binding system that can bind to toxic CUG repeat RNA, and a vector comprising the same. Such a composition can target toxic CUG repeats for either knockdown / degradation or blocking, and can bind to toxic CUG repeats for either of these purposes, and both mechanisms (degradation and blocking) result in MBNL sequestration, alternative splicing, and correction of myotonia.In fact, in one embodiment, a gene therapy blocking composition comprising PUF (CUG) can target CUG repeats. exp By directly binding to RNA, they prevent MBNL sequestration, preserving near-normal free MBNL levels and function, thereby reversing DM1 disease phenotypes, such as splicing dysfunction and myotonia. In some embodiments, compositions suitable for blocking CAG repeat RNA bind to CUG repeat-containing RNA and prevent the translation of CUG repeat RNA. In some embodiments, this translation prevention results in reduced protein expression from CUG repeat-containing RNA sequences. These systems disclosed herein include RNA-guided RNase Cas or unguided PUF, PUMBY, or PPR protein configurations.

[0101] In some embodiments, the guided or unguided CUG repeat targeting system is a CUG repeat targeting system. 50 or more expanded CUG repeats (CUG exp In some embodiments, the CUG repeat is CUG 100 In some embodiments, the CUG repeat is CUG 500 In some embodiments, the CUG repeat is CUG 960 In some embodiments, the CUG 1000 The repeats may be 1000 CUG repeats or more. For clarity, CUG 50 or CUG 100 or CUG 960 or CUG1000 refers to 50 CUG repeats or 100 CUG repeats or 960 CUG repeats or 1000 CUG repeats, respectively, in a CUG repeat-containing gene. Any other number or range of CUG repeats is possible, including 50, 55, 60, 65, 70, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 90, 95, 100, 105, 110, 115, 120, 150, 180, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 960, 1000 CUG repeats, or any other number in between.

[0102] In any of the foregoing or subsequent RNA targeting compositions for treating DM1, any particular construct element (e.g., linker, promoter, signal sequence, etc.) described in the context of a particular RNA targeting composition can be substituted for another of the same element type (e.g., linker, promoter, signal sequence, etc.). In some embodiments, any particular construct element (e.g., tag sequence) can be deleted or removed. In other words, the exemplary combinations of elements in any particular gene therapy composition described herein are not intended to be limiting. An RNA-guided CUG repeat RNA-binding system.

[0103] In some embodiments, the non-Cas9 binding system comprises an RNA-guided RNA-binding polypeptide. In some embodiments, the nucleic acid sequence encodes the RNA-guided RNA-binding polypeptide, which is an RNase Cas protein (or an inactivated RNase Cas protein). In some embodiments, the nucleic acid sequence further comprises a gRNA sequence, which includes a spacer sequence that binds to a toxic target CUG repeat RNA and a direct repeat (DR) sequence that binds to the RNase Cas protein. In one embodiment, the Cas13d(CUG) system is catalytically active, in which the Cas13d nucleoprotein complex cleaves and destroys the toxic RNA CUG repeat. In another embodiment, the Cas13d(CUG) system is catalytically inactive, in which the Cas13d nucleoprotein complex binds to and blocks (does not cleave) the RNA CUG repeat. In yet another embodiment, the Cas13d(CUG) comprises a catalytically inactive Cas13d(CUG) fused to an endonuclease capable of cleaving the toxic RNA CUG repeat. In such embodiments, the endonuclease is an active RNase. Exemplary endonucleases with RNase activity can be found herein, including, for example, domains from ZC3H12A zinc finger (also referred to herein as E17) or PIN endonuclease. In some embodiments, the nucleic acid sequence encoding the CUG repeat targeting composition comprises a first promoter sequence that controls the expression of a Cas13d protein or a Cas13d fusion protein, and a second promoter sequence that controls the expression of at least one guide RNA sequence.

[0104] [Table 1]

[0105] In one embodiment, the RNase Cas protein is a Cas13 protein. In another embodiment, the Cas13 protein is a Cas13d protein. In another embodiment, the Cas13d protein is an inactivated RNase Cas13d protein (dCas13d). In another embodiment, the dCas13d protein is a fusion protein comprising 1) dCas13d and 2) a polypeptide encoding a protein or fragment thereof having nuclease activity. In another embodiment, the dCas13d protein is a fusion protein comprising 1) dCas13d and 2) ZC3H12A, a zinc finger endonuclease, or a truncated form thereof (also referred to herein as E17 or SEQ ID NO: 358). In some embodiments, the Cas construct comprises a signal sequence, e.g., an NLS and / or an NES. In some embodiments, dCas13d is linked to the E17 endonuclease via a linker sequence. In one embodiment, the linker sequence is VDTANGS (SEQ ID NO: 411). In some embodiments, the Cas13d or dCas13d fusion protein is operably linked to a promoter sequence. In some embodiments, the promoter sequence comprises an enhancer and / or an intron. In some embodiments, the promoter sequence is an EFS promoter sequence (Figures 4B and 4C).

[0106] In some embodiments, the disclosed CUG repeat-targeting cas13d or dCas13d proteins comprise, from N- to C-terminus, Cas13d (Seq212), a linker, and an SV-40 NLS. In some aspects, the disclosed CUG repeat-targeting dCas13d proteins are used in methods for blocking CUG repeat RNA sequence elongation. Active Cas13d (Seq212) with a truncated desmin promoter (A02207) [Table 54-1] [Table 54-2] An unguided CUG repeat RNA-binding system

[0107] In some embodiments, the non-Cas9 RNA-binding system does not include an RNA-guided RNA-binding polypeptide. Instead, the non-Cas9 RNA-binding system is comprised of an RNA-binding polypeptide that is not guided by RNA, such as a PUF or PUMBY protein, or an RNA-binding portion thereof. In one embodiment, the non-guided RNA-binding fusion protein disclosed herein comprises a) a PUF or PUMBY RNA-binding sequence capable of binding to a toxic target CUG repeat sequence comprising UGCUGCUG (SEQ ID NO: 453), and b) an endonuclease capable of cleaving the toxic target CUG repeat sequence.

[0108] In one embodiment, the target RNA sequence is selected from the group consisting of UGCUGCUGCUGCUG (SEQ ID NO: 454), UGCUGCUGCUGCUGC (SEQ ID NO: 455), and UGCUGCUGCUGCUGCU (SEQ ID NO: 456).

[0109] In one embodiment, the target RNA sequence is selected from the group consisting of CUGCUGCU (SEQ ID NO: 472), CUGCUGCUGCUGCU (SEQ ID NO: 473), CUGCUGCUGCUGCUG (SEQ ID NO: 474), and CUGCUGCUGCUGCUGC (SEQ ID NO: 475).

[0110] In one embodiment, the target RNA sequence is selected from the group consisting of GCUGCUGC (SEQ ID NO: 476), GCUGCUGCUGCUGC (SEQ ID NO: 477), GCUGCUGCUGCUGCU (SEQ ID NO: 478), and GCUGCUGCUGCUGCUG (SEQ ID NO: 479).

[0111] In one embodiment, the PUF or PUMBY RNA-binding fusion protein comprises a) a PUF or PUMBY CUG-targeting protein and b) ZC3H12A, a zinc finger endonuclease, or a truncated form thereof (also referred to herein as E17 or SEQ ID NO: 358). In some embodiments, the CUG-targeting PUF or PUMBY fusion protein is configured, from N-terminus to C-terminus, as follows:

[0112] PUF(CUG)-E17

[0113] E17-PUF(CUG)

[0114] PUMBY(CUG)-E17 or

[0115] E17-PUMBY(CUG).

[0116] In some embodiments, the PUF or PUMBY fusion construct comprises a linker between the PUF(CUG) or PUMBY(CUG) and E17. In one embodiment, the linker sequence is VDTANGS (SEQ ID NO: 411).

[0117] In some embodiments, the CUG-targeting PUF or PUMBY fusion protein, including the linker, is configured, from N-terminus to C-terminus, as follows:

[0118] PUF(CUG)-Linker-E17

[0119] E17-Linker-PUF(CUG)

[0120] PUMBY(CUG)-Linker-E17 or

[0121] E17-Linker-PUMBY(CUG).

[0122] An exemplary embodiment of an N to C-terminal orientation of PUF(CUG)-linker-E17 is the first oriented CUG frame (CUG-f1) in Figure 1 , oriented N to C-terminal as PUF(CUG)-E17. An exemplary embodiment of an N to C-terminal orientation of E17-linker-PUF(CUG) is the second oriented CUG frame (CUG-f2) in Figure 1 , oriented N to C-terminal as E17-linker-PUF(CUG).

[0123] In one embodiment, the CUG-targeted PUF or PUMBY fusion protein configuration, from N-terminus to C-terminus, is PUF(CUG)-VDTANGS-E17 or PUMBY(CUG)-VDTANGS-E17. In another embodiment, the CUG-targeted PUF or PUMBY fusion protein configuration, from N-terminus to C-terminus, is E17-VDTANGS-PUF(CUG) or E17-VDTANGS-PUMBY(CUG).

[0124] In some embodiments, the PUF or PUMBY construct comprises one or more tags or signal sequences and / or tags, such as FLAG, NLS, NES, or a combination thereof. In one embodiment, the FLAG tag sequence is DYKDDDDK (SEQ ID NO: 436). In one embodiment, the NLS signal sequence is a human NLS. In one embodiment, the NES is a human NES. In one embodiment, the NLS is an SV40 NLS. In another embodiment, the SV40 NLS sequence is PKKKRKV (SEQ ID NO: 437). In one embodiment, the construct comprises two different tag and / or signal sequences. In another embodiment, the construct comprises two or more signal sequences. In some embodiments, the tags and / or signals are located at the N-terminus. In some embodiments, the tags and / or signals are located at the C-terminus. In some embodiments, one tag and / or signal is located at the N-terminus and one tag and / or signal is located at the C-terminus. In one embodiment, a CUG-targeting PUF or PUMBY fusion protein comprising one or more tags and / or signals is configured, from N-terminus to C-terminus, as follows:

[0125] FLAG-NLS-PUF(CUG)-linker-E17; or

[0126] FLAG-NLS-PUMBY(CUG)-linker-E17;

[0127] NLS-PUF(CUG)-Linker-E17; or

[0128] NLS-PUMBY(CUG)-Linker-E17.

[0129] In one embodiment, a CUG-targeted PUF or PUMBY fusion protein comprising one or more tags and / or signals is configured, from N-terminus to C-terminus, as follows:

[0130] FLAG-NLS-PUF(CUG)-VDTANGS-E17; or

[0131] FLAG-NLS-PUMBY(CUG)-VDTANGS-E17;

[0132] NLS-PUF(CUG)-VDTANGS-E17; or

[0133] NLS-PUMBY(CUG)-VDTANGS-E17.

[0134] Table 2A-2B: Exemplary PUF configurations for targeting CUG MREs:

[0135] PUF with an endonuclease that targets CUG(DM1) for degradation: [Table 55]

[0136] Endonuclease-free PUFs targeting CUG(DM1) for blockage: [Table 56]

[0137] In some embodiments, an AAV vector of the disclosure comprising a CUG-targeting PUF protein is configured 5' to 3' as set forth in Table A. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 573 or 574.

[0138] Table A: PUF-CUG-E17 (A02205) with desmin (FL) promoter [Table A]

[0139] In one embodiment, the nucleic acid encoding the PUF(CUG) or PUMBY(CUG) fusion construct or the endonuclease-free PUF(CUG) or PUMBY(CUG) is operably linked to a promoter sequence for expression in a cell. In one embodiment, the promoter sequence is a truncated CAG (tCAG) promoter (FIG. 4A). In some embodiments, the promoter sequence includes an enhancer sequence and / or an intron sequence. In one embodiment, the promoter is an EFS / UBB promoter. In some embodiments, the promoter sequence is a muscle-specific promoter.

[0140] In one embodiment, a nucleic acid encoding a PUF(CUG) (with or without an endonuclease), a Cas13d(CUG), or a dCas13d(CUG) (dCas13d(CUG) with or without an endonuclease) is operably linked to a promoter sequence for expression in a cell (Figures 4B-4C and Figure 12B). In one embodiment, the promoter sequence is an EFS promoter (Figures 4B-4C). In one embodiment, the promoter is an EFS / UBB promoter (Figure 12B). In some embodiments, the promoter sequence comprises an enhancer sequence and / or an intron sequence. In some embodiments, the promoter sequence is a muscle-specific promoter (Figure 12B).

[0141] In some embodiments, the muscle-specific promoter is the desmin promoter, such as:

[0142] The sequence of the muscle-specific desmin promoter: [Table 58]

[0143] In another embodiment, PUF(CUG) or PUMBY(CUG) or Cas13d(CUG) or dCas13d(CUG) construct is packaged in AAV vector.In one embodiment, AAV vector is AAV9 vector.In another embodiment, AAV vector is AAVrh74 vector.

[0144] In another embodiment, PUF(CUG) or PUMBY(CUG) or Cas13d(CUG) or dCas13d(CUG) construct is packaged in AAV vector.In one embodiment, AAV vector is AAV9 vector.In another embodiment, AAV vector is AAVrh74 vector.

[0145] In some embodiments, an AAV vector of the disclosure comprising a CUG-targeting active Cas13d protein is configured 5' to 3' as shown in Table B. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 573 or 574. Table B: Exemplary CUG-targeting Cas13d AAV vectors [Table B-1] [Table B-2]

[0146] In some embodiments, an AAV vector of the disclosure, designated A02205, comprising a CUG-targeting PUF protein fused to an endonuclease, comprises, from 5' to 3', the elements as set forth in Table C. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 574 or 575. Table C: Exemplary CUG-targeting PUF-endonuclease AAV vectors A02205 [Table C-1] [Table C-2] [Table C-3] Endonuclease-free PUF-CUG (A02239) with desmin (FL) promoter

[0147] In some embodiments, the present disclosure provides a CUG-targeting PUF protein fused to an RB NLS as shown in Table D. Table D: Exemplary CUG-Targeted 8PUFs [Table D]

[0148] In some embodiments, an AAV vector of the present disclosure, designated A02239, comprising a CUG-targeting PUF protein comprises, from 5' to 3', the elements as set forth in Table E. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 576 or 577. Table E: Exemplary CUG-targeted PUF AAV vectors A02239 [Table E-1] [Table E-2] Exemplary Compositions Targeting RNA for Blockade

[0149] A CTG microsatellite expansion in the non-coding 3' untranslated region of DMPK causes DM1. The expanded CUG (CUG) in DMPK mRNA exp ) repeats directly sequester MBNL proteins, resulting in their loss of function. MBNL loss of function is the direct cause of the alternative splicing defects and clinical symptoms observed in DM1. PUF(CUG) or dCas13d(CUG) exp It directly binds to RNA and prevents MBNL sequestration, preserving near-normal free MBNL levels and function, thereby reversing DM1 disease phenotypes, such as splicing dysfunction, myotonia, etc. The following PUF(CUG) and dCas13d(CUG) RNA targeting constructs are exemplary embodiments for blockade.

[0150] In some embodiments, the present disclosure provides a CUG-targeting PUF protein fused to an RB NLS as shown in Table F. Table F: Exemplary CUG-targeted 8PUFs for blocking CUG RNA [Table F]

[0151] In some embodiments, an AAV vector of the present disclosure comprising a CUG-targeting PUF protein suitable for blocking comprises, from 5' to 3', the elements as set forth in Table G. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 578 or 579. Table G: Exemplary PUFs Targeting CUGs for Interruption Nucleotide sequences of the plasmid elements in N- to C-terminal order [Table G-1] [Table G-2] Endonuclease-free, myc-tagged PUF targeting CUG(DM1)

[0152] In some embodiments, the present disclosure provides a CUG-targeting PUF protein fused to an RB NLS as shown in Table H. Table H: Exemplary CUG-targeted 8PUFs for blocking CUG RNA [Table H-1] [Table H-2]

[0153] In some embodiments, an AAV vector of the present disclosure comprising a CUG-targeting PUF protein suitable for blocking comprises, from 5' to 3', the elements as set forth in Table I. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 581 or 582. Table I: Exemplary AAV vectors containing PUFs that target CUGs for blocking. [Table I-1] [Table I-2] A01560: Endonuclease-free, CUG-targeting dCas13d dSeq212 (four point mutations in the catalytic domain)

[0154] In some embodiments, the present disclosure provides a catalytically inactive Cas (dCas13d) that targets CUG and has four point mutations, as shown in Table J. Table J: Exemplary CUG-targeted dCas13d for blocking CUG RNA [Table J]

[0155] In some embodiments, an AAV vector of the present disclosure, designated A01560, comprising a CUG-targeting dCas13d protein comprises, from 5' to 3', the elements as set forth in Table K. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 584 or 585. Table K: Exemplary AAV vector A01560 containing CUG-targeted dCas13d [Table K-1] [Table K-2] [Table K-3] Cas13d:endonuclease-free, CUG-targeting dSeq212 (with one point mutation H919A in HEPN2)

[0156] In some embodiments, the disclosure provides a catalytically inactive Cas (dCas13d) that targets CUG and has the H919A mutation in HEPN2 as shown in Table L. Table L: Exemplary CUG-targeted dcas13d for blocking CUG RNA [Table L]

[0157] In some embodiments, an AAV vector of the present disclosure comprising a CUG-targeting dCas13d protein comprises, from 5' to 3', the elements as set forth in Table M. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 590 or 591. Table M: ​​Exemplary AAV vectors containing CUG-targeting dCas13d [Table M-1] [Table M-2] Cas13d:endonuclease-free, CUG-targeting dSeq212 (with one point mutation R914A in HEPN2)

[0158] In some embodiments, the disclosure provides a catalytically inactive Cas (dCas13d) that targets CUG and has the H914A mutation, as shown in Table N. Table N: Exemplary CUG-targeted dcas13d for blocking CUG RNA [Table N-1] [Table N-2]

[0159] In some embodiments, an AAV vector of the present disclosure comprising a CUG-targeting dCas13d protein comprises, from 5' to 3', the elements as set forth in Table O. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 592 or 593. Table O: Exemplary AAV vectors containing CUG-targeting dCas13d [Table O-1] [Table O-2] Cas13d:endonuclease-free, CUG-targeting dSeq212 (with one point mutation R293A in HEPN1)

[0160] In some embodiments, the disclosure provides a catalytically inactive Cas (dCas13d) that targets CUG and has an R293A mutation in HEPN1, as shown in Table P. Table P: Exemplary CUG-targeted dcas13d for blocking CUG RNA [Table P]

[0161] In some embodiments, an AAV vector of the present disclosure comprising a CUG-targeting dCas13d protein comprises, from 5' to 3', the elements as set forth in Table Q. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 594 or 595. Table Q: Exemplary AAV vectors containing CUG-targeting dCas13d [Table Q-1] [Table Q-2] Cas13d:endonuclease-free, CUG-targeting dSeq212 (with one point mutation H298A in HEPN1)

[0162] In some embodiments, the disclosure provides a catalytically inactive Cas (dCas13d) that targets CUG and has the H298A mutation in HEPN1, as shown in Table R. Table R: Exemplary CUG-targeted dcas13d for blocking CUG RNA [Table R]

[0163] In some embodiments, an AAV vector of the present disclosure comprising a CUG-targeting dCas13d protein comprises, from 5' to 3', the elements as set forth in Table S. In some aspects, the AAV vector comprises the nucleic acid sequence set forth in SEQ ID NO: 596 or 597. Table S: Exemplary AAV vectors containing CUG-targeting dCas13d [Table S-1] [Table S-2] [Table S-3] Guide RNA for RNA-guided RNA-binding proteins

[0164] The terms guide RNA (gRNA) and single guide RNA (sgRNA) are used interchangeably throughout this disclosure.

[0165] A guide RNA (gRNA) of the present disclosure may be composed of a spacer sequence and a "direct repeat" (DR) sequence. In some embodiments, the guide RNA is a single guide RNA (sgRNA), which comprises a contiguous spacer sequence and a DR sequence. In some embodiments, the spacer sequence and the DR sequence are not contiguous. In some embodiments, the gRNA comprises a DR sequence. DR sequences refer to repeat sequences within a CRISPR locus (naturally occurring in a bacterial genome or a plasmid) that are interspersed with spacer sequences. It is well known that if the sequence of the associated CRISPR locus is known, the DR sequence of the corresponding (or cognate) Cas protein can be inferred. In some embodiments, the guide RNA comprises a direct repeat (DR) sequence and a spacer sequence. In some embodiments, a sequence encoding a guide RNA or single guide RNA of the present disclosure comprises or consists of a spacer sequence and a DR sequence separated by a linker sequence. In some embodiments, the linker sequence may comprise or consist of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or any number of nucleotides (nt) in between. In some embodiments, the linker sequence may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or any number of nucleotides in between. In some embodiments, the DR sequence is a Cas13d DR sequence.

[0166] In one embodiment, the gRNA that hybridizes to one or more target RNA molecules in a Cas13d-mediated manner comprises one or more direct repeat (DR) sequences, one or more spacer sequences, such as one or more sequences comprising a DR-spacer-DR-spacer array. In one embodiment, multiple gRNAs are generated from a single array, each of which may be different, e.g., targeting different RNAs, or multiple target regions from a single RNA, or a combination thereof. In some embodiments, the isolated gRNA comprises one or more direct repeat sequences, e.g., unprocessed (e.g., about 36 nt) or processed DR (e.g., about 30 nt). In some embodiments, the gRNA may further comprise one or more spacer sequences specific to the target RNA (e.g., complementary to the target RNA). In certain such embodiments, multiple polIII promoters can be used to drive multiple gRNAs, spacers, and / or DRs. In one embodiment, the guide array comprises DR(about 36 nt)-spacer(about 30 nt)-DR(about 36 nt)-spacer(about 30 nt).

[0167] The guide RNA (gRNA) of the present disclosure may contain non-naturally occurring nucleotides. In some embodiments, the guide RNA of the present disclosure, or the sequence encoding the guide RNA, comprises or consists of modified or synthetic RNA nucleotides. Exemplary modified RNA nucleotides include, but are not limited to, pseudouridine (Ψ), dihydrouridine (D), inosine (I), 7-methylguanosine (m7G), hypoxanthine, xanthine, xanthosine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine, 5-methylcytidine, 5-hydroxymethylcytosine, isoguanine, and isocytosine.

[0168] The guide RNA (gRNA) of the present disclosure can bind to modified RNA in target sequence.The guide RNA (gRNA) of the present disclosure can bind to modified or mutant (e.g., pathogenic) RNA in target sequence.Exemplary epigenetic or post-transcriptionally modified RNA includes, but is not limited to, 2'-O-methylated (2'-OMe) (2'-O-methylated is present on the free 2'-OH oxygen of the ribose moiety), N6-methyladenosine (m6A), and 5-methylcytosine (m5C).

[0169] In some embodiments of the composition of the present disclosure, the guide RNA of the present disclosure comprises at least one sequence encoding a non-coding C / D box small nucleolar RNA (snoRNA) sequence. In some embodiments, the snoRNA sequence comprises at least one sequence complementary to the target RNA, wherein the target sequence of the RNA molecule comprises at least one 2'-OMe. In some embodiments, the snoRNA sequence comprises at least one sequence complementary to the target RNA, wherein the at least one sequence complementary to the target RNA comprises a box C motif (RUGAUGA) (SEQ ID NO: 523) and a box D motif (CUGA) (SEQ ID NO: 524).

[0170] The spacer sequences of the present disclosure bind to a target sequence of an RNA molecule. In some embodiments, the spacer sequences of the present disclosure bind to a pathogenic target RNA.

[0171] In some embodiments of the compositions of the present disclosure, the sequence comprising the gRNA further comprises a spacer sequence that specifically binds to the target RNA sequence. In some embodiments, the spacer sequence has at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 87%, 90%, 95%, 97%, 99%, or any percentage therebetween complementary to the target RNA sequence. In some embodiments, the spacer sequence has 100% complementary to the target RNA sequence. In some embodiments, the spacer sequence comprises or consists of 20 nucleotides. In some embodiments, the spacer sequence comprises or consists of 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, or 29 nucleotides. In some embodiments, the spacer sequence comprises or consists of 26 nucleotides. In some embodiments, the spacer sequence is unprocessed and comprises or consists of 30 nucleotides. In some embodiments, the unprocessed spacer sequence comprises or consists of 30 to 36 nucleotides.

[0172] The DR sequences of the present disclosure bind to the Cas polypeptides of the present disclosure. When the spacer sequence of the gRNA binds to the target RNA sequence, the Cas protein bound to the DR sequence of the gRNA is positioned at the target RNA sequence. A DR sequence with sufficient complementarity to its cognate Cas protein or nucleic acid selectively binds to the target nucleic acid sequence of the Cas protein and has at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96, 97%, 98%, 99%, or any percentage therebetween identity to that sequence. In some embodiments, a sequence with sufficient complementarity has 100% identity. In some embodiments, the DR sequences of the present disclosure comprise a secondary or tertiary structure. Exemplary secondary structures include, but are not limited to, helices, stem-loops, bulges, tetraloops, and pseudoknots. Exemplary tertiary structures include, but are not limited to, A-type helix, B-type helix, and Z-type helix. Exemplary tertiary structures include, but are not limited to, twisted or spiral stem-loop. Exemplary tertiary structures include, but are not limited to, twisted or spiral pseudoknot. In some embodiments, the DR sequence of the present disclosure comprises at least one secondary structure or at least one tertiary structure. In some embodiments, the DR sequence of the present disclosure comprises one or more secondary structures or one or more tertiary structures.

[0173] In some embodiments of the composition of the present disclosure, guide RNA or its part selectively binds to the tetraloop motif in the RNA molecule of the present disclosure.In some embodiments, the target sequence of the RNA molecule comprises a tetraloop motif.In some embodiments, the tetraloop motif is a "GRNA" motif that comprises or consists of one or more of the following sequences: GAAA, GUGA, GCAA or GAGA.

[0174] In some embodiments of the composition of the present disclosure, the guide RNA or a portion thereof that binds to the target sequence of the RNA molecule is hybridized with the target sequence of the RNA molecule.In some embodiments, the guide RNA or a portion thereof that binds to the first RNA binding protein or the second RNA binding protein is covalently bound to the first RNA binding protein or the second RNA binding protein.In some embodiments, the guide RNA or a portion thereof that binds to the first RNA binding protein or the second RNA binding protein is non-covalently bound to the first RNA binding protein or the second RNA binding protein.

[0175] In some embodiments of the compositions of the present disclosure, the guide RNA or a portion thereof comprises or consists of between 10 and 100 nucleotides, including the terminus. In some embodiments, the spacer sequence of the present disclosure comprises or consists of between 10 and 30 nucleotides, including the terminus. In some embodiments, the spacer sequence of the present disclosure comprises or consists of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the spacer sequence of the present disclosure comprises or consists of 20 nucleotides. In some embodiments, the spacer sequence of the present disclosure comprises or consists of 21 nucleotides. In some embodiments, the spacer sequence of the present disclosure comprises or consists of 26 nucleotides.

[0176] Guide molecules generally exist in various processing states. In one example, the unprocessed guide RNA is a 36-nt DR followed by a 30-32-nt spacer. The guide RNA is processed (shortened / modified) into a shorter "mature" form by Cas13d itself or other RNases. In some embodiments, the unprocessed guide sequence is about or at least about 30, 35, 40, 45, 50, 55, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, or more nucleotides (nt) in length. In some embodiments, the processed guide sequence is about 44-60 nt (e.g., 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 nt). In some embodiments, the unprocessed spacer is about 28-32 nt in length (e.g., 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nt), while the mature (processed) spacer can be about 10-30 nt, 10-25 nt, 14-25 nt, 20-22 nt, or 14-30 nt (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nt). In some embodiments, the unprocessed DR is about 36 nt (e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 nt), while the processed DR is about 30 nt (e.g., 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nt). In some embodiments, the DR sequence is truncated, e.g., at the 5' end, by 1-10 nucleotides (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, -10 nucleotides) and expressed as a mature, pre-processed guide RNA.

[0177] In some embodiments of the compositions of the present disclosure, the guide RNA or portion thereof does not comprise a nuclear localization sequence (NLS).

[0178] In some embodiments of the compositions of the present disclosure, the guide RNA or a portion thereof comprises a sequence complementary to a protospacer flanking sequence (PFS). In some embodiments, the first RNA-binding protein may comprise a sequence isolated from or derived from a Cas13 protein, including those in which the guide RNA or a portion thereof comprises a sequence complementary to the PFS. In some embodiments, the first RNA-binding protein may comprise a sequence encoding a Cas13 protein or an RNA-binding portion thereof, including those in which the guide RNA or a portion thereof comprises a sequence complementary to the PFS. In some embodiments, the guide RNA or a portion thereof does not comprise a sequence complementary to the PFS.

[0179] In some embodiments of the compositions of the present disclosure, the guide RNA sequence of the present disclosure comprises a promoter sequence for driving expression of the guide RNA. In some embodiments, a vector comprising the guide RNA sequence of the present disclosure comprises a promoter sequence for driving expression of the guide RNA. In some embodiments, the promoter for driving expression of the guide RNA is a constitutive promoter. In some embodiments, the promoter sequence is an inducible promoter. In some embodiments, the promoter sequence is a tissue-specific and / or cell-type-specific promoter. In some embodiments, the promoter is a hybrid or recombinant promoter. In some embodiments, the promoter is a promoter that can express the guide RNA in mammalian cells. In some embodiments, the promoter is a promoter that can express the guide RNA in human cells. In some embodiments, the promoter is a promoter that can express the guide RNA and restrict the guide RNA to the nucleus of the cell. In some embodiments, the promoter is a human RNA polymerase promoter or a sequence isolated or derived from a sequence encoding a human RNA polymerase promoter. In some embodiments, the promoter is a U6 promoter or a sequence isolated or derived from a sequence encoding a U6 promoter. In some embodiments, the U6 promoter is a human U6 promoter. In some embodiments, the promoter is a human tRNA promoter or a sequence isolated or derived from a sequence encoding a human tRNA promoter, hi some embodiments, the promoter is a human valine tRNA promoter or a sequence isolated or derived from a sequence encoding a human valine tRNA promoter.

[0180] In some embodiments of the compositions of the present disclosure, the promoter for driving the expression of the guide RNA further comprises a regulatory element. In some embodiments, the vector comprising a promoter sequence for driving the expression of the guide RNA further comprises a regulatory element. In some embodiments, the regulatory element enhances the expression of the guide RNA. Exemplary regulatory elements include, but are not limited to, an enhancer element, an intron, an exon, or a combination thereof. In some embodiments of the compositions of the present disclosure, the vector of the present disclosure comprises one or more of a sequence encoding the guide RNA, a promoter sequence for driving the expression of the guide RNA, and a sequence encoding a regulatory element. In some embodiments of the compositions of the present disclosure, the vector further comprises a sequence encoding the fusion protein of the present disclosure. RNA-guided RNA-binding proteins

[0181] In some embodiments of the compositions of the present disclosure, the gRNA corresponds to a target RNA molecule and an RNA-guided RNA-binding protein. In some embodiments, the gRNA corresponds to an RNA-guided RNA-binding fusion protein, which fusion protein comprises a first and a second RNA-binding protein. In some embodiments, the first RNA-binding protein in the fusion protein is an inactivated RNA-binding protein, such as an inactivated Cas or a catalytically inactive Cas protein. In some embodiments, the sequence encoding the first RNA-binding protein is located 5' to the sequence encoding the second RNA-binding protein along the sequence encoding the RNA-binding fusion protein. In some embodiments, the sequence encoding the first RNA-binding protein is located 3' to the sequence encoding the second RNA-binding protein along the sequence encoding the fusion protein.

[0182] In some embodiments of the compositions of the present disclosure, the sequence encoding the first RNA-binding protein comprises a sequence isolated or derived from a protein capable of binding to an RNA molecule. In some embodiments, the sequence encoding the first RNA-binding protein comprises a sequence isolated or derived from a protein that can selectively bind to an RNA molecule and not to a DNA molecule, not to a mammalian DNA molecule, or not to any DNA molecule. In some embodiments, the sequence encoding the first RNA-binding protein comprises a sequence isolated or derived from a protein that can bind to an RNA molecule and induce breaks in the RNA molecule. In some embodiments, the sequence encoding the first RNA-binding protein comprises a sequence isolated or derived from a protein that can bind to an RNA molecule and induce breaks in the RNA molecule and not to a DNA molecule, not to a mammalian DNA molecule, or not to any DNA molecule. In some embodiments, the sequence encoding the first RNA binding protein comprises a sequence isolated from or derived from a protein that can bind to and induce destruction of RNA molecules, but does not bind to and induce destruction of DNA molecules, does not bind to and induce destruction of mammalian DNA molecules, or does not bind to and induce destruction of any DNA molecules.

[0183] In some embodiments of the compositions of the present disclosure, the sequence encoding the RNA-binding protein guided by the first RNA comprises a sequence isolated or derived from a protein that does not have DNA nuclease activity.

[0184] In some embodiments of the compositions of the present disclosure, the sequence encoding the RNA-guided RNA-binding protein disclosed herein comprises a sequence isolated from or derived from a CRISPR Cas protein. In some embodiments, the CRISPR Cas protein is not a type II CRISPR Cas protein. In some embodiments, the CRISPR Cas protein is not a Cas9 protein.

[0185] In some embodiments of the compositions of the present disclosure, the sequence encoding the RNA-guided RNA-binding protein comprises a Type VI CRISPR Cas protein or a portion thereof. In some embodiments, the Type VI CRISPR Cas protein comprises a Cas13 protein or a portion thereof. Exemplary Cas13 proteins of the present disclosure can be isolated or derived from any species, including, but not limited to, bacteria or archaea. Exemplary Cas13 proteins of the present disclosure include, but are not limited to, Leptotrichia wadei, Listeria seeligeri serovar 1 / 2b (strain ATCC 35967 / DSM 20751 / CIP 100100 / SLCC 3954), Lachnospiraceae bacterium, Clostridium aminophilum DSM 10710, Carnobacterium gallinarum DSM 4847, Paludibacter propionicigenes WB4, Listeria weihenstephanensis FSL R9-0317, Listeria weihenstephanensis FSL R9-0317, bacterium FSL M6-0635 (Listeria newyorkensis), Leptotrichia wadei F0279, Rhodobacter capsulatus SB 1003, Rhodobacter capsulatus The Cas13 protein may be isolated or derived from any species, including Rhodobacter capsulatus DE442, R121, and Corynebacterium ulcerans. Exemplary Cas13 proteins of the present disclosure may be DNA nuclease inactivated. Exemplary Cas13 proteins of the present disclosure include, but are not limited to, Cas13a, Cas13b, Cas13c, Cas13d, and their orthologs. Exemplary Cas13b proteins of the present disclosure include, but are not limited to, subtypes 1 and 2, referred to herein as Csx27 and Csx28, respectively.

[0186] Exemplary Cas13a proteins include, but are not limited to, the following: [Table 77-1] [Table 77-2]

[0187] An exemplary wild-type Cas13a protein of the present disclosure may comprise or consist of the amino acid sequence of SEQ ID NO:408.

[0188] Exemplary Cas13b proteins include, but are not limited to, the following: [Table 78-1] [Table 78-2]

[0189] An exemplary wild-type Bergeyella zoohelcum ATCC 43767 Cas13b (BzCas13b) protein of the present disclosure can comprise or consist of the amino acid sequence of SEQ ID NO:409.

[0190] In some embodiments of the compositions of the present disclosure, the sequence encoding the RNA-binding protein comprises a sequence isolated or derived from a Cas13d protein. Cas13d is an effector of a type VI-D CRISPR-Cas system. In some embodiments, the Cas13d protein is an RNA-guided RNA endonuclease enzyme capable of cleaving or binding to RNA. In some embodiments, the Cas13d protein may comprise one or more higher eukaryotic and prokaryotic nucleotide-binding (HEPN) domains. In some embodiments, the Cas13d protein may comprise either a wild-type HEPN domain or a mutant HEPN domain. In some embodiments, the Cas13d protein comprises a mutant HEPN domain that cannot cleave RNA but can process guide RNA. In some embodiments, the Cas13d protein does not require a protospacer flanking sequence. For further examples and sequences of Cas13d proteins, see also WO Publication Nos. WO2019 / 040664 and US2019 / 0062724, which are incorporated by reference in their entireties, without limitation.

[0191] In some embodiments, Cas13d sequences of the present disclosure include, without limitation, SEQ ID NOs: 1-296 of WO2019 / 040664, which are so numbered and incorporated herein.

[0192] SEQ ID NO: 1 is an exemplary Cas13d sequence from Eubacterium siraeum containing a HEPN site.

[0193] SEQ ID NO: 2 is an exemplary Cas13d sequence from Eubacterium siraeum containing a mutated HEPN site.

[0194] SEQ ID NO: 3 is an exemplary Cas13d sequence from an uncultured Ruminococcus sp. containing a HEPN site.

[0195] SEQ ID NO: 4 is an exemplary Cas13d sequence from an uncultured Ruminococcus sp. containing a mutated HEPN site.

[0196] SEQ ID NO: 5 is an exemplary Cas13d sequence from Gut_metagenome_contig2791000549.

[0197] SEQ ID NO: 6 is an exemplary Cas13d sequence from Gut_metagenome_contig855000317.

[0198] SEQ ID NO: 7 is an exemplary Cas13d sequence from Gut_metagenome_contig3389000027.

[0199] SEQ ID NO: 8 is an exemplary Cas13d sequence from Gut_metagenome_contig8061000170.

[0200] SEQ ID NO: 9 is an exemplary Cas13d sequence from Gut_metagenome_contigl509000299.

[0201] SEQ ID NO: 10 is an exemplary Cas13d sequence from Gut_metagenome_contig9549000591.

[0202] SEQ ID NO: 11 is an exemplary Cas13d sequence from Gut_metagenome_contig71000500.

[0203] SEQ ID NO: 12 is an exemplary Cas13d sequence from a human stomach metagenome.

[0204] SEQ ID NO: 13 is an exemplary Cas13d sequence from Gut_metagenome_contig3915000357.

[0205] SEQ ID NO: 14 is an exemplary Cas13d sequence from Gut_metagenome_contig4719000173.

[0206] SEQ ID NO: 15 is an exemplary Cas13d sequence from Gut_metagenome_contig6929000468.

[0207] SEQ ID NO: 16 is an exemplary Cas13d sequence from Gut_metagenome_contig7367000486.

[0208] SEQ ID NO: 17 is an exemplary Cas13d sequence from Gut_metagenome_contig7930000403.

[0209] SEQ ID NO: 18 is an exemplary Cas13d sequence from Gut_metagenome_contig993000527.

[0210] SEQ ID NO: 19 is an exemplary Cas13d sequence from Gut_metagenome_contig6552000639.

[0211] SEQ ID NO: 20 is an exemplary Cas13d sequence from Gut_metagenome_contigll932000246.

[0212] SEQ ID NO: 21 is an exemplary Cas13d sequence from Gut_metagenome_contigl2963000286.

[0213] SEQ ID NO: 22 is an exemplary Cas13d sequence from Gut_metagenome_contig2952000470.

[0214] SEQ ID NO: 23 is an exemplary Cas13d sequence from Gut_metagenome_contig451000394.

[0215] SEQ ID NO: 24 is an exemplary Cas13d sequence from Eubacterium_siraeum_DSM_l5702.

[0216] SEQ ID NO: 25 is an exemplary Cas13d sequence from gut_metagenome_P19E0k2120140920,_c369000003.

[0217] SEQ ID NO: 26 is an exemplary Cas13d sequence from Gut_metagenome_contig7593000362.

[0218] SEQ ID NO: 27 is an exemplary Cas13d sequence from Gut_metagenome_contigl2619000055.

[0219] SEQ ID NO: 28 is an exemplary Cas13d sequence from Gut_metagenome_contigl405000151.

[0220] SEQ ID NO: 29 is an exemplary Cas13d sequence from Chicken_gut_metagenome_c298474.

[0221] SEQ ID NO: 30 is an exemplary Cas13d sequence from Gut_metagenome_contigl516000227.

[0222] SEQ ID NO: 31 is an exemplary Cas13d sequence from Gut_metagenome_contigl838000319.

[0223] SEQ ID NO: 32 is an exemplary Cas13d sequence from Gut_metagenome_contig13123000268.

[0224] SEQ ID NO: 33 is an exemplary Cas13d sequence from Gut_metagenome_contig5294000434.

[0225] SEQ ID NO: 34 is an exemplary Cas13d sequence from Gut_metagenome_contig6415000192.

[0226] SEQ ID NO: 35 is an exemplary Cas13d sequence from Gut_metagenome_contig6144000300.

[0227] SEQ ID NO: 36 is an exemplary Cas13d sequence from Gut_metagenome_contig9118000041.

[0228] SEQ ID NO: 37 is an exemplary Cas13d sequence from Activated_sludge_metagenome_transcript_124486.

[0229] SEQ ID NO: 38 is an exemplary Cas13d sequence from Gut_metagenome_contig1322000437.

[0230] SEQ ID NO: 39 is an exemplary Cas13d sequence from Gut_metagenome_contig4582000531.

[0231] SEQ ID NO: 40 is an exemplary Cas13d sequence from Gut_metagenome_contig9190000283.

[0232] SEQ ID NO: 41 is an exemplary Cas13d sequence from Gut_metagenome_contigl709000510.

[0233] SEQ ID NO: 42 is an exemplary Cas13d sequence from M24_(LSQX01212483_Anaerobic_digester_metagenome) with a HEPN domain.

[0234] SEQ ID NO: 43 is an exemplary Cas13d sequence from Gut_metagenome_contig3833000494.

[0235] SEQ ID NO: 44 is an exemplary Cas13d sequence from Activated_sludge_metagenome_transcript_117355.

[0236] SEQ ID NO: 45 is an exemplary Cas13d sequence from Gut_metagenome_contigll061000330.

[0237] SEQ ID NO: 46 is an exemplary Cas13d sequence from Gut_metagenome_contig338000322 from a sheep stomach metagenome.

[0238] SEQ ID NO: 47 is an exemplary Cas13d sequence from a human stomach metagenome.

[0239] SEQ ID NO: 48 is an exemplary Cas13d sequence from Gut_metagenome_contig9530000097.

[0240] SEQ ID NO: 49 is an exemplary Cas13d sequence from Gut_metagenome_contigl750000258.

[0241] SEQ ID NO: 50 is an exemplary Cas13d sequence from Gut_metagenome_contig5377000274.

[0242] SEQ ID NO: 51 is an exemplary Cas13d sequence from gut_metagenome_P19E0k2120140920_c248000089.

[0243] SEQ ID NO: 52 is an exemplary Cas13d sequence from Gut_metagenome_contigll400000031.

[0244] SEQ ID NO: 53 is an exemplary Cas13d sequence from Gut_metagenome_contig7940000191.

[0245] SEQ ID NO: 54 is an exemplary Cas13d sequence from Gut_metagenome_contig6049000251.

[0246] SEQ ID NO: 55 is an exemplary Cas13d sequence from Gut_metagenome_contigl137000500.

[0247] SEQ ID NO: 56 is an exemplary Cas13d sequence from Gut_metagenome_contig9368000105.

[0248] SEQ ID NO: 57 is an exemplary Cas13d sequence from Gut_metagenome_contig546000275.

[0249] SEQ ID NO: 58 is an exemplary Cas13d sequence from Gut_metagenome_contig7216000573.

[0250] SEQ ID NO: 59 is an exemplary Cas13d sequence from Gut_metagenome_contig4806000409.

[0251] SEQ ID NO: 60 is an exemplary Cas13d sequence from Gut_metagenome_contigl0762000480.

[0252] SEQ ID NO: 61 is an exemplary Cas13d sequence from Gut_metagenome_contig4114000374.

[0253] SEQ ID NO: 62 is an exemplary Cas13d sequence from Ruminococcus_flavefaciens_FD1.

[0254] SEQ ID NO: 63 is an exemplary Cas13d sequence from Gut_metagenome_contig7093000170.

[0255] SEQ ID NO: 64 is an exemplary Cas13d sequence from Gut_metagenome_contigl1113000384.

[0256] SEQ ID NO: 65 is an exemplary Cas13d sequence from Gut_metagenome_contig6403000259.

[0257] SEQ ID NO: 66 is an exemplary Cas13d sequence from Gut_metagenome_contig6193000124.

[0258] SEQ ID NO: 67 is an exemplary Cas13d sequence from Gut_metagenome_contig721000619.

[0259] SEQ ID NO: 68 is an exemplary Cas13d sequence from Gut_metagenome_contigl666000270.

[0260] SEQ ID NO: 69 is an exemplary Cas13d sequence from Gut_metagenome_contig2002000411.

[0261] SEQ ID NO: 70 is an exemplary Cas13d sequence from Ruminococcus albus.

[0262] SEQ ID NO: 71 is an exemplary Cas13d sequence from Gut_metagenome_contig13552000311.

[0263] SEQ ID NO: 72 is an exemplary Cas13d sequence from Gut_metagenome_contigl0037000527.

[0264] SEQ ID NO: 73 is an exemplary Cas13d sequence from Gut_metagenome_contig238000329.

[0265] SEQ ID NO: 74 is an exemplary Cas13d sequence from Gut_metagenome_contig2643000492.

[0266] SEQ ID NO: 75 is an exemplary Cas13d sequence from Gut_metagenome_contig874000057.

[0267] SEQ ID NO: 76 is an exemplary Cas13d sequence from Gut_metagenome_contig4781000489.

[0268] SEQ ID NO: 77 is an exemplary Cas13d sequence from Gut_metagenome_contigl2144000352.

[0269] SEQ ID NO: 78 is an exemplary Cas13d sequence from Gut_metagenome_contig5590000448.

[0270] SEQ ID NO: 79 is an exemplary Cas13d sequence from Gut_metagenome_contig9269000031.

[0271] SEQ ID NO: 80 is an exemplary Cas13d sequence from Gut_metagenome_contig8537000520.

[0272] SEQ ID NO: 81 is an exemplary Cas13d sequence from Gut_metagenome_contigl845000130.

[0273] SEQ ID NO: 82 is an exemplary Cas13d sequence from gut_metagenome_P13E0k2l20140920_c3000072.

[0274] SEQ ID NO: 83 is an exemplary Cas13d sequence from gut_metagenome_P1 E0k2l20140920 _c I000078.

[0275] SEQ ID NO: 84 is an exemplary Cas13d sequence from Gut_metagenome_contigl2990000099.

[0276] SEQ ID NO: 85 is an exemplary Cas13d sequence from Gut_metagenome_contig525000349.

[0277] SEQ ID NO: 86 is an exemplary Cas13d sequence from Gut_metagenome_contig7229000302.

[0278] SEQ ID NO: 87 is an exemplary Cas13d sequence from Gut_metagenome_contig3227000343.

[0279] SEQ ID NO: 88 is an exemplary Cas13d sequence from Gut_metagenome_contig7030000469.

[0280] SEQ ID NO: 89 is an exemplary Cas13d sequence from Gut_metagenome_contig5149000068.

[0281] SEQ ID NO: 90 is an exemplary Cas13d sequence from Gut_metagenome_contig400200045.

[0282] SEQ ID NO: 91 is an exemplary Cas13d sequence from Gut_metagenome_contigl0420000446.

[0283] SEQ ID NO: 92 is an exemplary Cas13d sequence from new_flavefaciens_strain_XPD3002 (CasRx).

[0284] SEQ ID NO: 93 is an exemplary Cas13d sequence from M26_Gut_metagenome_contig698000307.

[0285] SEQ ID NO: 94 is an exemplary Cas13d sequence from M36_Uncultured_Eubacterium_sp_TS28_c40956.

[0286] SEQ ID NO: 95 is an exemplary Cas13d sequence from M12_gut_metagenome_P25C0k2l20140920 _c134000066.

[0287] SEQ ID NO: 96 is an exemplary Cas13d sequence from a human stomach metagenome.

[0288] SEQ ID NO: 97 is an exemplary Cas13d sequence from MlO_gut_metagenome _P25C90k2120 l 40920_c28000041.

[0289] SEQ ID NO: 98 is an exemplary Cas13d sequence from 30 Ml I_gut_metagenome_P25C7k2120140920_c4078000105.

[0290] SEQ ID NO: 99 is an exemplary Cas13d sequence from gut_metagenome_P25C0k2120l40920_c32000045.

[0291] SEQ ID NO: 100 is an exemplary Cas13d sequence from M13_gut_metagenome _P23C7k2l20140920 _c3000067.

[0292] SEQ ID NO: 101 is an exemplary Cas13d sequence from M5_gut_metagenome_Pl8E90k2120140920.

[0293] SEQ ID NO: 102 is an exemplary Cas13d sequence from M2l_gut_metagenome_Pl8E0k2120140920.

[0294] SEQ ID NO: 103 is an exemplary Cas13d sequence from M7_gut_metagenome _P38C7k2120 l 40920_c484 l 000003.

[0295] SEQ ID NO: 104 is an exemplary Cas13d sequence from Ruminococcus bicirculans.

[0296] SEQ ID NO: 105 is an exemplary Cas13d sequence.

[0297] SEQ ID NO: 106 is an exemplary Cas13d consensus sequence.

[0298] SEQ ID NO: 107 is an exemplary Cas13d sequence from M18_gut_metagenome _P22EOk2l20140920_c3395000078.

[0299] SEQ ID NO: 108 is an exemplary Cas13d sequence from M17_gut_metagenome_P22E90k2120140920_c114.

[0300] SEQ ID NO: 109 is an exemplary Cas13d sequence from Ruminococcus_sp_CAG57.

[0301] SEQ ID NO: 110 is an exemplary Cas13d sequence from gut_metagenome_Pl 1E90k2120 l 40920_c43000123.

[0302] SEQ ID NO: 111 is an exemplary Cas13d sequence from M6_gut_metagenome_P13E90k2120 l 40920_c7000009.

[0303] SEQ ID NO: 112 is an exemplary Cas13d sequence from Ml9_gut_metagenome_Pl 7E90k2120140920.

[0304] SEQ ID NO: 113 is an exemplary Cas13d sequence from gut_metagenome_Pl7E0k2120l40920,_c87000043.

[0305] SEQ ID NO: 114 is an exemplary human codon-optimized Eubacterium siraeum Cas13d nucleic acid sequence.

[0306] SEQ ID NO: 115 is an exemplary human codon-optimized Eubacterium siraeum Cas13d nucleic acid sequence having a mutant HEPN domain.

[0307] SEQ ID NO: 116 is an exemplary human codon-optimized Eubacterium siraeum Cas13d nucleic acid sequence with an N-terminal NLS.

[0308] SEQ ID NO: 117 is an exemplary human codon-optimized Eubacterium siraeum Cas13d nucleic acid sequence with N- and C-terminal NLS tags.

[0309] SEQ ID NO: 118 is an exemplary human codon-optimized uncultured Ruminococcus sp. Cas13d 30 nucleic acid sequence.

[0310] SEQ ID NO: 119 is an exemplary human codon-optimized uncultured Ruminococcus sp. Cas13d nucleic acid sequence having a variant HEPN domain.

[0311] SEQ ID NO: 120 is an exemplary human codon-optimized uncultured Ruminococcus sp. Cas13d nucleic acid sequence with an N-terminal NLS.

[0312] SEQ ID NO: 121 is an exemplary human codon-optimized uncultured Ruminococcus sp. Cas13d nucleic acid sequence with N- and C-terminal NLS tags.

[0313] SEQ ID NO: 122 is an exemplary human codon-optimized uncultured Ruminococcus flavefaciens FDl Cas13d nucleic acid sequence.

[0314] SEQ ID NO: 123 is an exemplary human codon-optimized uncultured Ruminococcus flavefaciens FDl Casl3d nucleic acid sequence having a mutated HEPN domain.

[0315] SEQ ID NO: 124 is an exemplary Cas13d nucleic acid sequence from Ruminococcus bicirculans.

[0316] SEQ ID NO: 125 is an exemplary Cas13d nucleic acid sequence from Eubacterium siraeum.

[0317] SEQ ID NO: 126 is an exemplary Cas13d nucleic acid sequence from Ruminococcus flavefaciens FD1.

[0318] SEQ ID NO: 127 is an exemplary Cas13d nucleic acid sequence from Ruminococcus albus.

[0319] SEQ ID NO: 128 is an exemplary Cas13d nucleic acid sequence from Ruminococcus flavefaciens XPD.

[0320] SEQ ID NO: 129 is an exemplary consensus DR nucleic acid sequence for E. siraeum Cas13d.

[0321] SEQ ID NO: 130 is an exemplary consensus DR nucleic acid sequence for Rum. Sp. Cas13d.

[0322] SEQ ID NO: 131 is an exemplary consensus DR nucleic acid sequence for Rum. Flavefaciens strain XPD3002 Cas13d (CasRx).

[0323] SEQ ID NOs: 132-137 are exemplary consensus DR nucleic acid sequences.

[0324] SEQ ID NO: 138 is an exemplary 50% consensus sequence of seven full-length Cas13d orthologs.

[0325] SEQ ID NO: 139 is an exemplary Cas13d nucleic acid sequence from the gut metagenome PlEO.

[0326] SEQ ID NO: 140 is an exemplary Cas13d nucleic acid sequence from Anaerobic digester.

[0327] SEQ ID NO: 141 is an exemplary Cas13d nucleic acid sequence from Ruminococcus sp. CAG:57.

[0328] SEQ ID NO: 142 is an exemplary human codon-optimized uncultured gut metagenomic PlEO Cas13d nucleic acid sequence.

[0329] SEQ ID NO: 143 is an exemplary human codon-optimized Anaerobic Digester Cas13d nucleic acid sequence.

[0330] SEQ ID NO: 144 is an exemplary human codon-optimized Ruminococcus flavefaciens XPD Cas13d nucleic acid sequence.

[0331] SEQ ID NO: 145 is an exemplary human codon-optimized Ruminococcus albus Cas13d nucleic acid sequence.

[0332] SEQ ID NO: 146 is an exemplary processing of the Ruminococcus sp. CAG:57 CRISPR array.

[0333] SEQ ID NO: 147 is an exemplary Cas13d protein sequence from contig emb|OBVH01003037.1, a human gut metagenomic sequence (also found in WGS contigs emb|OBXZ01000094.1| and emb|OBJFO1000033.1).

[0334] SEQ ID NO: 148 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 147).

[0335] SEQ ID NO: 149 is an exemplary Cas13d protein sequence from contig tpg|DBYI01000091.1| (uncultivated Ruminococcus flavefaciens UBA1190 assembled from bovine intestinal metagenome).

[0336] SEQ ID NOs: 150-152 are exemplary consensus DR nucleic acid sequences (paired with SEQ ID NO: 149).

[0337] SEQ ID NO: 153 is an exemplary Cas13d protein sequence from contig tpg|DJXD01000002.1| (uncultivated Ruminococcus assembly from sheep intestinal metagenome, UBA7013).

[0338] SEQ ID NO: 154 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 153).

[0339] SEQ ID NO: 155 is an exemplary Cas13d protein sequence from contig OGZC01000639.1 (human gut metagenome assembly).

[0340] SEQ ID NOs: 156-177 are exemplary consensus DR nucleic acid sequences (paired with SEQ ID NO: 155).

[0341] SEQ ID NO: 158 is an exemplary Cas13d protein sequence from contig emb|OHBM01000764.1 (human gut metagenome assembly).

[0342] SEQ ID NO: 159 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 158).

[0343] SEQ ID NO: 160 is an exemplary Cas13d protein sequence from contig emb|0HCP01000044.1 (human gut metagenome assembly).

[0344] SEQ ID NO: 161 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 160).

[0345] SEQ ID NO: 162 is an exemplary Cas13d protein sequence from contig embl0GDF01008514.1| (human gut metagenome assembly).

[0346] SEQ ID NO: 163 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 162).

[0347] SEQ ID NO: 164 is an exemplary Cas13d protein sequence from contig emb|0GPN01002610.1 (human gut metagenome assembly).

[0348] SEQ ID NO: 165 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 164).

[0349] SEQ ID NO: 166 is an exemplary Cas13d protein sequence from contig NFIR01000008.1 (Eubacterium sp. An3, from the chicken gut metagenome).

[0350] SEQ ID NO: 167 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 166).

[0351] SEQ ID NO: 168 is an exemplary Cas13d protein sequence from contig NFLV01000009.1 (Eubacterium sp. An11, from the chicken gut metagenome).

[0352] SEQ ID NO: 169 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 168).

[0353] SEQ ID NOs: 171-174 are exemplary Cas13d motif sequences.

[0354] SEQ ID NO: 175 is an exemplary Cas13d protein sequence from contig OJMM01002900 human gut metagenomic sequence.

[0355] SEQ ID NO: 176 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 175).

[0356] SEQ ID NO: 177 is an exemplary Cas13d protein sequence from the contig ODAI011611274.1 gut metagenomic sequence.

[0357] SEQ ID NO: 178 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 177).

[0358] SEQ ID NO: 179 is an exemplary Cas13d protein sequence from contig OIZX01000427.1.

[0359] SEQ ID NO: 180 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 179).

[0360] SEQ ID NO: 181 is an exemplary Cas13d protein sequence from contig emb|OCVV012889144.1|.

[0361] SEQ ID NO: 182 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 181).

[0362] SEQ ID NO: 183 is an exemplary Cas13d protein sequence from contig OCTW011587266.1

[0363] SEQ ID NO: 184 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 183).

[0364] SEQ ID NO: 185 is an exemplary Cas13d protein sequence from contig emb|OGNFO 1009141.1.

[0365] SEQ ID NO: 186 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 185).

[0366] SEQ ID NO: 187 is an exemplary Cas13d protein sequence from contig emb|OIEN01002l96.1.

[0367] SEQ ID NO: 188 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 187).

[0368] SEQ ID NO: 189 is an exemplary Cas13d protein sequence from contig e-k87_11092736.

[0369] SEQ ID NOs: 190-193 are exemplary consensus DR nucleic acid sequences (paired with SEQ ID NO: 189).

[0370] SEQ ID NO: 194 is an exemplary Cas13d sequence from Gut_metagenome_contig6893000291.

[0371] SEQ ID NOs: 195-197 are exemplary Cas13d motif sequences.

[0372] SEQ ID NO: 198 is an exemplary Cas13d protein sequence from Ga0224415_10007274.

[0373] SEQ ID NO: 199 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 198).

[0374] SEQ ID NO: 200 is an exemplary Cas13d protein sequence from EMG_l0003641.

[0375] SEQ ID NO: 202 is an exemplary Cas13d protein sequence from Ga0129306_1000735.

[0376] SEQ ID NO:201 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:200).

[0377] SEQ ID NO: 202 is an exemplary Cas13d protein sequence from Ga0129306_1000735.

[0378] SEQ ID NO: 203 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 203

[0379] SEQ ID NO: 204 is an exemplary Cas13d protein sequence from GaO129317_1008067.

[0380] SEQ ID NO:205 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:204).

[0381] SEQ ID NO: 206 is an exemplary Cas13d protein sequence from Ga0224415_10048792.

[0382] SEQ ID NO:207 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:206).

[0383] SEQ ID NO: 208 is an exemplary Cas13d protein sequence from 160582958_gene49834.

[0384] SEQ ID NO: 209 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 208).

[0385] SEQ ID NO: 210 is an exemplary Cas13d protein sequence from 250twins_35838_GL0110300.

[0386] SEQ ID NO:211 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:210).

[0387] SEQ ID NO: 212 is an exemplary Cas13d protein sequence from 250twins_36050_GLOI58985.

[0388] SEQ ID NO:213 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:212).

[0389] SEQ ID NO: 214 is an exemplary Cas13d protein sequence from 31009_GL0034153.

[0390] SEQ ID NO:215 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:214).

[0391] SEQ ID NO: 216 is an exemplary Cas13d protein sequence from 530373_GL0023589.

[0392] SEQ ID NO:217 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:216).

[0393] SEQ ID NO: 218 is an exemplary Cas13d protein sequence from BMZ-1 1B_GL0037771.

[0394] SEQ ID NO:219 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:218).

[0395] SEQ ID NO: 220 is an exemplary Cas13d protein sequence from BMZ-1 1B_GL0037915.

[0396] SEQ ID NO: 221 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 220).

[0397] SEQ ID NO: 222 is an exemplary Cas13d protein sequence from BMZ-1 1B_GL006961 7.

[0398] SEQ ID NO:223 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:222).

[0399] SEQ ID NO: 224 is an exemplary Cas13d protein sequence from DLF014_GL0011914.

[0400] SEQ ID NO: 225 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 224).

[0401] SEQ ID NO: 226 is an exemplary Cas13d protein sequence from EYZ-362B_GL0088915.

[0402] SEQ ID NOs:227-228 are exemplary consensus DR nucleic acid sequences (paired with SEQ ID NO:226).

[0403] SEQ ID NO: 229 is an exemplary Cas13d protein sequence from Ga0099364 10024192.

[0404] SEQ ID NO: 230 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 229).

[0405] SEQ ID NO: 231 is an exemplary Cas13d protein sequence from Ga0187910_10006931.

[0406] SEQ ID NO: 232 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 231).

[0407] SEQ ID NO: 233 is an exemplary Cas13d protein sequence from Ga0187910_10015336.

[0408] SEQ ID NO:234 ​​is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:233).

[0409] SEQ ID NO: 235 is an exemplary Cas13d protein sequence from Ga0187910_10040531.

[0410] SEQ ID NO:236 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:23).

[0411] SEQ ID NO: 237 is an exemplary Cas13d protein sequence from Ga0187911_10069260.

[0412] SEQ ID NO:238 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:237).

[0413] SEQ ID NO: 239 is an exemplary Cas13d protein sequence from MH0288_GL0082219.

[0414] SEQ ID NO:240 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:239).

[0415] SEQ ID NO: 241 is an exemplary Cas13d protein sequence from O2.UC29-0_GL0096317.

[0416] SEQ ID NO:242 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:241).

[0417] SEQ ID NO: 243 is an exemplary Cas13d protein sequence from PIG-014_GL0226364.

[0418] SEQ ID NO:244 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:243).

[0419] SEQ ID NO: 245 is an exemplary Cas13d protein sequence from PIG-018_GL0023397.

[0420] SEQ ID NO:246 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:245).

[0421] SEQ ID NO: 247 is an exemplary Cas13d protein sequence from PIG-025_GL0099734.

[0422] SEQ ID NO:248 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:247).

[0423] SEQ ID NO: 249 is an exemplary Cas13d protein sequence from PIG-028_GL0185479.

[0424] SEQ ID NO: 250 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 249).

[0425] SEQ ID NO: 251 is an exemplary Cas13d protein sequence from -Ga0224422_10645759.

[0426] SEQ ID NO: 252 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO: 251).

[0427] SEQ ID NO: 253 is an exemplary Cas13d protein sequence from the ODAI chimera.

[0428] SEQ ID NO:254 is an exemplary consensus DR nucleic acid sequence (paired with SEQ ID NO:253).

[0429] SEQ ID NO: 255 is the HEPN motif.

[0430] SEQ ID NOs: 256 and 257 are exemplary Cas13d nuclear localization signal amino acid and nucleic acid sequences, respectively.

[0431] SEQ ID NOs:258 and 260 are exemplary SV40 large T antigen nuclear localization signal amino acid and nucleic acid sequences, respectively.

[0432] SEQ ID NO: 259 is the dCas9 target sequence.

[0433] SEQ ID NO: 261 is an artificial Eubacterium siraeum nCasl array targeting ccdB.

[0434] SEQ ID NO: 262 is a perfect 36 nt direct repeat.

[0435] SEQ ID NOs: 263 to 266 are spacer sequences.

[0436] SEQ ID NO: 267 is an artificial uncultured Ruminoccus sp. nCasl array targeting ccdB.

[0437] SEQ ID NO: 268 is a perfect 36 nt direct repeat.

[0438] SEQ ID NOs: 269 to 272 are spacer sequences.

[0439] SEQ ID NO: 273 is the ccdB target RNA sequence.

[0440] SEQ ID NOs: 274 to 277 are spacer sequences.

[0441] SEQ ID NO: 278 is a mutant Cas13d sequence, NLS-Ga_053l(trunc)-NLS-HA. This mutant has a non-conserved N-terminal deletion.

[0442] SEQ ID NO: 279 is a mutant Cas13d sequence, NES-Ga_053l(trunc)-NES-HA. This mutant has a non-conserved N-terminal deletion.

[0443] SEQ ID NO: 280 is the full-length Cas13d sequence, NLS-RfxCas13d-NLS-HA.

[0444] SEQ ID NO: 281 is the mutant Cas13d sequence NLS-RfxCas13d(del5)-NLS-HA. This mutant has a deletion of amino acids 558-587.

[0445] SEQ ID NO: 282 is the mutant Cas13d sequence, NLS-RfxCas13d(del5.12)-NLS-HA. This mutant has a deletion of amino acids 558-587 and 953-966.

[0446] SEQ ID NO: 283 is the mutant Cas13d sequence, NLS-RfxCas13d(del5.13)-NLS-HA. This mutant has a deletion of amino acids 376-392 and 558-587.

[0447] SEQ ID NO: 284 is the mutant Cas13d sequence, NLS-RfxCas13d(del5.12+5.13)-NLS-HA. This mutant has deletions of amino acids 376-392, 558-587, and 953-966.

[0448] SEQ ID NO: 285 is the mutant Cas13d sequence NLS-RfxCas13d(dell3)-NLS-HA. This mutant has a deletion of amino acids 376-392.

[0449] SEQ ID NO: 286 is the effector sequence used to edit expression of ADAR2. Amino acids 1-969 are dRfxCas13, aa 970-991 are the NLS sequence, and amino acids 992-1378 are ADAR2DD.

[0450] SEQ ID NO: 287 is an exemplary HIV NES protein sequence.

[0451] SEQ ID NOs: 288-291 are exemplary Cas13d motif sequences.

[0452] SEQ ID NO: 292 is the Cas13d ortholog sequence MH_4866.

[0453] SEQ ID NO: 293 is an exemplary Cas13d protein sequence from 037_-_emblOIZA01000315.ll.

[0454] SEQ ID NO: 294 is an exemplary Cas13d protein sequence from PIG-022 GL0026351.

[0455] SEQ ID NO: 295 is an exemplary Cas13d protein sequence from PIG-046_GL0077813.

[0456] SEQ ID NO: 296 is an exemplary Cas13d protein sequence from pig_chimera.

[0457] SEQ ID NO: 297 is an exemplary nuclease-inactive or inactivated Cas13d (dCas13d) protein sequence from Ruminococcus flavefaciens XPD3002 (CasRx).

[0458] SEQ ID NO: 298 is an exemplary Cas13d protein sequence.

[0459] SEQ ID NO: 299 is an exemplary Cas13d protein sequence from (contig tpg|DJXD01000002.1|; uncultured Ruminococcus assembly from sheep intestinal metagenome, UBA7013).

[0460] SEQ ID NO: 300 is an exemplary Cas13d direct repeat nucleotide sequence from Cas13d (contig tpg|DJXD01000002.1|; uncultured Ruminococcus assembly from sheep intestinal metagenome, UBA7013) (paired with SEQ ID NO: 299).

[0461] SEQ ID NO: 301 is an exemplary Cas13d protein contig emb|OBLI01020244.

[0462] Yan et al. (2018) Mol Cell. 70(2):327-339 (doi: 10.1016 / j.molcel.2018.02.2018) and Konermann et al. (2018) Cell 173(3):665-676 (doi: 10.1016 / j.cell / 2018.02.033) describe the Cas13d protein, both of which are incorporated by reference in their entireties. See also WO Publication Nos. WO2018 / 183403 (CasM, which is Cas13d) and WO2019 / 006471 (Cas13d), which are incorporated by reference in their entireties.

[0463] SEQ ID NO: 586 is an exemplary catalytically inactive Cas13d, referred to as inactivated Cas13d or dCas13d.

[0464] SEQ ID NO: 587 is an exemplary catalytically inactive Cas13d, referred to as inactivated Cas13d or dCas13d.

[0465] SEQ ID NO: 588 is an exemplary catalytically inactive Cas13d, referred to as inactivated Cas13d or dCas13d.

[0466] SEQ ID NO: 589 is an exemplary catalytically inactive Cas13d, referred to as inactivated Cas13d or dCas13d.

[0467] SEQ ID NO: 303 is an exemplary CasM protein from Eubacterium siraeum.

[0468] SEQ ID NO:304 is an exemplary CasM protein from Ruminococcus sp., isolate 2789STDY5834971.

[0469] SEQ ID NO:305 is an exemplary CasM protein from Ruminococcus bicirculans.

[0470] SEQ ID NO: 306 is an exemplary CasM protein from Ruminococcus sp., isolate 2789STDY5608892.

[0471] SEQ ID NO:307 is an exemplary CasM protein from Ruminococcus sp., CAG:57.

[0472] SEQ ID NO:308 is an exemplary CasM protein from Ruminococcus flavefaciens FD-1.

[0473] SEQ ID NO:309 is an exemplary CasM protein from Ruminococcus albus strain KH2T6.

[0474] SEQ ID NO:310 is an exemplary CasM protein from Ruminococcus flavefaciens strain XPD3002.

[0475] SEQ ID NO:311 is an exemplary CasM protein from Ruminococcus sp., isolate 2789STDY5834894.

[0476] SEQ ID NO: 312 is an exemplary RtcB homolog.

[0477] SEQ ID NO: 313 is an exemplary WYL+C-terminal NLS from Eubacterium siraeum.

[0478] SEQ ID NO: 314 is an exemplary WYL+C-terminal NLS from Ruminococcus sp. isolate 2789STDY5834971.

[0479] SEQ ID NO: 315 is an exemplary WYL+C-terminal NLS from Ruminococcus bicirculans.

[0480] SEQ ID NO: 316 is an exemplary WYL+C-terminal NLS from Ruminococcus sp. isolate 2789STDY5608892.

[0481] SEQ ID NO: 317 is an exemplary WYL+C-terminal NLS from Ruminococcus sp. CAG:57.

[0482] SEQ ID NO: 318 is an exemplary WYL+C-terminal NLS from Ruminococcus flavefaciens FD-1.

[0483] SEQ ID NO: 319 is an exemplary WYL+C-terminal NLS from Ruminococcus albus strain KH2T6.

[0484] SEQ ID NO: 320 is an exemplary WYL+C-terminal NLS from Ruminococcus flavefaciens strain XPD3002.

[0485] SEQ ID NO: 321 is an exemplary RtcB+C-terminal NLS from Eubacterium siraeum.

[0486] SEQ ID NO: 322 is an exemplary direct repeat sequence of Ruminococcus flavefaciens XPD3002 Cas13d (CasRx).

[0487] SEQ ID NO: 530 is an exemplary Cas13d nucleic acid sequence, seq198.

[0488] SEQ ID NO: 535 is an exemplary Cas13d nucleic acid sequence, seq179.

[0489] SEQ ID NO: 538 is an exemplary Cas13d nucleic acid sequence, seq42.

[0490] SEQ ID NO:540 is an exemplary Cas13d nucleic acid sequence, seq212.

[0491] SEQ ID NO:537 is an exemplary nucleic acid sequence that encodes an exemplary DR nucleic acid sequence corresponding to SEQ ID NO:538.

[0492]

[0493] Exemplary wild-type Cas13d proteins of the present disclosure can comprise or consist of the amino acid sequence SEQ ID NO: 92 or SEQ ID NO: 298 (Cas13d protein also known as CasRx).

[0494] An exemplary direct repeat sequence of Ruminococcus flavefaciens XPD3002 Cas13d (CasRx) comprises the nucleic acid sequence: AACCCCTACCAACTGGTCGGGGTTTGAAAC (SEQ ID NO: 302). gRNA target sequence

[0495] The compositions of the present disclosure bind to and destroy target sequences in RNA molecules containing pathogenic repeat sequences. In one embodiment, the target RNA contains a sequence motif corresponding to the spacer sequence of a guide RNA corresponding to an RNA-guided RNA-binding protein. In some embodiments, one or more spacer sequences are used to target one or more target sequences. In some embodiments, multiple spacers are used to target multiple target RNAs. Such target RNAs may be different target sites within the same RNA molecule or different target sites within different RNA molecules. The spacer sequence may also target a non-coding RNA. In some embodiments, multiple promoters, e.g., Pol III promoters, can be used to drive multiple spacers within a gRNA to target multiple target RNAs. In one embodiment, degradation of the target RNA or target sequence motif reduces expression of the pathogenic CUG repeat RNA, thereby treating DM1 and / or ameliorating one or more symptoms associated with DM1.

[0496] In some embodiments of the compositions and methods of the present disclosure, the sequence motif of the target RNA is a signature of a disease or disorder.

[0497] The target sequence motifs of the present disclosure may be isolated from or derived from the sequence of a foreign or exogenous sequence found within a genomic sequence and thus translated into the sequence of a foreign or exogenous sequence found within an mRNA molecule of the present disclosure or an RNA sequence of the present disclosure.

[0498] The target sequence motifs of the present disclosure may comprise or consist of a mutation in an endogenous sequence that causes a disease or disorder. The mutation may comprise, consist of, be located near, or be associated with a sequence substitution, inversion, deletion, insertion, translocation, or any combination thereof.

[0499] The target sequence motif of the present disclosure can comprise or consist of a repeat sequence. In some embodiments, the repeat sequence can be associated with microsatellite instability (MSI). MSI at one or more loci is caused by the impairment of the DNA mismatch repair mechanism of the cell of the present disclosure. The hypervariable sequence of DNA can be transcribed into the mRNA of the present disclosure, which comprises a target sequence comprising or consisting of a hypervariable sequence.

[0500] The target sequence motif of the present disclosure may comprise or consist of a biomarker. A biomarker may indicate a risk of developing a disease or disorder. A biomarker may indicate a healthy gene (a determinable low or no risk of developing a disease or disorder). A biomarker may indicate an edited gene. Exemplary biomarkers include, but are not limited to, single nucleotide polymorphisms (SNPs), sequence variations or mutations, epigenetic marks, splice acceptor sites, exogenous sequences, heterologous sequences, and any combination thereof.

[0501] The sequence motifs of the present disclosure may comprise or consist of a secondary, tertiary, or quaternary structure. The secondary, tertiary, or quaternary structure may be endogenous or naturally occurring. The secondary, tertiary, or quaternary structure may be induced or non-naturally occurring. The secondary, tertiary, or quaternary structure may be encoded by an endogenous, exogenous, or heterologous sequence.

[0502] In some embodiments of the compositions and methods of the present disclosure, the target sequence of the RNA molecule comprises or consists of between 2 and 100 nucleotides or nucleic acid bases, including the end points. In some embodiments, the target sequence of the RNA molecule comprises or consists of between 2 and 50 nucleotides or nucleic acid bases, including the end points. In some embodiments, the target sequence of the RNA molecule comprises or consists of between 2 and 20 nucleotides or nucleic acid bases, including the end points. In some embodiments, the target sequence of the RNA molecule comprises or consists of between 20 and 30 nucleotides or nucleic acid bases, including the end points. In some embodiments, the target sequence of the RNA molecule comprises or consists of about 26 nucleotides or nucleic acid bases, including the end points.

[0503] In some embodiments of the compositions and methods of the present disclosure, the target sequence of RNA molecule is continuous.In some embodiments, the target sequence of RNA molecule is not continuous.For example, the target sequence of RNA molecule can comprise or consist of one or more nucleotides or nucleic acid bases that are not continuous due to one or more intermittent nucleotides located between the nucleotides of target sequence.

[0504] In some embodiments of the compositions and methods of the present disclosure, the target sequence of the RNA molecule is naturally occurring.In some embodiments, the target sequence of the RNA molecule is not naturally occurring.Exemplary non-naturally occurring target sequences can comprise or consist of sequence variations or mutations, chimeric sequences, exogenous sequences, heterologous sequences, chimeric sequences, recombinant sequences, sequences that contain modified or synthetic nucleotides, or any combination thereof.

[0505] In some embodiments of the compositions and methods of the present disclosure, the target sequence of the RNA molecule is bound to the guide RNA of the present disclosure. In some embodiments of the compositions and methods of the present disclosure, one or more target sequences of the RNA molecule are bound to one or more guide RNA spacer sequences of the present disclosure.

[0506] In some embodiments of the compositions and methods of the present disclosure, a target sequence of an RNA molecule binds to a first RNA binding protein of the present disclosure.

[0507] In some embodiments of the compositions and methods of the present disclosure, the target sequence of the RNA molecule binds to a second RNA binding protein of the present disclosure.

[0508] The compositions of the present disclosure include a gRNA comprising a spacer sequence that specifically binds to a target toxic CUG RNA repeat sequence. In some embodiments, the spacer that binds to the target CUG RNA repeat sequence comprises or consists of about 20 to 30 nucleotides. In some embodiments, the gRNA comprises one or more spacer sequences.

[0509] Exemplary gRNA spacer sequences of the present disclosure that specifically bind to a target CUG sequence of an RNA molecule are shown in SEQ ID NOs: 457-459. Endonuclease

[0510] In some embodiments, the composition of the present disclosure comprises a second RNA-binding protein comprising or consisting of a nuclease or endonuclease domain. In some embodiments, the second RNA-binding protein is an effector protein. In some embodiments, the second RNA-binding protein binds to RNA in a manner that associates with RNA. In some embodiments, the second RNA-binding protein associates with RNA in a manner that cleaves RNA. In some embodiments, the second RNA-binding protein is fused with a first RNA-binding protein that is a PUF, PUMBY, or PPR-based protein. In one embodiment, the second RNA-binding protein is fused with a first RNA-binding protein that is an inactivated Cas-based (dCas-based) protein.

[0511] In some embodiments of the compositions of the present disclosure, the second RNA binding protein comprises or consists of an RNAse.

[0512] In some embodiments, the second RNA binding protein comprises or consists of RNAse 1. In some embodiments, the RNAse 1 protein comprises or consists of SEQ ID NO: 325.

[0513] In some embodiments, the second RNA binding protein comprises or consists of RNase 4. In some embodiments, the RNase 4 protein comprises or consists of SEQ ID NO:326.

[0514] In some embodiments, the second RNA binding protein comprises or consists of RNase 6. In some embodiments, the RNase 6 protein comprises or consists of SEQ ID NO:327.

[0515] In some embodiments, the second RNA binding protein comprises or consists of RNase 7. In some embodiments, the RNase 7 protein comprises or consists of SEQ ID NO:328.

[0516] In some embodiments, the second RNA binding protein comprises or consists of RNase 8. In some embodiments, the RNase 8 protein comprises or consists of SEQ ID NO:329.

[0517] In some embodiments, the second RNA binding protein comprises or consists of RNase 2. In some embodiments, the RNase 2 protein comprises or consists of SEQ ID NO: 330.

[0518] In some embodiments, the second RNA binding protein comprises or consists of RNase6PL. In some embodiments, the RNase6PL protein comprises or consists of SEQ ID NO:331.

[0519] In some embodiments, the second RNA binding protein comprises or consists of RNase L. In some embodiments, the RNase L protein comprises or consists of SEQ ID NO: 332.

[0520] In some embodiments, the second RNA binding protein comprises or consists of RNase T2. In some embodiments, the RNase T2 protein comprises or consists of SEQ ID NO: 333.

[0521] In some embodiments, the second RNA binding protein comprises or consists of RNase 11. In some embodiments, the RNase 11 protein comprises or consists of SEQ ID NO:334.

[0522] In some embodiments, the second RNA binding protein comprises or consists of RNase T2-like. In some embodiments, the RNase T2-like protein comprises or consists of SEQ ID NO: 335.

[0523] In some embodiments of the compositions of the present disclosure, the second RNA binding protein is a mutant RNase.

[0524] In some embodiments, the second RNA binding protein comprises or consists of a mutant RNase 1 (RNase 1(K41R)) polypeptide. In some embodiments, the RNase 1(K41R) polypeptide comprises or consists of SEQ ID NO: 336.

[0525] In some embodiments, the second RNA binding protein comprises or consists of a mutant RNase 1 (RNase 1(K41R, D121E)) polypeptide. In some embodiments, the RNase 1 (RNase 1(K41R, D121E)) polypeptide comprises or consists of SEQ ID NO: 337.

[0526] In some embodiments, the second RNA binding protein comprises or consists of a mutant RNase 1 (RNase 1(K41R, D121E, H119N)) polypeptide. In some embodiments, the RNase 1 (RNase 1(K41R, D121E, H119N)) polypeptide comprises or consists of SEQ ID NO: 338.

[0527] In some embodiments, the second RNA binding protein comprises or consists of a mutant RNase 1. In some embodiments, the second RNA binding protein comprises or consists of a mutant RNase 1 (RNase 1(H119N)) polypeptide. In some embodiments, the RNase 1 (RNase 1(H119N)) polypeptide comprises or consists of SEQ ID NO: 339.

[0528] In some embodiments, the second RNA binding protein comprises or consists of a mutant RNase 1 (RNase 1 (R39D, N67D, N88A, G89D, R91D, H119N)) polypeptide.

[0529] In some embodiments, the RNase 1 (RNase 1 (R39D, N67D, N88A, G89D, R91D, H119N)) polypeptide comprises or consists of SEQ ID NO: 340.

[0530] In some embodiments, the second RNA binding protein comprises or consists of a mutant RNase 1 (RNase 1 (R39D, N67D, N88A, G89D, R91D, H119N)) polypeptide. In some embodiments, the RNase 1 (RNase 1 (R39D, N67D, N88A, G89D, R91D, H119N, K41R, D121E)) polypeptide comprises or consists of SEQ ID NO: 341. In some embodiments, the second RNA binding protein comprises or consists of a mutant RNase 1 (RNase 1 (R39D, N67D, N88A, G89D, R91D, H119N)) polypeptide. In some embodiments, the RNase 1 (RNase 1 (R39D, N67D, N88A, G89D, R91D)) polypeptide comprises or consists of SEQ ID NO: 342. In some embodiments, the second RNA binding protein is a mutant RNase 1 (RNase 1 (R39D, N67D, N88A, G89D, R91D, H119N, K41R, D121E)) polypeptide comprising or consisting of SEQ ID NO: 343.

[0531] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a NOB1 polypeptide. In some embodiments, the NOB1 polypeptide comprises or consists of SEQ ID NO: 344.

[0532] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of an endonuclease. In some embodiments, the second RNA-binding protein comprises or consists of endonuclease V (ENDOV). In some embodiments, the ENDOV protein comprises or consists of SEQ ID NO: 345.

[0533] In some embodiments, the second RNA binding protein comprises or consists of endonuclease G (ENDOG). In some embodiments, the ENDOG protein comprises or consists of SEQ ID NO:346.

[0534] In some embodiments, the second RNA-binding protein comprises or consists of endonuclease D1 (ENDOD1). In some embodiments, the ENDOD1 protein comprises or consists of SEQ ID NO:347.

[0535] In some embodiments, the second RNA binding protein comprises or consists of human flap endonuclease-1 (hFEN1). In some embodiments, the hFEN1 polypeptide comprises or consists of SEQ ID NO:348.

[0536] In some embodiments, the second RNA binding protein comprises or consists of a DNA repair endonuclease XPF (ERCC4) polypeptide. In some embodiments, the ERCC4 polypeptide comprises or consists of SEQ ID NO: 349.

[0537] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of an endonuclease III-like protein 1 (NTHL) polypeptide. In some embodiments, the NTHL polypeptide comprises or consists of SEQ ID NO: 340.

[0538] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a human Schlafen14 (hSLFN14) polypeptide. In some embodiments, the hSLFN14 polypeptide comprises or consists of SEQ ID NO: 351.

[0539] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a human beta-lactamase-like protein 2 (hLACTB2) polypeptide. In some embodiments, the hLACTB2 polypeptide comprises or consists of SEQ ID NO: 352.

[0540] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of an apurinic / apyrimidinic (AP) endodeoxyribonuclease (APEX) polypeptide. In some embodiments, the second RNA-binding protein comprises or consists of an apurinic / apyrimidinic (AP) endodeoxyribonuclease (APEX2) polypeptide. In some embodiments, the APEX2 polypeptide comprises or consists of SEQ ID NO: 353.

[0541] In some embodiments, the APEX2 polypeptide comprises or consists of SEQ ID NO:354.

[0542] In some embodiments, the second RNA-binding protein comprises or consists of an apurinic or apyrimidinic site lyase (APEX1) polypeptide. In some embodiments, the APEX1 polypeptide comprises or consists of SEQ ID NO: 355.

[0543] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of an angiogenin (ANG) polypeptide. In some embodiments, the ANG polypeptide comprises or consists of SEQ ID NO: 356.

[0544] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a heat-responsive protein 12 (HRSP12) polypeptide. In some embodiments, the HRSP12 polypeptide comprises or consists of SEQ ID NO: 357.

[0545] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a zinc finger CCCH-type, 12A-containing (ZC3H12A) polypeptide. In some embodiments, the Z3H12A polypeptide is an endonuclease domain of a polypeptide, which comprises or consists of SEQ ID NO: 358, also referred to herein as E17. In some embodiments, the ZC3H12A polypeptide comprises or consists of SEQ ID NO: 359.

[0546] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a reactive intermediate imine deaminase A (RIDA) polypeptide. In some embodiments, the RIDA polypeptide comprises or consists of SEQ ID NO: 360.

[0547] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a phospholipase D family member 6 (PDL6) polypeptide. In some embodiments, the PDL6 polypeptide comprises or consists of SEQ ID NO: 361.

[0548] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a mitochondrial ribonuclease P catalytic subunit (KIAA0391) polypeptide. In some embodiments, the KIAA0391 polypeptide comprises or consists of SEQ ID NO: 362.

[0549] In some embodiments of the compositions of the present disclosure, the second RNA binding protein comprises or consists of an Argonaute 2 (AGO2) polypeptide. In some embodiments of the compositions of the present disclosure, the AGO2 polypeptide comprises or consists of SEQ ID NO:363.

[0550] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a mitochondrial nuclease EXOG (EXOG) polypeptide. In some embodiments, the EXOG polypeptide comprises or consists of SEQ ID NO: 364.

[0551] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a zinc finger CCCH-type, 12D-containing (ZC3H12D) polypeptide. In some embodiments, the ZC3H12D polypeptide comprises or consists of SEQ ID NO: 365.

[0552] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of an endoplasmic reticulum-nuclear signaling 2 (ERN2) polypeptide. In some embodiments, the ERN2 polypeptide comprises or consists of SEQ ID NO: 366.

[0553] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a Pelota mRNA survival and ribosome rescue factor (PELO) polypeptide. In some embodiments, the PELO polypeptide comprises or consists of SEQ ID NO: 367.

[0554] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a YBEY metallopeptidase (YBEY) polypeptide. In some embodiments, the YBEY polypeptide comprises or consists of SEQ ID NO: 368.

[0555] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a cleavage and polyadenylation specificity factor 4-like (CPSF4L) polypeptide. In some embodiments, the CPSF4L polypeptide comprises or consists of SEQ ID NO: 369.

[0556] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of an hCG_2002731 polypeptide. In some embodiments, the hCG_2002731 polypeptide comprises or consists of SEQ ID NO: 370.

[0557] In some embodiments, the hCG_2002731 polypeptide comprises or consists of SEQ ID NO:371.

[0558] In some embodiments of the compositions of the present disclosure, the second RNA binding protein comprises or consists of an excision repair reciprocal complementation group 1 (ERCC1) polypeptide. In some embodiments, the ERCC1 polypeptide comprises or consists of SEQ ID NO: 372.

[0559] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a ras-related C3 botulinum toxin substrate 1 isoform (RAC1) polypeptide. In some embodiments, the RAC1 polypeptide comprises or consists of SEQ ID NO: 373.

[0560] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a ribonuclease AA1 (RAA1) polypeptide. In some embodiments, the RAA1 polypeptide comprises or consists of SEQ ID NO: 374.

[0561] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a Ras-associated protein (RAB1) polypeptide. In some embodiments, the RAB1 polypeptide comprises or consists of SEQ ID NO: 375.

[0562] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a DNA replicative helicase / nuclease 2 (DNA2) polypeptide. In some embodiments, the DNA2 polypeptide comprises or consists of SEQ ID NO: 376.

[0563] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a FLJ35220 polypeptide. In some embodiments, the FLJ35220 polypeptide comprises or consists of SEQ ID NO: 377.

[0564] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a FLJ13173 polypeptide. In some embodiments, the FLJ13173 polypeptide comprises or consists of SEQ ID NO: 378.

[0565] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a Teneurin transmembrane protein (TENM) polypeptide. In some embodiments, the second RNA-binding protein comprises or consists of a Teneurin transmembrane protein 1 (TENM1) polypeptide. In some embodiments, the TENM1 polypeptide comprises or consists of SEQ ID NO: 379. In some embodiments, the second RNA-binding protein comprises or consists of a Teneurin transmembrane protein 2 (TENM2) polypeptide. In some embodiments, the TENM2 polypeptide comprises or consists of SEQ ID NO: 380. In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a ribonuclease Kappa (RNase K) polypeptide. In some embodiments, the RNase K polypeptide comprises or consists of SEQ ID NO: 381.

[0566] In some embodiments of the composition of the present disclosure, the second RNA binding protein comprises or consists of a transcription activator-like effector nuclease (TALEN) polypeptide or its nuclease domain.In some embodiments, the TALEN polypeptide comprises or consists of SEQ ID NO: 382.In some embodiments, the TALEN polypeptide comprises or consists of SEQ ID NO: 383.

[0567] In some embodiments of the composition of the present disclosure, the second RNA binding protein comprises or consists of a zinc finger nuclease polypeptide or its nuclease domain.In some embodiments, the second RNA binding protein comprises or consists of a ZNF638 polypeptide or its nuclease domain.In some embodiments, the ZNF638 polypeptide comprises or consists of SEQ ID NO: 384.

[0568] In some embodiments of the compositions of the present disclosure, the second RNA-binding protein comprises or consists of a PIN domain from the human SMG6 protein, also commonly known as telomerase-binding protein EST1A isoform 3, NCBI Reference Sequence: NP_001243756.1. In some embodiments, for example and without limitation, PIN from hSMG6 is used herein as an internal control in the form of a Cas fusion protein. In some embodiments, the PIN polypeptide comprises or consists of SEQ ID NO: 598.

[0569]

[0570] In some embodiments of the composition of the present disclosure, the composition further comprises (a) a sequence comprising a gRNA that specifically binds to the interior of the RNA molecule, and (b) a sequence encoding a nuclease. In some embodiments, the nuclease comprises a sequence isolated from or derived from a CRISPR / Cas protein. In some embodiments, the nuclease comprises a sequence isolated from or derived from a TALEN or its nuclease domain. In some embodiments, the nuclease comprises a sequence isolated from or derived from a zinc finger nuclease or its nuclease domain. AAV vectors

[0571] As used herein, "AAV vector" refers to a vector that comprises, consists essentially of, or consists of one or more nucleic acid molecules and one or more AAV inverted terminal repeats (ITRs). In some embodiments, the nucleic acid molecule encodes a CAG repeat-targeting protein and / or composition of the present disclosure. Such an AAV vector can be replicated and packaged into infectious viral particles when present in a host cell that provides the function of the rep and cap gene products, for example, by transfection into the host cell. In some embodiments, the AAV vector contains a promoter, at least one nucleic acid that can encode at least one protein or RNA, and / or an enhancer and / or terminator within the flanking ITRs that are packaged into infectious AAV particles. The encapsidated nucleic acid portion may be referred to as the AAV vector genome. A plasmid containing an AAV vector may also contain manufacturing elements, such as antibiotic resistance genes, origin of replication sequences, etc., but these are not encapsidated and therefore do not form part of the AAV particle.

[0572] In some embodiments, the AAV vector may comprise at least one nucleic acid molecule encoding the CUG repeat-targeting composition of the present disclosure. In some embodiments, the AAV vector may comprise at least one regulatory sequence. In some embodiments, the AAV vector may comprise at least one AAV inverted terminal repeat (ITR) sequence. In some embodiments, the AAV vector may comprise a first ITR sequence and a second ITR sequence. In some embodiments, the AAV vector may comprise at least one promoter sequence. In some embodiments, the AAV vector may comprise at least one enhancer sequence. In some embodiments, the AAV vector may comprise at least one polyA sequence. In some embodiments, the AAV vector may comprise at least one linker sequence. In some embodiments, the AAV vector of the present disclosure may comprise at least one nuclear localization signal. In some embodiments, the AAV vector of the present disclosure may comprise a CUG repeat-targeting PUF or PUMBY protein, peptide, or fragment thereof. In some embodiments, the AAV vector of the present disclosure may comprise a Cas protein, peptide, or fragment thereof. In some embodiments, the AAV vector of the present disclosure may comprise an endonuclease protein, peptide, or fragment thereof. In some embodiments, the AAV vector of the present disclosure may comprise a guide RNA, in some cases a CUG repeat-targeting guide RNA. In some embodiments, the AAV vector of the present disclosure may comprise a fusion protein comprising one or more elements of the present disclosure, including, but not limited to, a CUG repeat-targeting protein (e.g., Cas, PUF, or PUMBY) and an endonuclease. Optionally, the fusion protein of the AAV vector may further comprise a linker amino acid sequence between one or more elements of the present disclosure.

[0573] In some embodiments, the AAV vector may comprise a first AAV ITR sequence, a promoter sequence, a CUG repeat-targeting composition nucleic acid molecule, a regulatory sequence, and a second AAV ITR sequence. In some embodiments, the AAV vector may comprise, from 5' to 3', a first AAV ITR sequence, a promoter sequence, a transgene nucleic acid molecule, and a second AAV ITR sequence. CUG-targeting Cas13d vector

[0574] In some embodiments of the compositions of the present disclosure, the CUG-targeted Cas13d compositions are packaged as AAV unitary vectors. In some embodiments, the CUG-targeted Cas13d compositions packaged as AAV unitary vectors are set forth in SEQ ID NOs: 518, 528, 534, 536, and 539.

[0575] In some embodiments, the CUG-targeting Cas13d composition comprises, from 5' to 3': a human U6 promoter, a Cas13d gRNA (wherein the gRNA comprises a direct repeat sequence and a CUG-targeting spacer sequence), an EFS promoter, a Kozak sequence, an SV40 NLS sequence, a linker sequence, a Cas13d-encoding sequence, a linker sequence, an SV40 NLS sequence, a linker sequence, an HA tag sequence, and a BGH sequence. In some embodiments, the nucleic acid encoding the CUG-targeting Cas13d composition is set forth in SEQ ID NO: 518. In some embodiments, the CUG-targeting Cas13d composition is sequenced as depicted in Table 3.

[0576] [Table 3-1] [Table 3-2]

[0577] In some embodiments, the AAV vector comprising the CUG-targeting Cas13d composition comprises, from 5' to 3': a human U6 promoter, a Cas13d gRNA (where the gRNA comprises a direct repeat sequence and a CUG-targeting spacer sequence), an EFS promoter, a Kozak sequence, a Cas13d encoding sequence, a linker sequence, an SV40 NLS sequence, and an SV40 poly(a) sequence. In some embodiments, the nucleic acid encoding the CUG-targeting Cas13d composition is set forth in SEQ ID NO: 528. In some embodiments, the CUG-targeting Cas13d composition is arranged as depicted in Table 4.

[0578] [Table 4-1] [Table 4-2]

[0579] In some embodiments, the AAV vector comprising the CUG-targeting Cas13d composition comprises, from 5' to 3': a human U6 promoter, a Cas13d gRNA (where the gRNA comprises a direct repeat sequence and a CUG-targeting spacer sequence), an EFS promoter, a Kozak sequence, a Cas13d encoding sequence, a linker sequence, an SV40 NLS sequence, and an SV40 poly(a) sequence. In some embodiments, the nucleic acid encoding the CUG-targeting Cas13d composition is set forth in SEQ ID NO: 534. In some embodiments, the CUG-targeting Cas13d composition is arranged as depicted in Table 5.

[0580] [Table 5-1] [Table 5-2]

[0581] In some embodiments, the AAV vector comprising the CUG-targeting Cas13d composition comprises, from 5' to 3': a human U6 promoter, a Cas13d gRNA (where the gRNA comprises a direct repeat sequence and a CUG-targeting spacer sequence), an EFS promoter, a Kozak sequence, a Cas13d encoding sequence, a linker sequence, an SV40 NLS sequence, and an SV40 poly(a) sequence. In some embodiments, the nucleic acid encoding the CUG-targeting Cas13d composition is set forth in SEQ ID NO: 536. In some embodiments, the CUG-targeting Cas13d composition is arranged as depicted in Table 6.

[0582] [Table 6-1] [Table 6-2]

[0583]

[0584] In some embodiments, the AAV vector comprising the CUG-targeting Cas13d composition comprises, from 5' to 3': a human U6 promoter, a Cas13d gRNA (where the gRNA comprises a direct repeat sequence and a CUG-targeting spacer sequence), an EFS promoter, a Kozak sequence, a Cas13d encoding sequence, a linker sequence, an SV40 NLS sequence, and an SV40 poly a sequence. In some embodiments, the nucleic acid encoding the CUG-targeting Cas13d composition is set forth in SEQ ID NO: 539. In some embodiments, the CUG-targeting Cas13d composition is sequenced as depicted in Table 7.

[0585] [Table 7-1] [Table 7-2]

[0586] In some embodiments, the nucleic acid sequence encoding the CUG-targeting Cas13d protein of the present disclosure is a codon-optimized nucleic acid sequence. In some embodiments, the codon-optimized sequence encoding the CUG-targeting Cas13d protein exhibits at least a 5%, at least a 10%, at least a 20%, at least a 30%, at least a 50%, at least a 75%, at least a 100%, at least a 200%, at least a 300%, at least a 500%, or at least a 1000% increase in translation in a human subject compared to a wild-type or non-codon-optimized nucleic acid sequence.

[0587] In some aspects, codon-optimized nucleic acid sequences encoding CUG-targeted Cas13d proteins, such as those set forth in SEQ ID NOs: 518, 528, 534, 536, and 539, exhibit increased stability. In some aspects, codon-optimized nucleic acid sequences encoding CUG-targeted Cas13d proteins exhibit increased stability due to increased resistance to hydrolysis. In some embodiments, codon-optimized sequences encoding CUG-targeted Cas13d proteins exhibit at least a 5%, at least a 10%, at least a 20%, at least a 30%, at least a 50%, at least a 75%, at least a 100%, at least a 200%, at least a 300%, at least a 500%, or at least a 1000% increase in stability compared to wild-type or non-codon-optimized nucleic acid sequences. In some embodiments, the codon-optimized sequence encoding the CUG-targeting Cas13d protein exhibits at least a 5%, at least a 10%, at least a 20%, at least a 30%, at least a 50%, at least a 75%, at least a 100%, at least a 200%, at least a 300%, at least a 500%, or at least a 1000% increase in hydrolysis resistance compared to a wild-type or non-codon-optimized nucleic acid sequence in a human subject.

[0588] In some embodiments, a codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein, such as those set forth in SEQ ID NOs: 518, 528, 534, 536, and 539, may contain no donor splice sites. In some embodiments, a codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein may contain no more than about one, or about two, or about three, or about four, or about five, or about six, or about seven, or about eight, or about nine, or about ten donor splice sites. In some embodiments, a codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein contains at least one, or at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten fewer donor splice sites compared to a non-codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein.

[0589] Without wishing to be bound by theory, the removal of donor splice sites in codon-optimized nucleic acid sequences can unexpectedly and unpredictably increase the expression of CUG-targeted Cas13d proteins in vivo, since cryptic splicing is prevented. Furthermore, cryptic splicing can vary between subjects, which means that the expression level of CUG-targeted Cas13d proteins containing donor splice sites can vary unpredictably between subjects. For human treatment, such unpredictability is unacceptable. Accordingly, the codon-optimized nucleic acid sequences represented by SEQ ID NOs: 518, 528, 534, 536 and 539, which lack donor splice sites, unexpectedly and surprisingly, can increase the expression of CUG-targeted Cas13d proteins in human subjects, and regulate the expression of CUG-targeted Cas13d proteins across different human subjects.

[0590] In some embodiments, a codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein, such as those set forth in SEQ ID NOs: 518, 528, 534, 536, and 539, may have a GC content that differs from the GC content of a non-codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein. In some embodiments, the GC content of a codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein is more evenly distributed throughout the nucleic acid sequence compared to a non-codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein.

[0591] Without wishing to be bound by theory, by distributing GC content more evenly throughout the nucleic acid sequence, codon-optimized nucleic acid sequences exhibit a more uniform melting temperature ("Tm") across the transcript length. Uniformity in melting temperature unexpectedly results in increased expression of the codon-optimized nucleic acid in human subjects, as transcription and / or translation of the nucleic acid sequence occurs with less stalling of polymerases and / or ribosomes.

[0592] In some embodiments, a codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein, such as those set forth in SEQ ID NOs: 518, 528, 534, 536, and 539, may have fewer inhibitory microRNA target binding sites compared to a non-codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein. In some embodiments, a codon-optimized nucleic acid sequence encoding a CUG-targeted Cas13d protein may have at least one, or at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten, or at least ten fewer inhibitory microRNA target binding sites compared to a non-codon-optimized nucleic acid sequence, CUG-targeted Cas13d protein.

[0593] Without wishing to be bound by theory, by having fewer inhibitory microRNA target binding sites, codon-optimized nucleic acid sequences encoding CUG-targeting Cas13d proteins unexpectedly exhibit increased expression in human subjects. fusion proteins

[0594] In some embodiments of the compositions and methods of the present disclosure, the composition comprises a sequence encoding a target RNA-binding fusion protein comprising (a) a sequence encoding a first RNA-binding polypeptide, or a portion thereof, and optionally (b) a sequence encoding a second RNA-binding polypeptide, wherein the first RNA-binding polypeptide binds to the target RNA and the second RNA-binding polypeptide comprises RNA nuclease activity.

[0595] In some embodiments, the target RNA-binding fusion protein is a target RNA-binding fusion protein guided by RNA.The target RNA-binding fusion protein guided by RNA comprises at least one RNA-binding polypeptide corresponding to a gRNA that guides the RNA-binding polypeptide to the target RNA.The target RNA-binding fusion protein guided by RNA includes, but is not limited to, a CRISPR / Cas-based RNA-binding polypeptide or an RNA-binding polypeptide that is a part thereof.

[0596] signal sequence

[0597] In some embodiments, the target RNA-binding fusion protein of the present disclosure comprises a signal sequence. In some embodiments, the target RNA-binding fusion protein comprises one or more signal sequences. In some embodiments, the signal sequence is a nuclear localization sequence (NLS), a nuclear export signal (NES), or a combination thereof. In some embodiments, the signal sequence comprises one or more nuclear localization sequences (NLS). In some embodiments, the one or more NLS sequences comprise a sequence listed in Table 8. In some embodiments, the NLS signal sequence is the SV40 NLS signal sequence. In some embodiments, the SV40 NLS signal sequence is PKKKRKV (SEQ ID NO: 437).

[0598] [Table 8]

[0599] In some embodiments, the signal sequence comprises one or more NES sequences. In some embodiments, the one or more NES sequences comprise a sequence listed in Table 9.

[0600] [Table 9]

[0601] In some embodiments, the target RNA-binding fusion protein of the present disclosure comprises a tag sequence. In some embodiments, the tag sequence is a FLAG tag. In some embodiments, the FLAG tag sequence is DYKDDDDK (SEQ ID NO: 436). Linker sequence

[0602] In some embodiments, the target RNA-binding fusion protein comprises a linker sequence. In some embodiments, the linker sequence can comprise or consist of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or any number of amino acids therebetween. In some embodiments, the linker sequence comprises a linker sequence listed in Table 10.

[0603] [Table 10-1] [Table 10-2] Promoter sequence

[0604] In some aspects, the CUG targeting composition of the present disclosure comprises a promoter sequence. In some embodiments, any promoter disclosed herein can be used in place of any of the other promoters described with respect to the RNA targeting constructs disclosed herein. In some aspects, the CUG targeting composition comprises a truncated CAG (tCAG) promoter (SEQ ID NO: 385). In some aspects, the CUG targeting composition comprises a short EF1-alpha (EFS) promoter set forth in SEQ ID NO: 520. In some aspects, the CUG targeting composition comprises a human U6 promoter as set forth in SEQ ID NO: 519. In some aspects, the CUG targeting composition comprises an EFS-UBB promoter set forth in SEQ ID NO: 609. In some aspects, the CUG targeting composition comprises a muscle-specific promoter. In some aspects, the CUG targeting composition comprises a muscle-specific promoter that is the desmin promoter set forth in SEQ ID NO: 568 (full length), SEQ ID NO: 608 (full length), or SEQ ID NO: 569 (truncated). In some aspects, the CAG targeting composition comprises a synapsin promoter set forth in SEQ ID NO: 619. In some embodiments, the promoter sequence of the present disclosure comprises a human EF1-alpha core promoter (SEQ ID NO: 642). In some embodiments, the promoter sequence of the present disclosure comprises a modified UBB intron (SEQ ID NO: 643). In some embodiments, the promoter sequence of the present disclosure comprises a modified CMV enhancer sequence (SEQ ID NO: 644). In some embodiments, the promoter sequence of the present disclosure comprises an eCMV-EFS-UBB promoter sequence (SEQ ID NO: 645).

[0605] In some embodiments, expression control by the promoter is constitutive or ubiquitous. Non-limiting exemplary promoters include Pol III promoters, such as U6 and H1 promoters, and / or Pol II promoters, such as SV40, CMV (optionally containing a CMV enhancer), RSV (Rous sarcoma virus) LTR promoter (optionally containing a RSV enhancer), CBA (hybrid CMV enhancer / chicken β-actin), CAG (hybrid CMV enhancer fused to chicken β-actin), truncated CAG, Cbh (hybrid CBA), EF-1a (human elongation factor alpha-1), or EFS (short, intronless EF-1 alpha). α), PGK (phosphoglycerol kinase), CEF (chick embryo fibroblast), UBC (ubiquitin C), GUSB (lysosomal enzyme beta-glucuronidase), UCOE (ubiquitous chromatin opening element), hAAT (alpha-1 antitrypsin), TBG (thyroxine-binding globulin), desmin (full length or truncated), MCK (muscle creatine kinase), C5-12 (synthetic muscle promoter), CK8e (creatin kinase 8), NSE (neuronal endothelial cell line) These include IL-1, IL-1, IL-2, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-36, IL-37, IL-38, IL-49, IL-59, IL-60, IL-61, IL-62, IL-70, IL-71, IL-72, IL-73, IL-74, IL-75, IL-76, IL-77, IL-78, IL-79, IL-80, IL-81, IL-82, IL-83, IL-84, IL-85, IL-86, IL-87, IL-88, IL-89, IL-90, IL-91, IL-92, IL-93, IL-94, IL-95, IL-95, IL-96, IL-97, IL-98, IL-99, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-19, IL-19, IL-19, IL-19, IL-104, IL-105, IL-106, IL-107, IL-108, IL-119, IL-129, ILAn "enhancer" is a region of DNA to which an activating protein can bind to increase the likelihood or frequency of transcription. Non-limiting exemplary enhancers and post-transcriptional regulatory elements include the CMV enhancer, the MCK enhancer, the R-U5' segment in the HTLV-1 LTR, the SV40 enhancer, the intron sequence between exons 2 and 3 of rabbit β-globin, and the WPRE. In some embodiments, an intron, such as the UBB intron, is used to enhance promoter activity. In some embodiments, the UBB intron is used in conjunction with the EFS promoter. In some embodiments, an enhancer sequence can be added within the 5' or 3' UTR. In some embodiments, the 5' enhancer is SEQ ID NO: 652: [ka] The Hsp70 may be Hsp70, as shown in Unguided RNA-binding fusion proteins

[0606] In some embodiments, the target RNA-binding fusion protein is not an RNA-guided target RNA-binding fusion protein and therefore includes at least one RNA-binding polypeptide capable of binding to a target RNA that does not have a corresponding gRNA sequence. Such unguided RNA-binding polypeptides include, without limitation, at least one RNA-binding protein or RNA-binding portion thereof that is a PUF (Pumilio and FBF homology family) protein. This type of RNA-binding polypeptide can be used instead of a gRNA-guided RNA-binding protein, such as CRISPR / Cas. The unique RNA recognition mechanisms of PUF proteins (derived from Drosophila Pumilio and C. elegans fem-3 binding factor), which are involved in mediating mRNA stability and translation, are well known in the art. The PUF domain of human Pumilio1, also known in the art, tightly binds to cognate RNA sequences, and its specificity can be modified. The PUF domain of human Pumilio1 contains eight PUF modules that recognize eight consecutive RNA bases, each recognizing a single base. Two amino acid side chains in each module recognize the Watson-Crick ends of corresponding bases, determining the specificity of the module. PUF modules can be designed to specifically bind to RNAs up to 8-16 nt in length. Wang et al., Nat Methods. 2009;6(11):825-830. See also WO2012 / 068627, incorporated herein by reference in its entirety.

[0607] The modular nature of PUF-RNA interactions has been used to rationally engineer the binding specificity of PUF domains (Cheong, CG & Hall, TM (2006) PNAS 103: 13635-13639; Wang, X. et al (2002) Cell 110: 501-512). However, only successful design of PUF domains with modules that recognize adenine, guanine, or uracil has been reported prior to the teachings of WO2012 / 06827, supra. Wild-type PumHD does not bind to cytosine (C), but it has been shown that, through molecular engineering, some of the Pum units can be mutated to bind to C with good yield and specificity. See, for example, Dong, S. et al. Specific and modular binding code for cytosine recognition in Pumilio / FBF (PUF) RNA-binding domains, The Journal of biological chemistry 286, 26732-26742 (2011). Thus, PumHD is a modified version of the WT Pumilio protein that exhibits programmable binding to any eight-base sequence of RNA. Each of the eight units of PumHD can bind to all four RNA bases, and RNA bases flanking the target sequence do not affect binding.See also the following references for art-recognized RNA binding rules for PUF design: Filipovska A, Razif MF, Nygard KK, & Rackham O. A universal code for RNA recognition by PUF proteins. Nature chemical biology, 7(7), 425-427 (2011); Filipovska A, & Rackham O. Modular recognition of nucleic acids by PUF, TALE, and PPR proteins. Molecular BioSystems, 8(3), 699-708 (2012); Abil Z, Denard CA, & Zhao H. Modular assembly of designer PUF proteins for specific post-transcriptional regulation of endogenous RNA. Journal of biological engineering, 8(1), 7 (2014); Zhao Y, Mao M, Zhang W, Wang J, Li H, Yang Y, Wang Z, & Wu J. Expanding RNA binding specificity and affinity of engineered PUF domains. Nucleic Acids Research, 46(9), 4771-4782 (2018);Shinoda K, Tsuji S, Futaki S, & Imanishi M. Nested PUF Proteins: Extending Target RNA Elements for Gene Regulation. ChemBioChem, 19(2), 171-176 (2018);Koh YY, Wang Y, Qiu C, Opperman L, Gross L, Tanaka Hall TM, & Wickens M. Stacking Interactions in PUF-RNA Complexes. RNA, 17(4), 718-727 (2011).

[0608] Therefore, it is well known in the art that human PUM1 (1,186 amino acids) contains an RNA-binding domain (RBD) at the C-terminus of the protein (also known as the Pumilio homology domain PUM-HD, amino acids 828 to 1,175), and that PUFs are based on the RBD of human PUM1. There are eight repeat modules of 36 amino acids for RNA binding (excluding module 7, which has 43 amino acids), as well as flanking N- or C-terminal regions important for protein structure and stability. Within each module, amino acids 12, 13, and 16 are important for RNA binding, and 12 and 16 are involved in RNA base recognition. Amino acid 13 stacks with the RNA base and can be modified to tune specificity and affinity. Alternatively, PUF designs can maintain amino acid 13 as the native residue of human PUM1. In some embodiments of the PUF(CUG) or PUMBY(CUG) compositions disclosed herein, amino acid 13 (for stacking) will be engineered with H, and in other embodiments, with Y. In some embodiments, the stacking residues can be modified to improve binding and specificity. Recognition occurs from the N-terminus to the C-terminus, in the opposite orientation to how PUFs recognize RNA from 3' to 5'. Thus, engineering 8-module (8PUF) PUFs known in the art mimics human proteins. An exemplary 8-mer RNA recognition (8PUF) will be designed as follows: R1'-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In one embodiment, the 8PUF is used as an RBD. In another embodiment, variations on the 8PUF design are used to create a 14-mer RNA recognition (14PUF) RBD, a 15-mer RNA recognition (15PUF) RBD, or a 16-mer RNA recognition (16PUF) RBD. In another embodiment, the PUF can be engineered to contain a 4-mer, 5-mer, 6-mer, 7-mer, 8-mer, 9-mer, 10-mer, 11-mer, 12-mer, 13-mer, 14-mer, 15-mer, 16-mer, 24-mer, 30-mer, 36-mer, or any number of modules in between.Shinoda et al., 2018; Criscuolo et al., 2020. Repeats 1-8 of wild-type human PUM1 are hereby provided as SEQ ID NOs: 462-469, respectively. The nucleic acid sequence encoding the PUF domain from human PUM1 is SEQ ID NO: 470, and the amino acid sequence of the PUF domain from human PUM1 amino acids 828-1176 is SEQ ID NO: 471. See also U.S. Patent 9,580,714, which is incorporated herein in its entirety.

[0609] In some embodiments of the unguided RNA-binding fusion proteins of the present disclosure, the fusion protein comprises at least one RNA-binding protein, or an RNA-binding portion thereof, that is a PUMBY (Pumilio-based assembly) protein. The RNA-binding protein PumHD, widely used in its native and modified forms to target RNA, has been engineered into a protein structure designed to result in a set of four standard protein modules, each targeting a single RNA base. These modules (i.e., Pumby, for Pumilio-based assembly) are linked to strands of various compositions and lengths to bind to the desired target RNA. Essentially, PUMBY is a simpler, modular form of PumHD, in which single protein units of PumHD are linked to form arrays of arbitrary size and binding sequence specificity. Such Pumby-RNA interactions are highly specific, with undetectable binding of Pumby strands to RNA sequences with three or more mismatches from the target sequence. (Katarzyna et al., PNAS, 2016; 113 (19): E2579-E2588). See also US2016 / 0238593, which is incorporated by reference in its entirety.

[0610] In some embodiments of the compositions of the present disclosure, the first RNA-binding protein comprises a Pumilio and FBF (PUF) protein. In some embodiments, the first RNA-binding protein comprises a Pumilio-based assembly (PUMBY) protein. In some embodiments, the PUF or PUMBY RNA-binding protein is fused to a nuclease domain, such as E17 (SEQ ID NO: 358). In another embodiment, a single vector comprises the dCas13d RNA-binding system fused to a nuclease domain from ZC3H12A, such as E17 (SEQ ID NO: 359).

[0611] In some embodiments of the compositions of the present disclosure, at least one of the RNA-binding proteins or RNA-binding portions thereof is a PPR protein. PPR proteins (proteins with pentatricopeptide repeat (PPR) motifs derived from plants) are nuclear-encoded and exclusively regulate genes that specifically affect organelles (chloroplasts and mitochondria), cutting, translation, splicing, RNA editing, and RNA stability at the RNA level. PPR proteins generally have a 35-amino acid motif structure, with the PPR motif consisting of approximately 10 consecutive amino acids. Combinations of PPR motifs can be used for sequence-selective binding to RNA. PPR proteins are often composed of approximately 10 repeat domains of the PPR motif. The PPR domain or RNA-binding domain can be configured to be catalytically inactive. WO2013 / 058404, the entire contents of which are incorporated herein by reference.

[0612] In some embodiments, the fusion proteins disclosed herein comprise a linker between at least two RNA-binding polypeptides. In some embodiments, the linker is a peptide linker. In some embodiments, the linker is VDTANGS (SEQ ID NO: 411). In some embodiments, the peptide linker comprises one or more repeats of the tripeptide GGS. In other embodiments, the linker is a non-peptide linker. In some embodiments, the non-peptide linker comprises polyethylene glycol (PEG), polypropylene glycol (PPG), co-poly(ethylene / propylene) glycol, polyoxyethylene (POE), polyurethane, polyphosphazene, polysaccharide, dextran, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl ethyl ether, polyacrylamide, polyacrylate, polycyanoacrylate, lipid polymer, chitin, hyaluronic acid, heparin, or an alkyl linker.

[0613] In some embodiments, at least one RNA binding protein does not require multimerization for RNA binding activity. In some embodiments, at least one RNA binding protein is not a monomer of a multimeric complex. In some embodiments, the multimeric protein complex does not comprise an RNA binding protein. In some embodiments, at least one RNA binding protein selectively binds to a target sequence within an RNA molecule. In some embodiments, at least one RNA binding protein does not have affinity for a second sequence within the RNA molecule. In some embodiments, at least one RNA binding protein does not have high affinity for or selectively bind to a second sequence within the RNA molecule. In some embodiments, at least one RNA binding protein comprises between 2 amino acids and 1300 amino acids, including the end point.

[0614] In some embodiments, at least one RNA-binding protein of a fusion protein disclosed herein further comprises a sequence encoding a nuclear localization signal (NLS). In some embodiments, the nuclear localization signal (NLS) is located at the N-terminus of the RNA-binding protein. In some embodiments, at least one RNA-binding protein comprises an NLS at the C-terminus. In some embodiments, at least one RNA-binding protein further comprises a first sequence encoding a first NLS and a second sequence encoding a second NLS. In some embodiments, the first NLS or the second NLS is located at the N-terminus of the RNA-binding protein. In some embodiments, at least one RNA-binding protein comprises a first NLS or a second NLS at the C-terminus. In some embodiments, at least one RNA-binding protein further comprises an NES (nuclear export signal) or other peptide tag or secretion signal. In some embodiments, the tag is a FLAG tag.

[0615] In some embodiments, the fusion proteins disclosed herein comprise at least one RNA binding protein as a first RNA binding protein, together with a second RNA binding protein that comprises or consists of a nuclease domain.

[0616] In some embodiments, the second RNA-binding polypeptide is configured to operate relative to the first RNA-binding polypeptide at the C-terminus of the first RNA-binding polypeptide. In some embodiments, the second RNA-binding polypeptide is configured to operate relative to the first RNA-binding polypeptide at the N-terminus of the first RNA-binding polypeptide. In one embodiment, an exemplary fusion protein is a PUF- or PUMBY-based first RNA-binding protein fused to a second RNA-binding protein (also referred to as E17), which is a zinc finger endonuclease known as ZC3H12A or a truncation thereof set forth in SEQ ID NO: 358.

[0617] An exemplary 14-mer RNA recognition (14PUMBY) targeting UGCUGCUGCUGCUG (SEQ ID NO: 454) has the amino acid sequence: [ka] Includes:

[0618] In some embodiments, SEQ ID NO:547 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:547 consists of the sequences detailed in Table 11.

[0619] [Table 11]

[0620] An exemplary 14-mer RNA recognition (14PUMBY) targeting UGCUGCUGCUGCUG (SEQ ID NO: 454) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:547 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R8'. In some embodiments, SEQ ID NO:547 consists of the sequence detailed in Table 12.

[0621] [Table 12]

[0622] An exemplary 14-mer RNA recognition (14PUMBY) targeting CUGCUGCUGCUGCU (SEQ ID NO: 473) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:548 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R8'. In some embodiments, SEQ ID NO:548 consists of the sequence detailed in Table 13.

[0623] [Table 13]

[0624] An exemplary 14-mer RNA recognition (14PUMBY) targeting CUGCUGCUGCUGCU (SEQ ID NO: 477) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:558 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R6-R8'. In some embodiments, SEQ ID NO:558 consists of the sequence detailed in Table 14.

[0625] [Table 14]

[0626]

[0627] An exemplary 8-mer RNA recognition (8PUF) targeting UGCUGCUG (SEQ ID NO: 453) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:444 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:444 consists of the sequence detailed in Table 15.

[0628] [Table 15]

[0629] In some embodiments, the nucleic acid sequence encoding the PUF protein of the present disclosure is a codon-optimized nucleic acid sequence. In some embodiments, the codon-optimized sequence encoding the PUF protein exhibits at least a 5%, at least a 10%, at least a 20%, at least a 30%, at least a 50%, at least a 75%, at least a 100%, at least a 200%, at least a 300%, at least a 500%, or at least a 1000% increase in expression in a human subject compared to a wild-type or non-codon-optimized nucleic acid sequence. In some embodiments, the 8PUF protein of the present disclosure is encoded by a nucleic acid sequence comprising SEQ ID NO: 452. In some embodiments, the nucleotide sequence encoding the fusion protein comprising the CUG-targeted 8PUF and E17 nuclease comprises SEQ ID NO: 460. In some embodiments, the nucleotide sequence encoding the CUG-targeted fusion protein comprises, from 5' to 3', a flag tag, an SV-40 nuclear localization sequence, an 8PUF, and an E17 nuclease, and is set forth in SEQ ID NO: 515. In some embodiments, the nucleotide sequence encoding the CUG-targeted fusion protein comprises, from 5' to 3', an SV-40 nuclear localization sequence, 8PUF, and E17 nuclease, and is set forth in SEQ ID NO: 517. In some embodiments, the nucleotide sequence encoding the CUG-targeted fusion protein comprises, from 5' to 3', 8PUF, and E17 nuclease, and is set forth in SEQ ID NO: 516.

[0630] In some embodiments, a nucleic acid sequence encoding a PUF protein of the present disclosure is a codon-optimized nucleic acid sequence. In some embodiments, the codon-optimized sequence encoding a PUF protein exhibits at least a 5%, at least a 10%, at least a 20%, at least a 30%, at least a 50%, at least a 75%, at least a 100%, at least a 200%, at least a 300%, at least a 500%, or at least a 1000% increase in translation in a human subject compared to a wild-type or non-codon-optimized nucleic acid sequence.

[0631] In some aspects, codon-optimized nucleic acid sequences encoding PUF proteins, such as those set forth in SEQ ID NOs: 452 and 515-517, exhibit increased stability. In some aspects, codon-optimized nucleic acid sequences encoding PUF proteins exhibit increased stability due to increased hydrolysis resistance. In some embodiments, codon-optimized sequences encoding PUF proteins exhibit at least a 5%, at least a 10%, at least a 20%, at least a 30%, at least a 50%, at least a 75%, at least a 100%, at least a 200%, at least a 300%, at least a 500%, or at least a 1000% increase in stability compared to a wild-type or non-codon-optimized nucleic acid sequence. In some embodiments, the codon-optimized sequence encoding the PUF protein exhibits at least a 5%, at least a 10%, at least a 20%, at least a 30%, at least a 50%, at least a 75%, at least a 100%, at least a 200%, at least a 300%, at least a 500%, or at least a 1000% increase in hydrolysis resistance compared to a wild-type or non-codon-optimized nucleic acid sequence in a human subject.

[0632] In some embodiments, a codon-optimized nucleic acid sequence encoding a PUF protein, such as those set forth in SEQ ID NOs: 452 and 515-517, may contain no donor splice sites. In some embodiments, a codon-optimized nucleic acid sequence encoding a PUF protein may contain no more than about one, or about two, or about three, or about four, or about five, or about six, or about seven, or about eight, or about nine, or about ten donor splice sites. In some embodiments, a codon-optimized nucleic acid sequence encoding a PUF protein contains at least one, or at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten fewer donor splice sites compared to a non-codon-optimized nucleic acid sequence encoding a PUF protein.

[0633] Without wishing to be bound by theory, removal of the donor splice site in a codon-optimized nucleic acid sequence can unexpectedly and unpredictably increase expression of a PUF protein in vivo because cryptic splicing is prevented. Furthermore, cryptic splicing can vary between subjects, meaning that the expression level of a PUF protein containing a donor splice site can vary unpredictably between subjects. For human therapy, such unpredictability is unacceptable. Accordingly, the codon-optimized nucleic acid sequences set forth in SEQ ID NOS: 452 and 515-517, which lack a donor splice site, unexpectedly and surprisingly enable increased expression of a PUF protein in a human subject, regulating the expression of the PUF protein across different human subjects.

[0634] In some embodiments, a codon-optimized nucleic acid sequence encoding a PUF protein, such as those set forth in SEQ ID NOs: 452 and 515-517, can have a GC content that differs from the GC content of a non-codon-optimized nucleic acid sequence encoding the PUF protein. In some embodiments, the GC content of a codon-optimized nucleic acid sequence encoding a PUF protein is more evenly distributed throughout the nucleic acid sequence compared to a non-codon-optimized nucleic acid sequence encoding a PUF protein.

[0635] Without wishing to be bound by theory, by distributing GC content more evenly throughout the nucleic acid sequence, codon-optimized nucleic acid sequences exhibit a more uniform melting temperature ("Tm") across the transcript length. Uniformity in melting temperature unexpectedly results in increased expression of the codon-optimized nucleic acid in human subjects, as transcription and / or translation of the nucleic acid sequence occurs with less stalling of polymerases and / or ribosomes.

[0636] In some embodiments, a codon-optimized nucleic acid sequence encoding a PUF protein, such as those set forth in SEQ ID NOs: 452 and 515-517, may have fewer inhibitory microRNA target binding sites compared to a non-codon-optimized nucleic acid sequence encoding a PUF protein. In some embodiments, a codon-optimized nucleic acid sequence encoding a PUF protein may have at least one, or at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten, or at least ten fewer inhibitory microRNA target binding sites compared to a non-codon-optimized nucleic acid sequence, PUF protein.

[0637] Without wishing to be bound by theory, by having fewer inhibitory microRNA target binding sites, codon-optimized nucleic acid sequences encoding PUF proteins unexpectedly exhibit increased expression in human subjects.

[0638]

[0639] In some embodiments, the 8PUF protein is [ka] It can be encoded by a nucleic acid sequence comprising:

[0640] An exemplary 14-mer RNA recognition (14PUF) targeting UGCUGCUGCUGCUG (SEQ ID NO: 454) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:445 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R1-R2-R3-R4-R5-R6-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:445 consists of the sequence detailed in Table 16.

[0641] [Table 16-1] [Table 16-2]

[0642] An exemplary 14-mer RNA recognition (14PUF) targeting UGCUGCUGCUGCUG (SEQ ID NO: 454) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:446 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:446 consists of the sequence detailed in Table 17.

[0643] [Table 17]

[0644] An exemplary 15-mer RNA recognition (15PUF) targeting UGCUGCUGCUGCUGC (SEQ ID NO: 455) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:447 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R1-R2-R3-R4-R5-R6-R7-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:447 consists of the sequence detailed in Table 18.

[0645] [Table 18]

[0646] An exemplary 15-mer RNA recognition (15PUF) targeting UGCUGCUGCUGCUGC (SEQ ID NO: 455) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:448 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R1-R2-R3-R4-R5-R6-R7-R7-R8-R8'. In some embodiments, SEQ ID NO:448 consists of the sequence detailed in Table 19.

[0647] [Table 19]

[0648] An exemplary 15-mer RNA recognition (15PUF) targeting UGCUGCUGCUGCUGC (SEQ ID NO: 455) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:461 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:461 consists of the sequences detailed in Table 20.

[0649] [Table 20]

[0650] An exemplary 16-mer RNA recognition (16PUF) targeting UGCUGCUGCUGCUGCU (SEQ ID NO: 456) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:449 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R1-R2-R3-R4-R5-R6-R7-R8-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:449 consists of the sequence detailed in Table 21.

[0651] [Table 21]

[0652] An exemplary 16-mer RNA recognition (16PUF) targeting UGCUGCUGCUGCUGCU (SEQ ID NO: 456) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:450 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R1-R2-R3-R4-R5-R6-R7-R8-R7-R8-R8'. In some embodiments, SEQ ID NO:450 consists of the sequences detailed in Table 22.

[0653] [Table 22-1] [Table 22-2]

[0654] An exemplary 16-mer RNA recognition (16PUF) targeting UGCUGCUGCUGCUGCU (SEQ ID NO: 456) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:451 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R8-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:451 consists of the sequence detailed in Table 23.

[0655] [Table 23-1] [Table 23-2]

[0656] An exemplary 8-mer RNA recognition (8PUF) targeting CUGCUGCU (SEQ ID NO: 472) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:480 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:480 consists of the sequences detailed in Table 24.

[0657] [Table 24-1] [Table 24-2]

[0658] An exemplary 14-mer RNA recognition (14PUF) targeting CUGCUGCUGCUGCU (SEQ ID NO: 473) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:481 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R1-R2-R3-R4-R5-R6-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:481 consists of the sequence detailed in Table 25.

[0659] [Table 25-1] [Table 25-2]

[0660] An exemplary 14-mer RNA recognition (14PUF) targeting CUGCUGCUGCUGCU (SEQ ID NO: 473) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:482 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:482 consists of the sequence detailed in Table 26.

[0661] [Table 26-1] [Table 26-2]

[0662] An exemplary 15-mer RNA recognition (15PUF) targeting CUGCUGCUGCUGCUG (SEQ ID NO: 474) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:483 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R1-R2-R3-R4-R5-R6-R7-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:483 consists of the sequence detailed in Table 27.

[0663] [Table 27-1] [Table 27-2]

[0664] An exemplary 15-mer RNA recognition (15PUF) targeting CUGCUGCUGCUGCUG (SEQ ID NO: 474) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:484 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R1-R2-R3-R4-R5-R6-R7-R7-R8-R8'. In some embodiments, SEQ ID NO:484 consists of the sequence detailed in Table 28.

[0665] [Table 28-1] [Table 28-2]

[0666] An exemplary 15-mer RNA recognition (15PUF) targeting CUGCUGCUGCUGCUG (SEQ ID NO: 474) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:485 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:485 consists of the sequence detailed in Table 29.

[0667] [Table 29-1] [Table 29-2]

[0668] An exemplary 16-mer RNA recognition (16PUF) targeting CUGCUGCUGCUGCUGC (SEQ ID NO: 475) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:486 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R1-R2-R3-R4-R5-R6-R7-R8-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:486 consists of the sequence detailed in Table 30.

[0669] [Table 30-1] [Table 30-2]

[0670] An exemplary 16-mer RNA recognition (16PUF) targeting CUGCUGCUGCUGCUGC (SEQ ID NO: 475) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:487 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R1-R2-R3-R4-R5-R6-R7-R8-R7-R8-R8'. In some embodiments, SEQ ID NO:487 consists of the sequence detailed in Table 31.

[0671] [Table 31-1] [Table 31-2]

[0672] An exemplary 16-mer RNA recognition (16PUF) targeting CUGCUGCUGCUGCUGC (SEQ ID NO: 475) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:488 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R8-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:488 consists of the sequence detailed in Table 32.

[0673] [Table 32-1] [Table 32-2]

[0674] An exemplary 8-mer RNA recognition (8PUF) targeting GCUGCUGC (SEQ ID NO: 476) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:549 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:549 consists of the sequence detailed in Table 33.

[0675] [Table 33-1] [Table 33-2]

[0676] An exemplary 14-mer RNA recognition (14PUF) targeting GCUGCUGCUGCUGC (SEQ ID NO: 477) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:550 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R1-R2-R3-R4-R5-R6-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:550 consists of the sequences detailed in Table 34.

[0677] [Table 34-1] [Table 34-2]

[0678] An exemplary 14-mer RNA recognition (14PUF) targeting GCUGCUGCUGCUGC (SEQ ID NO: 477) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:551 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:551 consists of the sequences detailed in Table 35.

[0679] [Table 35-1] [Table 35-2]

[0680] An exemplary 15-mer RNA recognition (15PUF) targeting GCUGCUGCUGCUGCU (SEQ ID NO: 478) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:552 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R1-R2-R3-R4-R5-R6-R7-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:552 consists of the sequence detailed in Table 36.

[0681] [Table 36-1] [Table 36-2]

[0682] An exemplary 15-mer RNA recognition (15PUF) targeting GCUGCUGCUGCUGCU (SEQ ID NO: 478) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:553 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R1-R2-R3-R4-R5-R6-R7-R7--R8-R8'. In some embodiments, SEQ ID NO:553 consists of the sequence detailed in Table 37.

[0683] [Table 37-1] [Table 37-2]

[0684] An exemplary 15-mer RNA recognition (15PUF) targeting GCUGCUGCUGCUGCU (SEQ ID NO: 478) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:554 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:554 consists of the sequence detailed in Table 38.

[0685] [Table 38-1] [Table 38-2]

[0686] An exemplary 16-mer RNA recognition (16PUF) targeting GCUGCUGCUGCUGCUG (SEQ ID NO: 479) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:555 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R1-R2-R3-R4-R5-R6-R7-R8-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:555 consists of the sequences detailed in Table 39.

[0687] [Table 39]

[0688] An exemplary 16-mer RNA recognition (16PUF) targeting GCUGCUGCUGCUGCUG (SEQ ID NO: 479) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:556 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R1-R2-R3-R4-R5-R6-R7-R8-R7-R8-R8'. In some embodiments, SEQ ID NO:556 consists of the sequences detailed in Table 40.

[0689] [Table 40]

[0690] An exemplary 16-mer RNA recognition (16PUF) targeting GCUGCUGCUGCUGCUG (SEQ ID NO: 479) has the amino acid sequence: [ka] In some embodiments, SEQ ID NO:557 comprises an architecture proceeding from N-terminus to C-terminus according to R1'-R1-R2-R3-R4-R5-R6-R7-R8-R1-R2-R3-R4-R5-R6-R7-R8-R8'. In some embodiments, SEQ ID NO:557 consists of the sequence detailed in Table 41.

[0691] [Table 41]

[0692] In some aspects, a fusion protein of the present disclosure comprises a PUF according to SEQ ID NOs: 444-451, 461, 480-488, 547-558, 570, or 638-649. In some aspects, a fusion protein of the present disclosure comprises a PUF according to SEQ ID NO: 444. In some aspects, a fusion protein of the present disclosure comprises, from N-terminus to C-terminus: a human NLS sequence, a PUF according to SEQ ID NO: 444, a linker sequence, and an endonuclease. In some aspects, an exemplary 8PUF-targeted CUG fusion protein of the present disclosure is arranged N-terminus to C-terminus according to elements listed in any one of Tables 42-50. In some embodiments, a CUG-targeted fusion protein comprising an 8PUF protein of the present disclosure comprises SEQ ID NO: 559. In some embodiments, a CUG-targeted fusion protein comprising a 14PUF protein of the present disclosure comprises SEQ ID NO: 560. In some embodiments, a CUG-targeted fusion protein comprising a 14PUF protein of the present disclosure comprises SEQ ID NO: 561. In some embodiments, a CUG-targeted fusion protein comprising a 15PUF protein of the present disclosure comprises SEQ ID NO: 562. In some embodiments, a CUG-targeted fusion protein comprising a 15PUF protein of the present disclosure comprises SEQ ID NO: 563. In some embodiments, a CUG-targeted fusion protein comprising a 15PUF protein of the present disclosure comprises SEQ ID NO: 567. In some embodiments, a CUG-targeted fusion protein comprising a 16PUF protein of the present disclosure comprises SEQ ID NO: 565. In some embodiments, a CUG-targeted fusion protein comprising a 16PUF protein of the present disclosure comprises SEQ ID NO: 566. In some embodiments, a CUG-targeted fusion protein comprising a 16PUF protein of the present disclosure comprises SEQ ID NO: 567.

[0693] [Table 42]

[0694] [Table 43]

[0695] [Table 44]

[0696] [Table 45]

[0697] [Table 46-1] [Table 46-2]

[0698] [Table 47]

[0699] [Table 48]

[0700] [Table 49-1] [Table 49-2]

[0701] [Table 79]

[0702] Additional PUF(CUG) RNA targeting compositions are as follows: 16PUFN5 targeting CUGf3 (DM1) with or without endonucleases [Table 80] Table T: Exemplary 16 PUF-targeted CUG fusion proteins (blocking or *cleavage) [Table T] 16PUFN6 targeting CUGf3 (DM1) with or without endonucleases [Table 82] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 83] 16PUFN0 targeting CUGf3 (DM1) with or without endonucleases [Table 84] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 85] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 86] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 87] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 88] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 89] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 90] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 91] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 92] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 93] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 94] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 95] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 96] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 97] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 98] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 99] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 100] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 101] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 102] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 103] Eight PUFs targeting CUGf3 (DM1) with or without endonucleases, with stacking mutations to C [Table 104] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 105] Eight PUFs targeting CUGf3 (DM1) with stacking mutations for use with or without endonucleases [Table 106] Amino acid sequence of the transgene element in N- to C-terminal order (blocked or *truncated) [Table 107] vector

[0703] In some embodiments of the compositions and methods of the present disclosure, the vector comprises a guide RNA of the present disclosure. In some embodiments, the vector comprises at least one guide RNA of the present disclosure. In some embodiments, the vector comprises one or more guide RNAs of the present disclosure. In some embodiments, the vector comprises two or more guide RNAs of the present disclosure. In one embodiment, the vector comprises three guide RNAs. In one embodiment, the vector comprises four guide RNAs. In some embodiments, the vector further comprises a guided or non-guided RNA-binding protein of the present disclosure. In some embodiments, the vector further comprises an RNA-binding fusion protein of the present disclosure. In some embodiments, the fusion protein comprises a first RNA-binding protein and a second RNA-binding protein. In some embodiments, the RNA-guided RNA-binding system comprising the RNA-binding protein and the gRNA is present in a single vector. In certain embodiments, a single vector comprises an RNA-guided RNA-binding system that is a Cas13d RNA-guided RNA-binding system or a catalytically inactivated Cas13d (dCas13d) RNA-guided RNA-binding system. In one embodiment, a single vector comprises a Cas13d RNA-guided RNA-binding system that is a CasRx or dCasRx RNA-guided RNA-binding system. In another embodiment, a single vector comprises an unguided RNA-binding system comprising a PUF- or PUMBY-based protein fused to a nuclease domain from ZC3H12A, such as E17 (SEQ ID NO: 358). In another embodiment, a single vector comprises a dCas13d RNA-binding system fused to a nuclease domain from ZC3H12A, such as E17 (SEQ ID NO: 358).

[0704] In some embodiments of the compositions and methods of the present disclosure, a first vector comprises a guide RNA of the present disclosure, and a second vector comprises an RNA-binding protein or an RNA-binding fusion protein of the present disclosure. In some embodiments, the first vector comprises at least one guide RNA of the present disclosure. In some embodiments, the first vector comprises one or more guide RNAs of the present disclosure. In some embodiments, the first vector comprises two or more guide RNAs of the present disclosure. In some embodiments, the fusion protein comprises a first RNA-binding protein and a second RNA-binding protein. In some embodiments, the first vector and the second vector are the same vector or vector serotype. In some embodiments, the first vector and the second vector are non-identical vectors or vector serotypes. In some embodiments of the compositions and methods of the present disclosure, the RNA-binding system capable of targeting toxic CUG RNA repeats is present in a single vector.

[0705] One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be inserted, for example, by standard molecular cloning techniques. Another type of vector is a viral vector, in which viral-derived DNA or RNA sequences are present within the vector for packaging into a virus (e.g., retrovirus, replication-deficient retrovirus, adenovirus, replication-deficient adenovirus, and adeno-associated virus). Viral vectors also contain polynucleotides carried by the virus for transfection into host cells. In some embodiments, the vector is a lentivirus (e.g., integration-deficient lentiviral vector) or adeno-associated virus (AAV) vector. Vectors, such as bacterial vectors with a bacterial origin of replication, can autonomously replicate in host cells into which they are introduced, while episomal mammalian vectors and other vectors, such as non-episomal mammalian vectors, are integrated into the genome of the host cell upon introduction into the host cell, thereby replicating along with the host genome.

[0706] In some embodiments, vectors, such as expression vectors, can direct the expression of genes to which they are operably linked. Common expression vectors are often in the form of plasmids. In some embodiments, recombinant expression vectors contain nucleic acids provided herein, such as guide RNAs that can be expressed from DNA sequences and nucleic acids encoding Cas13d proteins, in a form suitable for protein expression in host cells. The recombinant expression vector contains one or more regulatory elements that can be selected based on the host cell to be used for expression, and the regulatory elements are operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to a regulatory element in a manner that allows expression of the nucleotide sequence, for example, in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell. Certain embodiments of the vector depend on factors such as the selection of the host cell to be transformed and the desired expression level. The vectors can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by the nucleic acids described herein, such as, for example, CRISPR transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.

[0707] In some embodiments of the compositions and methods of the present disclosure, the vector of the present disclosure is a viral vector. In some embodiments, the viral vector comprises a sequence isolated or derived from a retrovirus. In some embodiments, the viral vector comprises a sequence isolated or derived from a lentivirus. In some embodiments, the viral vector comprises a sequence isolated or derived from an adenovirus. In some embodiments, the viral vector comprises a sequence isolated or derived from an adeno-associated virus (AAV). In some embodiments, the viral vector is replication-incompetent. In some embodiments, the viral vector is isolated or recombinant. In some embodiments, the viral vector is self-complementary.

[0708] The term "adeno-associated virus" or "AAV" as used herein refers to a member of the class of viruses related to this name, belonging to the Parvoviridae family, Dependoparvovirus genus. Adeno-associated viruses are single-stranded DNA viruses that grow in cells in which certain functions are provided by co-infection with a helper virus. General information and reviews of AAV can be found, for example, in Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228, and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York). It is fully expected that the same principles described in these reviews will be applicable to additional AAV serotypes characterized after the publication date of these reviews, since it is well known that the various serotypes are closely related structurally, functionally, and even at the genetic level. (See, e.g., Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, J.R. Pattison, ed.; and Rose, Comprehensive Virology 3: 1-61 (1974).) For example, all AAV serotypes appear to exhibit very similar replication properties mediated by homologous rep genes, and all possess three related capsid proteins, such as those expressed in AAV2. This similarity is further suggested by heteroduplex analysis, which reveals extensive cross-hybridization between serotypes along the length of the genome; and by the presence of similar self-annealing segments at the ends corresponding to "inverted terminal repeats" (ITRs). Similar infectivity patterns also suggest that the replication functions in each serotype are under similar regulatory control. Multiple serotypes of this virus are known to be suitable for gene delivery, and all known serotypes can infect cells from a variety of tissue types.

[0709] AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is noncytopathic, and natural infection in humans and other animals is asymptomatic and symptomless. Furthermore, AAV infects many mammalian cell types, thereby enabling the potential for targeting many different tissues in vivo. Furthermore, AAV can slowly transduce dividing and nondividing cells and persist essentially as a transcriptionally active nuclear episome (extrachromosomal element) for the lifespan of these cells. The AAV proviral genome is inserted as cloned DNA into a plasmid, making the construction of recombinant genomes feasible. Furthermore, because signals directing AAV replication and genome encapsidation are contained within the ITRs of the AAV genome, part or all of the internal 4.3 kb genome (encoding the replication and structural capsid proteins, rep-cap) can be replaced with foreign DNA to generate AAV vectors. The rep and cap proteins can be provided in trans. Another significant feature of AAV is that it is an extremely stable and hardy virus. AAV easily withstands the conditions used to inactivate adenovirus (56°C-65°C for several hours), making cryopreservation of AAV less important. AAV can even be freeze-dried. Finally, AAV-infected cells are not resistant to superinfection.

[0710] The AAV (rAAV or AAV vector) genome of the present invention comprises, consists essentially of, or consists of a nucleic acid molecule encoding a CUG repeat targeting composition (e.g., PUF, PUMBY, or RNA-guided protein) and one or more AAV ITRs flanking the nucleic acid molecule. The production of pseudotyped AAV is disclosed, for example, in WO2001083692. Other types of AAV variants, such as rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014). The nucleotide sequences of the genomes of various AAV serotypes are known in the art.

[0711] In some embodiments of the compositions and methods of the present disclosure, the viral vector comprises a sequence isolated or derived from an adeno-associated virus (AAV). In some embodiments, the viral vector comprises an inverted terminal repeat or capsid sequence isolated or derived from an AAV of serotype AAVrh.74, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 (AAVrh10), AAV11, or AAV12. In one embodiment, the AAV vector comprises a modified capsid. In one embodiment, the AAV vector is an AAV2-Tyr mutant vector. In one embodiment, the AAV vector comprises a capsid in which a non-tyrosine amino acid is located at a position corresponding to the surface-exposed tyrosine residue at position Tyr252, Tyr272, Tyr275, Tyr281, Tyr508, Tyr612, Tyr704, Tyr720, Tyr730, or Tyr673 in wild-type AAV2. See also WO2008 / 124724, which is incorporated herein in its entirety. In some embodiments, the AAV vector comprises an engineered capsid. AAV vectors comprising engineered capsids include, but are not limited to, AAV2.7m8, AAV9.7m8, AAV2 2tYF, and AAV8 Y733F. In some embodiments, the viral vector is replication-incompetent. In some embodiments, the viral vector is isolated or recombinant (rAAV). In some embodiments, the viral vector is self-complementary (scAAV).

[0712] In some embodiments of the compositions and methods of the present disclosure, the vector of the present disclosure is a non-viral vector. In some embodiments, the vector comprises or consists of a nanoparticle, a micelle, a liposome or lipoplex, a polymersome, a polyplex, or a dendrimer. In some embodiments, the vector is an expression vector or a recombinant expression system. As used herein, the term "recombinant expression system" refers to a genetic construct for expressing a particular genetic material formed by recombination.

[0713] In some embodiments of the compositions and methods of the present disclosure, the expression vectors, viral vectors, or non-viral vectors presented herein include, but are not limited to, expression control elements. "Expression control element," as used herein, refers to any sequence that regulates the expression of a coding sequence, such as a gene. Exemplary expression control elements include, but are not limited to, promoters, enhancers, microRNAs, post-transcriptional regulatory elements, polyadenylation signal sequences, and introns. Expression control elements can be, for example, constitutive, inducible, repressible, or tissue-specific. A "promoter" is a regulatory sequence that is a region of a polynucleotide sequence where the initiation and rate of transcription are controlled. A promoter may contain genetic elements to which regulatory proteins and molecules, such as RNA polymerase and other transcription factors, can bind. In some embodiments, promoter-mediated expression control is tissue-specific. In some embodiments, promoter-mediated expression control is constitutive or ubiquitous.Non-limiting exemplary promoters include Pol III promoters, such as U6 and H1 promoters, and / or Pol II promoters, such as SV40, CMV (optionally containing a CMV enhancer), RSV (Rous sarcoma virus) LTR promoter (optionally containing a RSV enhancer), CBA (hybrid CMV enhancer / chicken β-actin), CAG (hybrid CMV enhancer fused to chicken β-actin), truncated CAG, Cbh (hybrid CBA), EF-1a (human elongation factor alpha-1), or EFS (short, intronless EF-1a). lfa), PGK (phosphoglycerol kinase), CEF (chick embryo fibroblast), UBC (ubiquitin C), GUSB (lysosomal enzyme beta-glucuronidase), UCOE (ubiquitous chromatin opening element), hAAT (alpha-1 antitrypsin), TBG (thyroxine-binding globulin), desmin (full length or truncated), MCK (muscle creatine kinase), C5-12 (synthetic muscle promoter), CK8e (creatine kinase 8), NSE (neuron-specific enolase), synapsin, synapsin-1 (SYN-1), opsin, PDGF (platelet-derived growth factor), PDGF-A, MecP2 (methyl-CpG-binding protein 2), CaMKII (calcium / calmodulin-dependent protein kinase II), mGluR2 (metabotropic glutamate receptor 2), NFL (neurofilament light chain), NFH (neurofilament heavy chain), nβ2, PPE (rat preproenkephalin), ENK (preproenkephalin), preproenkephalin-neurofilament chimeric promoter, EAAT2 (glutamate transporter), GFAP (glial fibrillary acidic protein), MBP (myelin basic protein), human rhodopsin kinase promoter (hGRK1), β-actin promoter, dihydrofolate reductase promoter, MHCK7 (hybrid promoter of the enhancer / promoter region of the muscle creatine kinase and alpha myosin heavy chain gene), and combinations thereof.An "enhancer" is a region of DNA to which an activating protein can bind to increase the likelihood or frequency of transcription. Non-limiting exemplary enhancers and post-transcriptional regulatory elements include the CMV enhancer, the MCK enhancer, the R-U5' segment in the LTR of HTLV-1, the SV40 enhancer, the intron sequence between exons 2 and 3 of rabbit β-globin, and the woodchuck hepatitis virus (WHP) post-transcriptional regulatory element (WPRE). In some embodiments, an intron, such as the UBB intron, is used to enhance promoter activity. In some embodiments, the UBB intron is used in conjunction with the EFS promoter.

[0714] In some embodiments of the compositions and methods of the present disclosure, the expression vectors, viral vectors, or non-viral vectors presented herein include, but are not limited to, IRES or 2A peptide sites for the configuration of "multicistronic" or "polycistronic" or "bicistronic" or "tricistronic" constructs, i.e., vector elements such as double, triple, or multiple coding regions or exons, thus enabling the expression of two or more proteins from an mRNA from a single construct. Multicistronic vectors simultaneously express two or more separate proteins from the same mRNA. The two most widely used strategies for constructing multicistronic configurations are the use of IRES or 2A self-cleaving sites. "IRES" refers to an internal ribosome entry site, or a portion thereof, of viral, prokaryotic, or eukaryotic origin used in polycistronic vector construction. In some embodiments, an IRES is an RNA element that enables translation initiation in a cap-dependent manner. The terms "self-cleaving peptide" or "sequence encoding a self-cleaving peptide" or "2A self-cleaving site" refer to a linking sequence used in a vector construct to incorporate a site for facilitating ribosomal skipping, thus producing two polypeptides from a single promoter. Such self-cleaving peptides include, but are not limited to, sequences encoding T2A peptides and P2A peptides or self-cleaving peptides.

[0715] In one embodiment, an exemplary vector configuration is shown in Figures 4A-4C. The exemplary vector configuration includes a promoter or regulatory sequence (promoter / enhancer combination) that drives expression of a nucleic acid encoding a CUG-targeting PUF-endonuclease fusion. In another embodiment, the vector configuration includes a promoter that drives RNA-guided expression of a Cas RNase RNA-binding protein, or a dCas protein fusion operably linked to a second promoter that drives expression of a cognate gRNA. In another embodiment, the vector configuration includes a linker and one or more tags.

[0716] In some embodiments, the vector is a viral vector. In some embodiments, the vector is an adenoviral vector, an adeno-associated viral (AAV) vector, or a lentiviral vector. In some embodiments, the vector is a retroviral vector, an adenoviral / retroviral chimeric vector, a herpes simplex virus I or II vector, a parvoviral vector, a reticuloendotheliosis virus vector, a poliovirus vector, a papillomavirus vector, a vaccinia virus vector, or any hybrid or chimeric vector that incorporates advantageous aspects of two or more viral vectors. In some embodiments, the vector further comprises one or more expression control elements operably linked to the polynucleotide. In some embodiments, the vector further comprises one or more selectable markers. In some embodiments, the AAV vector has low toxicity. In some embodiments, the AAV vector does not integrate into the host genome, thereby reducing the probability of causing insertional mutagenesis. In some embodiments, the AAV vector can encode a total polynucleotide ranging from 4.5 kb to 4.75 kb. In some embodiments, exemplary AAV vectors that can be used in any of the compositions, systems, methods, and kits described herein include AAV1 vectors, modified AAV1 vectors, AAV2 vectors, modified AAV2 vectors, AAV2-Tyr mutant vectors, AAV3 vectors, modified AAV3 vectors, AAV4 vectors, modified AAV4 vectors, AAV5 vectors, modified AAV5 vectors, AAV6 vectors, modified AAV6 vectors, AAV7 vectors, modified AAV7 vectors, AAV8 vectors, AAV9 vectors, AAV.rh10 vectors, modified AAV.rh10 vectors, AAV.rh32 / 33 vectors, modified AAV.rh32 / 33 vectors, AAV.rh43 vectors, modified AAV.rh43 vectors, AAV.rh64R1 vectors, AAV-Tyr mutant vectors, and modified AAV.rh64R1 vectors, and any combinations or equivalents thereof. In some embodiments, the lentiviral vector is an integrase-competent lentiviral vector (ICLV).In some embodiments, lentiviral vectors can refer to transgene plasmid vectors, as well as transgene plasmid vectors along with associated plasmids (e.g., packaging plasmids, rev expression plasmids, envelope plasmids), and lentivirus-based particles that can introduce exogenous nucleic acids into cells via viral or viral-like entry mechanisms. Lentiviral vectors are well known in the art (see, e.g., Trono D. (2002) Lentiviral vectors, New York: Spring-Verlag Berlin Heidelberg and Durand et al. (2011) Viruses 3 (2): 132-159 doi: 10.3390 / v3020132). In some embodiments, exemplary lentiviral vectors that can be used in any of the compositions, systems, methods, and kits described herein include human immunodeficiency virus (HIV) 1 vectors, modified human immunodeficiency virus (HIV) 1 vectors, human immunodeficiency virus (HIV) 2 vectors, modified human immunodeficiency virus (HIV) 2 vectors, and sooty mangabey sarcovirus (SIV). SM ) vector, modified Sooty mangabeyis immunodeficiency virus (SIV SM ) vector, African green monkey immunodeficiency virus (SIV AGM ) vector, modified African green monkey immunodeficiency virus (SIV AGM ) vector, equine infectious anemia virus (EIAV) vector, modified equine infectious anemia virus (EIAV) vector, feline immunodeficiency virus (FIV) vector, modified feline immunodeficiency virus (FIV) vector, visna / maedi virus (VNV / VMV) vector, modified visna / maedi virus (VNV / VMV) vector, caprine arthritis encephalitis virus (CAEV) vector, modified caprine arthritis encephalitis virus (CAEV) vector, bovine immunodeficiency virus (BIV), or modified bovine immunodeficiency virus (BIV). nucleic acid

[0717] Nucleic acid sequences encoding the RNA-binding CUG repeat targeting system disclosed herein are presented herein for use in the gene transfer and expression techniques described herein. It should be understood that, although not necessarily specified, the sequences presented herein can be used to produce expression products that result in proteins with the same biological properties, as well as substantially identical sequences. These "biologically equivalent" or "biologically active" or "equivalent" polypeptides are encoded by equivalent polynucleotides described herein. They can have a primary amino acid sequence that is at least 60%, alternatively at least 65%, alternatively at least 70%, alternatively at least 75%, alternatively at least 80%, alternatively at least 85%, alternatively at least 90%, alternatively at least 95%, or alternatively at least 98% identical to a reference polypeptide when compared using sequence identity methods performed under default conditions. Specific polypeptide sequences are presented as examples of specific embodiments. Alterations to amino acids in the sequence using alternative amino acids with similar charges are also provided. Furthermore, an equivalent polynucleotide is one that hybridizes under stringent conditions to a reference polynucleotide or its complement, or, with respect to polypeptides, a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a reference encoding polynucleotide or its complement. Alternatively, an equivalent polypeptide or protein is one that is expressed from an equivalent polynucleotide.

[0718] Nucleic acid sequences (e.g., polynucleotide sequences) disclosed herein can be codon-optimized, a technique well known in the art. In some embodiments disclosed herein, exemplary Cas sequences, such as the nucleic acid sequence encoding SEQ ID NO:92 (Cas13d, also known as CasRx) or the nucleic acid sequence encoding SEQ ID NO:298 (Cas13d, also known as CasRx), have been codon-optimized for expression in human cells. Codon optimization refers to the fact that different cells use certain codons differently. This codon bias corresponds to a bias in the relative abundance of certain tRNAs in a cell type. Expression can be increased by changing the codons in a sequence to match the relative abundance of the corresponding tRNA. Expression can also be reduced by deliberately selecting codons whose corresponding tRNAs are known to be rare in a particular cell type. Codon usage tables are known in the art for mammalian cells, as well as for various other organisms. Nucleic acid sequences encoding, for example, Cas proteins can be generated based on the genetic code. In some embodiments, such sequences are optimized for expression in a host or target cell, such as, for example, using a host cell that expresses the Cas protein or a cell in which the disclosed methods are performed (e.g., a mammalian cell, such as a human cell). Using the codon preference and codon usage table for a particular species, isolated nucleic acid molecules encoding Cas proteins (e.g., encoding proteins with at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the corresponding wild-type protein) can be engineered to exploit the codon usage preferences of that particular species. For example, the Cas proteins disclosed herein can be designed to have codons that are preferentially used by a particular organism of interest.In one example, the Cas nucleic acid sequence is optimized for expression in a human cell, e.g., having at least 70%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 98%, or at least 99% sequence identity to its corresponding wild-type or source nucleic acid sequence. In some embodiments, an isolated nucleic acid molecule encoding at least one Cas protein (which may be part of a vector) comprises at least one Cas protein coding sequence that has been codon-optimized for expression in a eukaryotic cell or at least one Cas protein coding sequence that has been codon-optimized for expression in a human cell. In one embodiment, such a codon-optimized Cas coding sequence has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to its corresponding wild-type or source sequence. In another embodiment, the eukaryotic codon-optimized nucleic acid sequence encodes a Cas protein having at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to its corresponding wild-type or native protein. In another embodiment, various clones containing functionally equivalent nucleic acids, such as nucleic acids that differ in sequence but encode the same Cas protein sequence, can be routinely generated. Silent mutations in the coding sequence result from the degeneracy (i.e., redundancy) of the genetic code, in which more than one codon can encode the same amino acid residue.Thus, for example, leucine can be encoded by CTT, CTC, CTA, CTG, TTA, or TTG; serine can be encoded by TCT, TCC, TCA, TCG, AGT, or AGC; asparagine can be encoded by AAT or AAC; aspartic acid can be encoded by GAT or GAC; cysteine ​​can be encoded by TGT or TGC; alanine can be encoded by GCT, GCC, GCA, or GCG; glutamine can be encoded by CAA or CAG; tyrosine can be encoded by TAT or TAC; and isoleucine can be encoded by ATT, ATC, or ATA. Tables showing the standard genetic code can be found in various sources (see, for example, Stryer, 1988, Biochemistry, 3rd Edition, WH 5 Freeman and Co., NY).

[0719] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex stabilized by hydrogen bonds between the bases of the nucleotide residues. The hydrogen bonds may exist through Watson-Crick base pairing, Hoogsteen binding, or any other sequence-specific manner. The complex may contain two strands forming a duplex structure, three or more strands forming a multistranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute the initiation of a PCR reaction or a step in a more extensive process, such as the enzymatic cleavage of a polynucleotide by a ribozyme.

[0720] Examples of stringent hybridization conditions include an incubation temperature of about 25°C to about 37°C, a hybridization buffer concentration of about 6xSSC to about 10xSSC, a formamide concentration of about 0% to about 25%, and a wash solution of about 4xSSC to about 8xSSC. Examples of moderate hybridization conditions include an incubation temperature of about 40°C to about 50°C, a buffer concentration of about 9xSSC to about 2xSSC, a formamide concentration of about 30% to about 50%, and a wash solution of about 5xSSC to about 2xSSC. Examples of high stringency conditions include an incubation temperature of about 55°C to about 68°C, a buffer concentration of about 1xSSC to about 0.1xSSC, a formamide concentration of about 55% to about 75%, and a wash solution of about 1xSSC, 0.1xSSC, or deionized water. Generally, hybridization incubation times range from 5 minutes to 24 hours, with one, two, or more wash steps, with wash incubation times of approximately 1, 2, or 15 minutes. SSC is a 0.15M NaCl and 15mM citrate buffer. It is understood that equivalents of SSC using other buffer systems can be used.

[0721] "Homology" or "identity" or "similarity" refers to the sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing a position in each sequence, which can be aligned for comparison. If the same base or amino acid occupies a position in the compared sequences, the molecules are homologous at that position. The degree of homology between sequences depends on the number of matching or homologous positions the sequences share. An "unrelated" or "non-homologous" sequence shares less than 40% identity or less than 25% identity with one of the sequences of the invention. cell

[0722] In some embodiments of the compositions and methods of the present disclosure, the cells of the present disclosure are prokaryotic cells.

[0723] In some embodiments of the compositions and methods of the present disclosure, the cells of the present disclosure are eukaryotic cells. In some embodiments, the cells are mammalian cells. In some embodiments, the cells are bovine, murine, feline, equine, porcine, canine, simian, or human cells. In some embodiments, the cells are non-human mammalian cells, such as non-human primate cells.

[0724] In some embodiments, the cells of the present disclosure are somatic cells. In some embodiments, the cells of the present disclosure are germline cells. In some embodiments, the germline cells of the present disclosure are not human cells.

[0725] In some embodiments of the compositions and methods of the present disclosure, the cells of the present disclosure are stem cells. In some embodiments, the cells of the present disclosure are embryonic stem cells. In some embodiments, the embryonic stem cells of the present disclosure are not human cells. In some embodiments, the cells of the present disclosure are multipotent stem cells or pluripotent stem cells. In some embodiments, the cells of the present disclosure are adult stem cells. In some embodiments, the cells of the present disclosure are induced pluripotent stem cells (iPSCs). In some embodiments, the cells of the present disclosure are hematopoietic stem cells (HSCs).

[0726] In some embodiments of the compositions and methods of the present disclosure, the somatic cells of the present disclosure are muscle cells. In some embodiments, the muscle cells of the present disclosure are myoblasts or myocytes. In some embodiments, the muscle cells of the present disclosure are cardiomyocytes, skeletal muscle cells, or smooth muscle cells. In some embodiments, the muscle cells of the present disclosure are striate cells. In one embodiment, the patient's cell(s) treated with the compositions disclosed herein include, but are not limited to, skeletal muscle (developing and mature muscle fibers and satellite cells), neuromuscular junctions, cardiomyocytes, smooth muscle cells, peripheral nervous system (neurons), peripheral motor neurons, and / or sensory neurons.

[0727] In some embodiments of the compositions and methods of the present disclosure, the somatic cells of the present disclosure are epithelial cells. In some embodiments, the epithelial cells of the present disclosure form fibroblasts, squamous epithelial cells, cuboidal epithelial cells, columnar epithelial cells, stratified epithelial cells, pseudostratified columnar epithelial cells, or transitional epithelial cells. In some embodiments, the epithelial cells of the present disclosure form glands, including but not limited to, the pineal gland, thymus, pituitary gland, thyroid gland, adrenal gland, apocrine gland, holocrine gland, partocrine gland, serous gland, mucous gland, and sebaceous gland. In some embodiments, the epithelial cells of the present disclosure are in contact with the outer surface of an organ, including but not limited to, the lung, spleen, stomach, pancreas, bladder, intestine, kidney, gallbladder, liver, larynx, or pharynx. In some embodiments, the epithelial cells of the present disclosure are in contact with the outer surface of a blood vessel or vein.

[0728] In some embodiments of the compositions and methods of the present disclosure, the somatic cells of the present disclosure are primary cells.

[0729] In some embodiments of the compositions and methods of the present disclosure, the somatic cells of the present disclosure are cultured cells.

[0730] In some embodiments of the compositions and methods of the present disclosure, the somatic cells of the present disclosure are in vivo, in vitro, ex vivo, or in situ.

[0731] In some embodiments of the compositions and methods of the present disclosure, the somatic cells of the present disclosure are autologous or allogeneic cells. How to use

[0732] The present disclosure provides a method of altering the level of expression of an RNA molecule of the present disclosure or a protein encoded by the RNA molecule, the method comprising contacting a composition of the present disclosure with the RNA molecule under conditions suitable for binding of one or more of a guide RNA or an RNA binding protein or an RNA binding fusion protein (or portion thereof) to the RNA molecule.

[0733] The present disclosure provides a method of altering the activity of a protein encoded by an RNA molecule, the method comprising contacting the RNA molecule with a composition of the present disclosure under conditions suitable for binding of one or more of a guide RNA or an RNA-binding protein or a fusion protein (or portion thereof) to the RNA molecule.

[0734] The present disclosure provides a method for modifying the level of expression of an RNA molecule of the present disclosure or the expression of a protein encoded by the RNA molecule, the method comprising contacting a composition of the present disclosure with a cell containing the RNA molecule under conditions suitable for binding of one or more of a guide RNA or an RNA-binding protein or a fusion protein (or a portion thereof) to the RNA molecule. In some embodiments, the cell is in vivo, in vitro, ex vivo, or in situ. In some embodiments, the composition of the present disclosure comprises a vector comprising a guide RNA of the present disclosure and an RNA-binding protein or a fusion protein of the present disclosure. In some embodiments, the vector is AAV.

[0735] The present disclosure provides a method for modifying the activity of a protein encoded by an RNA molecule, the method comprising contacting a composition of the present disclosure with a cell containing the RNA molecule under conditions suitable for binding of one or more of a guide RNA or an RNA-binding protein or a fusion protein (or portion thereof) to the RNA molecule.

[0736] The present disclosure provides a method for altering the level of expression of an RNA molecule of the present disclosure or the expression of a protein encoded by the RNA molecule, comprising contacting the RNA molecule with a composition of the present disclosure under conditions suitable for RNA nuclease activity of an RNA binding protein or fusion protein to induce breaks in the RNA molecule.

[0737] The present disclosure provides a method for altering the activity of a protein encoded by an RNA molecule, the method comprising contacting the RNA molecule with a composition of the present disclosure under conditions suitable for RNA nuclease activity of an RNA-binding protein or fusion protein to induce destruction of the RNA molecule.

[0738] The present disclosure provides a method for modifying the level of expression of an RNA molecule of the present disclosure or the expression of a protein encoded by the RNA molecule, the method comprising contacting a composition of the present disclosure with a cell containing the RNA molecule under conditions suitable for RNA nuclease activity of an RNA-binding protein or fusion protein to induce destruction of the RNA molecule. In some embodiments, the cell is in vivo, in vitro, ex vivo, or in situ. In some embodiments, the composition comprises a vector comprising a composition comprising a guide RNA of the present disclosure and an RNA-binding fusion protein of the present disclosure. In some embodiments, the vector is AAV.

[0739] The present disclosure provides a method for modifying the activity of a protein encoded by an RNA molecule, the method comprising contacting a composition with a cell containing the RNA molecule under conditions suitable for RNA nuclease activity, where the RNA-binding protein or fusion protein induces destruction of the RNA molecule. In some embodiments, the cell is in vivo, in vitro, ex vivo, or in situ. In some embodiments, the composition comprises a vector comprising a composition comprising a nucleic acid sequence encoding the guide RNA or single guide RNA of the present disclosure and the RNA-binding protein or fusion protein of the present disclosure. In some embodiments, the vector is AAV.

[0740] The present disclosure provides a method for treating a disease or disorder, comprising administering to a subject a therapeutically effective amount of a composition of the present disclosure. In one embodiment, the present disclosure provides a method for treating DM1.

[0741] The present disclosure provides a method of treating DM1 in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a composition of the present disclosure, the composition comprising a vector including a guide RNA of the present disclosure and a nucleic acid sequence encoding an RNA-binding protein or RNA-binding protein fusion protein of the present disclosure, wherein the composition modifies, reduces, disrupts, lowers, or reduces the level of expression of a toxic CUG repeat RNA (compared to the level of expression of the toxic CUG repeat RNA following treatment with a non-targeting (NT) control or compared to no treatment). In one embodiment, the level of reduction of the target toxic CUG repeat RNA or toxic repeats encoded by the target RNA is compared to the level of reduction of the target RNA or toxic repeats encoded by the target RNA upon treatment with the RCas9 system. In another embodiment, the level of reduction is 1-fold or more. In another embodiment, the level of reduction is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold. In another embodiment, the level of reduction is 10-fold or more. In another embodiment, the level of reduction is between 10-fold and 20-fold. In another embodiment, the level of reduction is 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold. In another embodiment, the gene therapy compositions disclosed herein, when administered to a DM1 patient, result in 20% to 100% degradation (or elimination) of toxic CUG repeat RNA. In one embodiment, the percent elimination of toxic CUG repeat RNA is 20-99%, 25% to 99%, 50% to 99%, 80% to 99%, 90% to 99%, or 95% to 99%. In one embodiment, the percent elimination is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In another embodiment, the % elimination is complete or 100% elimination of the toxic CUG repeat RNA.

[0742] In some embodiments of the compositions and methods of the present disclosure, the disease or disorder of the patient to be treated includes, but is not limited to, a disease or disorder associated with the expression of CTG microsatellite repeat expansion.In some embodiments, the disease or disorder is associated with CTG microsatellite repeat expansion in the 3' untranslated region of the DMPK gene.In some embodiments of the compositions and methods of the present disclosure, the disease or disorder of the present disclosure is myotonic dystrophy type 1 (DM1).

[0743] In some embodiments of the methods of the present disclosure, the subject of the present disclosure has been diagnosed with DM1. In some embodiments, the subject of the present disclosure exhibits at least one sign or symptom of DM1. At least one DM1 sign or symptom includes, but is not limited to, muscle rigidity, muscle atrophy, clustered myonuclei, muscle recovery, GI distress, cardiac conduction disorders, swallowing disorders, and respiratory capacity. In one embodiment, at least one sign or symptom of DM1 is improved by treatment with a composition disclosed herein. In some embodiments, the subject has a biomarker that predicts the risk of developing DM1. In some embodiments, the biomarker is a genetic mutation.

[0744] In some embodiments of the method of the present disclosure, the subject of the present disclosure is female.In some embodiments of the method of the present disclosure, the subject of the present disclosure is male.In some embodiments, the subject of the present disclosure has two chromosomes XX or XY.In some embodiments, the subject of the present disclosure has two chromosomes XX or XY and a third chromosome, either X or Y.

[0745] In some embodiments of the methods of the present disclosure, the subject of the present disclosure is a newborn, an infant, a child, an adult, an elderly adult, or a geriatric adult. In some embodiments of the methods of the present disclosure, the subject of the present disclosure is at least 1 day old, 2 days old, 3 days old, 4 days old, 5 days old, 6 days old, 7 days old, 8 days old, 9 days old, 10 days old, 11 days old, 12 days old, 13 days old, 14 days old, 15 days old, 16 days old, 17 days old, 18 days old, 19 days old, 20 days old, 21 days old, 22 days old, 23 days old, 24 days old, 25 days old, 26 days old, 27 days old, 28 days old, 29 days old, 30 days old, or 31 days old. In some embodiments of the methods of the present disclosure, the subject of the present disclosure is at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months old. In some embodiments of the methods of the present disclosure, the subject of the present disclosure is at least 1 year old, 2 years old, 3 years old, 4 years old, 5 years old, 6 years old, 7 years old, 8 years old, 9 years old, 10 years old, 15 years old, 20 years old, 25 years old, 30 years old, 35 years old, 40 years old, 45 years old, 50 years old, 55 years old, 60 years old, 65 years old, 70 years old, 75 years old, 80 years old, 85 years old, 90 years old, 95 years old, 100 years old, or any age or partial age in between.

[0746] In some embodiments of the methods of the present disclosure, the subject of the present disclosure is a mammal. In some embodiments, the subject of the present disclosure is a non-human mammal.

[0747] In some embodiments of the methods of the present disclosure, the subject of the present disclosure is a human.

[0748] In some embodiments of the method of the present disclosure, the therapeutically effective amount comprises a single dose of the composition of the present disclosure.In some embodiments, the therapeutically effective amount comprises at least one dose of the composition of the present disclosure.In some embodiments, the therapeutically effective amount comprises one or more doses of the composition of the present disclosure.

[0749] In some embodiments of the disclosed methods, a therapeutically effective amount is one that eliminates signs or symptoms of a disease or disorder, hi some embodiments, a therapeutically effective amount is one that reduces the severity of signs or symptoms of a disease or disorder.

[0750] In some embodiments of the methods of the present disclosure, the therapeutically effective amount is one that eliminates the disease or disorder.

[0751] In some embodiments of the disclosed methods, the therapeutically effective amount prevents the onset of a disease or disorder. In some embodiments, the therapeutically effective amount delays the onset of a disease or disorder. In some embodiments, the therapeutically effective amount reduces the severity of a sign or symptom of a disease or disorder. In some embodiments, the therapeutically effective amount improves the prognosis of a subject.

[0752] In some embodiments of the methods of the present disclosure, the composition of the present disclosure is administered intramuscularly to the subject. In some embodiments, the composition of the present disclosure is administered to the subject by intramuscular route. In some embodiments, the composition of the present disclosure is administered to the subject by injection or infusion. In some embodiments, the composition is administered systemically. In some embodiments of the methods of the present disclosure, the composition of the present disclosure is administered locally to the subject.

[0753] In some embodiments, the compositions disclosed herein are formulated as pharmaceutical compositions.Simply put, the pharmaceutical compositions for use disclosed herein can comprise the polynucleotide encoding protein(s) or optionally the protein(s) contained in AAV, which are optionally immuno-orthogonal, combined with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.Such compositions can comprise buffer solution, such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrate, such as glucose, mannose, sucrose or dextran, mannitol; protein; polypeptide or amino acid, such as glycine; antioxidant; chelating agent, such as EDTA or glutathione; adjuvant (for example, aluminum hydroxide); and preservative. The compositions of the present disclosure can be formulated for routes of administration, such as, for example, oral, enteral, topical, transdermal, intranasal, and / or inhalation routes of administration, as well as for routes of administration by injection or infusion, such as, for example, intravenous, intramuscular, subpial, intrathecal, intrastriatal, subcutaneous, intradermal, intraperitoneal, intratumoral, intravenous, intraocular, and / or parenteral administration. In certain embodiments, the compositions of the present disclosure are formulated for intravenous administration. [Example]

[0754] Example implementation: Embodiment 1. A method of treating myotonic dystrophy type 1 (DM1) in a mammal, comprising the step of administering a composition to a toxic target CUG microsatellite repeat expansion (MRE) molecule in a tissue of the mammal, wherein the composition comprises a nucleic acid sequence encoding a non-naturally occurring or engineered clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) system, wherein the nucleic acid sequence comprises (a) at least one RNA-guided RNase Cas protein (or dCas protein) and (b) at least one cognate CRISPR-Cas system guide RNA (gRNA) capable of forming a complex with one of the at least one Cas protein, wherein the gRNA comprises (i) a DR sequence and (ii) a spacer sequence, wherein the spacer sequence hybridizes to the target CUG MRE molecule, thereby treating DM1 in the mammal.

[0755] Embodiment 2: The method of any preceding embodiment, wherein the spacer sequence comprises a spacer sequence selected from the group consisting of agcagcagcagcagcagcagcagcag (SEQ ID NO: 457), gcagcagcagcagcagcagcagcagc (SEQ ID NO: 458), and cagcagcagcagcagcagcagcagca (SEQ ID NO: 459).

[0756] Embodiment 3: The method of any preceding embodiment, wherein the composition is administered to the mammalian tissue by intravenous administration.

[0757] Embodiment 4: The method of any preceding embodiment, wherein the RNA-guided RNase Cas protein is selected from the group consisting of Cas13a, Cas13b, Cas13c, Cas13d, and RNA-binding portions thereof.

[0758] Embodiment 5: The method of any preceding embodiment, wherein the RNA-guided RNase Cas protein is Cas13d or an RNA-binding portion thereof.

[0759] Embodiment 6: The method of any preceding embodiment, wherein the RNA-guided RNase Cas protein is inactivated (dCas).

[0760] Embodiment 7: The method of any preceding embodiment, wherein Cas13d is encoded by the nucleic acid sequence set forth in any one of SEQ ID NOs: 522, 530, 535, 538, or 540.

[0761] Embodiment 8: The method of any preceding embodiment, wherein the dCas protein is linked to an endonuclease.

[0762] Embodiment 9: The method of any preceding embodiment, wherein the endonuclease is a ZC3H12A zinc finger endonuclease.

[0763] Embodiment 10: The method of any preceding embodiment, wherein the ZC3H12A zinc finger nuclease comprises the amino acid sequence set forth in SEQ ID NO: 358 or SEQ ID NO: 359.

[0764]

[0765] Embodiment 11: A composition comprising a nucleic acid sequence encoding a non-naturally occurring or engineered clustered regularly interspaced short palindromic repeats (CRISPR) associated (Cas) system, wherein the nucleic acid sequence comprises (a) at least one RNA-guided RNase Cas protein; and b) at least one cognate CRISPR-Cas system guide RNA (gRNA) capable of forming a complex with one of the at least one Cas protein, wherein the gRNA comprises (i) a DR sequence and (ii) a spacer sequence, wherein the spacer sequence hybridizes to a target CUG MRE molecule, and wherein the spacer sequence comprises a spacer sequence selected from the group consisting of agcagcagcagcagcagcagcagcag (SEQ ID NO: 457), gcagcagcagcagcagcagcagc (SEQ ID NO: 458), and cagcagcagcagcagcagcagcagca (SEQ ID NO: 459), or a portion thereof.

[0766] Embodiment 12: An AAV vector comprising the composition of any preceding embodiment.

[0767] Embodiment 13: The AAV vector of any preceding embodiment, which is an AAV9 vector.

[0768] Embodiment 14: A method of treating myotonic dystrophy type 1 (DM1) in a mammal, comprising: administering a composition to a toxic target CUG microsatellite repeat expansion (MRE) molecule in a tissue of the mammal, wherein the composition comprises a nucleic acid sequence encoding an unguided RNA-binding fusion protein comprising: a) a PUF or PUMBY RNA-binding sequence capable of binding to the toxic target CUG RNA repeat sequence, wherein the toxic target CUG repeat sequence comprises UGCUGCUG (SEQ ID NO: 453); and b) an endonuclease capable of cleaving the toxic target CUG RNA repeat sequence, thereby reducing the expression level of the toxic target RNA.

[0769] Embodiment 15: The embodiment of any preceding embodiment, wherein the administration of the composition is by intravenous administration.

[0770] Embodiment 16: A method of eliminating a toxic CUG microsatellite repeat expansion (MRE) RNA in the tissue of a mammal with DM1, comprising contacting the CUG MRE RNA sequence with a composition under conditions suitable for binding of the composition to the CUG MRE RNA, wherein the composition comprises a nucleic acid sequence encoding a fusion protein comprising: a) a PUF or PUMBY RNA-binding sequence capable of binding to a toxic target sequence comprising UGCUGCUG (SEQ ID NO: 453); and b) an endonuclease capable of cleaving the toxic target RNA sequence, thereby eliminating the toxic target RNA. In one embodiment, cleavage of the toxic target RNA reduces the expression level of the toxic target RNA. In another embodiment, reduction in the expression level of the toxic target RNA eliminates the toxic target RNA.

[0771] Embodiment 17: A composition comprising a nucleic acid sequence encoding an unguided RNA-binding fusion protein comprising: a) a PUF or PUMBY protein capable of binding to a toxic target sequence comprising UGCUGCUG (SEQ ID NO: 453); and b) an endonuclease capable of cleaving the toxic target RNA sequence.

[0772] Embodiment 18: The AAV vector comprises the composition of any preceding embodiment.

[0773] Embodiment 19: The AAV vector of any preceding embodiment, which is AAV9.

[0774] Embodiment 20: The endonuclease is selected from the group consisting of RNase1, RNase4, RNase6, RNase7, RNase8, RNase2, RNase6PL, RNaseL, RNaseT2, RNase11, RNaseT2-like, NOB1, ENDOV, ENDOG, ENDOD1, hFEN1, hSLFN14, hLACTB2, APEX2, ANG, HRSP12, ZC3H12A, RIDA, PDL6, NTHL, KIAA0391, APEX1, AGO2, EXOG, ZC3H12D, ERN2, PELO, YBEY, CPSF4L, hCG_2002731, ERCC1, RAC1, RAA1, RAB1, DNA2, FLJ35220, 10. The method or composition of any preceding embodiment, wherein the gene is selected from the group consisting of FLJ13173, ERCC4, RNase 1(K41R), RNase 1(K41R, D121E), RNase 1(K41R, D121E, H119N), RNase 1(H119N), RNase 1(R39D, N67D, N88A, G89D, R91D, H119N), RNase 1(R39D, N67D, N88A, G89D, R91D, H119N, K41R, D121E), RNase 1(R39D, N67D, N88A, G89D, R91D), TENM1, TENM2, RNaseK, TALEN, ZNF638, and hSMG6(PIN). Embodiment XX: The method or composition of any preceding embodiment, wherein the endonuclease is __.

[0775] In some embodiments of the methods and compositions disclosed herein, the RNA-binding polypeptide is an RNA-guided RNase Cas protein. In some embodiments, the Cas protein is Cas13a, Cas13b, Cas13c, or Cas13d. In some embodiments, the Cas protein is Cas13d.

[0776] In some embodiments, the RNA-binding polypeptide is an unguided RNA-binding polypeptide. In some embodiments, the unguided RNA-binding polypeptide is a PUF protein or a PUMBY protein. In some embodiments, the PUF or PUMBY protein is a human PUF or PUMBY protein. In some embodiments, the unguided RNA-binding polypeptide is a PUF or PUMBY fusion protein. In one embodiment, the first RNA-binding protein based on PUF or PUMBY is fused with a second RNA-binding protein. In some embodiments, the second RNA-binding protein is the nuclease domain of the zinc finger endonuclease known as ZC3H12A of SEQ ID NO: 358 (also referred to herein as E17).

[0777] In some embodiments of the methods and compositions disclosed herein, the nucleic acid sequence comprises at least one promoter. In some embodiments, the at least one promoter is a constitutive promoter or a tissue-specific promoter. In one embodiment, the promoter is a CAG or truncated CAG (tCAG) promoter. In another embodiment, the promoter is an EFS promoter. In one embodiment, the tissue-specific promoter is a muscle-specific promoter. In another embodiment, the muscle-specific promoter is an MHCK7 promoter. In another embodiment, the muscle-specific promoter is a desmin promoter. In one embodiment, the desmin promoter is a full-length desmin promoter. In another embodiment, the desmin promoter is a truncated desmin promoter.

[0778] In some embodiments of the methods and compositions disclosed herein, the RNA-guided RNase Cas protein or the unguided RNA-binding polypeptide is a first RNA-binding polypeptide fused with a second RNA-binding polypeptide. In one embodiment, the second RNA-binding polypeptide can bind to RNA in a manner that associates with RNA. In some embodiments, the second RNA-binding polypeptide can associate with RNA in a manner that cleaves RNA. In some embodiments, the second RNA-binding polypeptide is selected from the group consisting of RNase 1, RNase 4, RNase 6, RNase 7, RNase 8, RNase 2, RNase 6PL, RNase L, RNase T2, RNase 11, RNase T2-like, NOB1, ENDOV, ENDOG, ENDOD1, hFEN1, hSLFN14, hLACTB2, APEX2, ANG, HRSP12, ZC3H12A, RIDA, PDL6, NTHL, KIAA0391, APEX1, AGO2, EXOG, ZC3H12D, ERN2, PELO, YBEY, CPSF4L, hCG_2002731, ERCC1, RAC1, RAA1, RAB 1, DNA2, FLJ35220, FLJ13173, ERCC4, RNase1(K41R), RNase1(K41R, D121E), RNase1(K41R, D121E, H119N), RNase1(H119N), RNase1(R39D, N67D, N88A, G89D, R91D, H119N), RNase1(R39D, N67D, N88A, G89D, R91D, H119N, K41R, D121E), RNase1(R39D, N67D, N88A, G89D, R91D), TENM1, TENM2, RNaseK, TALEN, ZNF638, and hSMG6(PIN). In one embodiment, the second RNA-binding polypeptide is the nuclease domain (E17) from ZC3H12A. In some embodiments, the first RNA-binding protein is an inactivated, RNA-guided RNase Cas protein.

[0779] In some embodiments, disclosed herein is a vector comprising the CUG-targeted DM1 composition disclosed herein. In some embodiments, the vector is selected from the group consisting of an adeno-associated virus, a retrovirus, a lentivirus, an adenovirus, a nanoparticle, a micelle, a liposome, a lipoplex, a polymersome, a polyplex, and a dendrimer. In one embodiment, an AAV vector comprises the CUG-targeted DM1 composition disclosed herein. In one embodiment, the AAV vector is AAV9. In another embodiment, the AAV vector is AAVrh.74. In some embodiments, disclosed herein is a cell comprising the vector(s) disclosed herein.

[0780] In some embodiments of the compositions of the present disclosure, the sequence comprising the gRNA further comprises a sequence encoding a promoter capable of expressing the gRNA in a eukaryotic cell.

[0781] In some embodiments of the compositions of the present disclosure, the eukaryotic cell is an animal cell. In some embodiments, the animal cell is a mammalian cell. In some embodiments, the animal cell is a human cell. In some embodiments, the human cell is a muscle cell.

[0782] In some embodiments of the compositions of the present disclosure, the promoter is a constitutively active promoter. In some embodiments, the promoter sequence is isolated or derived from a promoter capable of driving the expression of RNA polymerase. In some embodiments, the promoter sequence is a Pol III promoter. In some embodiments, the promoter sequence is isolated or derived from a human U6 promoter. In some embodiments, the promoter is a sequence isolated or derived from a promoter capable of driving the expression of transfer RNA (tRNA). In some embodiments, the promoter is isolated or derived from alanine tRNA promoter, arginine tRNA promoter, asparagine tRNA promoter, aspartic acid tRNA promoter, cysteine ​​tRNA promoter, glutamine tRNA promoter, glutamic acid tRNA promoter, glycine tRNA promoter, histidine tRNA promoter, isoleucine tRNA promoter, leucine tRNA promoter, lysine tRNA promoter, methionine tRNA promoter, phenylalanine tRNA promoter, proline tRNA promoter, serine tRNA promoter, threonine tRNA promoter, tryptophan tRNA promoter, tyrosine tRNA promoter or valine tRNA promoter.In some embodiments, the promoter is isolated or derived from valine tRNA promoter.

[0783] In some embodiments of the compositions of the present disclosure, the DR sequence of the gRNA is a Cas13d DR sequence.

[0784] In some embodiments of the compositions of the present disclosure, the first RNA-binding protein comprises a CRISPR-Cas protein that is not a Cas9 CRISPR-Cas protein. In some embodiments, the CRISPR-Cas protein comprises native RNA nuclease activity. In some embodiments, the native RNA nuclease activity is reduced or inhibited. In some embodiments, the native RNA nuclease activity is increased or induced. In some embodiments, the CRISPR-Cas protein and / or cognate gRNA comprises a mutation. In some embodiments, the nuclease domain of the CRISPR-Cas protein comprises a mutation. In some embodiments, the DR sequence of the gRNA comprises a mutation. In some embodiments, the mutation is present in a nucleic acid encoding the CRISPR-Cas protein or a nucleic acid encoding the gRNA. In some embodiments, the mutation is present in an amino acid encoding the CRISPR-Cas protein. In some embodiments, the mutation comprises a substitution, insertion, deletion, frameshift, inversion, or translocation. In some embodiments, the mutation comprises a deletion of the nuclease domain, a binding site within the nuclease domain, an active site within the nuclease domain, or at least one essential amino acid residue within the nuclease domain. In some embodiments, the mutation is a point mutation in the DR sequence of the gRNA.

[0785] In some embodiments, the CRISPR-Cas protein is a type VI CRISPR-Cas protein. In some embodiments, the RNA-binding protein comprises a Cas13 polypeptide or an RNA-binding portion thereof. In some embodiments, the RNA-binding protein comprises a Cas13d polypeptide or an RNA-binding portion thereof. In some embodiments, the CRISPR-Cas protein comprises native RNA nuclease activity. In some embodiments, the native RNA nuclease activity is reduced or inhibited. In some embodiments, the native RNA nuclease activity is increased or induced. In some embodiments, the CRISPR-Cas protein and / or its cognate gRNA comprises a mutation. In some embodiments, the nuclease domain of the CRISPR-Cas protein comprises a mutation. In some embodiments, the mutation is present in a nucleic acid encoding the CRISPR-Cas protein or in a nucleic acid encoding the gRNA. In some embodiments, the mutation is present in the amino acid sequence of the CRISPR-Cas protein. In some embodiments, the mutation comprises a substitution, insertion, deletion, frameshift, inversion, or translocation. In some embodiments, the mutation comprises the deletion of nuclease domain, the binding site in nuclease domain, the active site in nuclease domain, or at least one essential amino acid residue in nuclease domain.In some embodiments, the mutation is a point mutation in the DR sequence of gRNA.In one embodiment, the mutant DR sequence is the Cas13d DR sequence that comprises point mutation.

[0786] In some embodiments of the method and / or composition of the present disclosure, unguided RNA binding protein does not require multimer formation for RNA binding activity.In some embodiments, unguided RNA binding protein is not the monomer of multimeric complex.In some embodiments, multimeric protein complex does not comprise RNA binding protein.

[0787] In some embodiments of the methods and / or compositions of the present disclosure, the RNA binding protein selectively binds to the target sequence within the RNA molecule.In some embodiments, the RNA binding protein does not have affinity for the second sequence within the RNA molecule.In some embodiments, the RNA binding protein does not have high affinity for the second sequence within the RNA molecule and does not selectively bind to it.

[0788] In some embodiments of the methods and / or compositions of the disclosure, the RNA genome or RNA transcriptome comprises RNA molecules.

[0789] In some embodiments of the disclosed methods and / or compositions, the RNA binding protein comprises between 2 amino acids and 1300 amino acids, inclusive.

[0790] In some embodiments of the disclosed methods and / or compositions, the RNA-binding fusion protein comprises between 2 amino acids and 2000 amino acids, inclusive.

[0791] In some embodiments of the methods and / or compositions of the present disclosure, the sequence encoding the RNA-binding protein further comprises a sequence encoding a nuclear localization signal (NLS), a nuclear export signal (NES), or a tag. In some embodiments, the sequence encoding the nuclear localization signal (NLS) is located at the N-terminus of the sequence encoding the RNA-binding protein. In some embodiments, the RNA-binding protein comprises an NLS at the C-terminus of the protein. In some embodiments, the sequence encoding the RNA-binding protein or system comprises two NLSs or two NESs.

[0792] In some embodiments of the methods and / or compositions of the present disclosure, the sequence encoding the RNA-binding protein further comprises a first sequence encoding a first NLS and a second sequence encoding a second NLS. In some embodiments, the sequence encoding the first NLS or the second NLS is located at the N-terminus of the sequence encoding the RNA-binding protein. In some embodiments, the RNA-binding protein comprises the first NLS or the second NLS at the C-terminus of the protein. In some embodiments, the RNA-binding composition comprises at least one linker.

[0793] In some embodiments of the methods and / or compositions of the present disclosure, the composition further comprises a second RNA binding protein. In some embodiments, the second RNA binding protein comprises or consists of a nuclease domain. In some embodiments, the second RNA binding protein binds to RNA in a manner that associates with RNA. In some embodiments, the second RNA binding protein associates with RNA in a manner that cleaves RNA. In some embodiments of the compositions of the present disclosure, the sequence encoding the second RNA binding protein comprises or consists of RNase.

[0794] Also disclosed herein are methods for producing the compositions and / or vectors comprising the compositions disclosed herein.

[0795] Any of the preceding embodiments, wherein the nucleic acid sequence comprises at least one promoter, wherein at least one promoter is a constitutive promoter or a tissue-specific promoter, wherein at least one promoter is an EFS promoter or a tCAG promoter, wherein the tissue-specific promoter is a muscle-specific promoter, wherein the muscle-specific promoter is an MHCK7 promoter, and / or wherein any of said promoters comprises an enhancer and / or an intron.

[0796] Any of the preceding embodiments, wherein the expression level of a toxic target RNA is reduced compared to the reduction in the expression level of an untreated toxic target RNA, wherein the expression level of a toxic target RNA is reduced compared to the reduction in the expression level of a toxic target RNA treated with an RCas9-based system, the level of reduction being 1-fold or more, the level of reduction being 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold, the level of reduction being 10-fold or more, and the level of reduction being between 10-fold and 20-fold.

[0797] the nucleic acid sequence comprises a promoter capable of expressing the gRNA in a human cell, the promoter being a human U6 promoter; the promoter being a sequence isolated from or derived from a promoter capable of driving expression of a transfer RNA (tRNA), the promoter being selected from the group consisting of an alanine tRNA promoter, an arginine tRNA promoter, an asparagine tRNA promoter, an aspartate tRNA promoter, a cysteine ​​tRNA promoter, a glutamine tRNA promoter, a glutamate tRNA promoter, a glycine tRNA promoter, a histidine tRNA promoter, an isoleucine tRNA promoter, a leucine tRNA promoter, a lysine tRNA promoter, a methionine tRNA promoter, a phenylalanine tRNA promoter, a proline tRNA promoter, a serine tRNA promoter, a threonine tRNA promoter, a tryptophan tRNA promoter, a tyrosine tRNA promoter, and a valine tRNA promoter; and the DR sequence of the gRNA is selected from the group consisting of a Cas13d tRNA promoter, ... The method and composition of any preceding embodiment, wherein the nucleic acid sequence is a DR sequence, and the nucleic acid sequence further comprises a sequence encoding at least one nuclear localization signal (NLS), nuclear export signal (NES) or tag, wherein the at least one nuclear localization signal (NLS) is located at the N-terminus of the sequence encoding the RNA-binding protein, and the at least one nuclear localization signal (NLS) is located at the C-terminus of the sequence encoding the RNA-binding protein, and the nucleic acid sequence further comprises a sequence encoding two nuclear localization signals (NLS) or two nuclear export signals (NES), and the RNA-binding protein or the fusion protein comprises at least one linker.

[0798] Example 1 The Cas13d system degrades DM1 toxic CUG repeats material Plasmid: pcDNA3.1 expressing CTG960 (960 CTG repeats), Tet transactivator, Cas, and sgRNA under the human U6 promoter

[0799] Transfection reagent: Lipofectamine 3000, opti-MEM, PBS, DMEM

[0800] RNA extraction kit: RNEASY PLUS (Qiagen)

[0801] qScript(TM) One-Step SYBR(R) Green qRT-PCR Kit, Quantabio method Transfection, RNA extraction, RNA-FISH, and qRT-PCR analysis

[0802] To assess knockdown of CUG repeat-containing RNAs, 5 × 10 4 COSM6 cells were seeded in 24-well plates and transfected with 50 ng of DMPK-CTG960 plasmid (where CUG-960 expression is driven under the control of a tetracycline-regulatable promoter element (TRE)), 25 ng of Tet transactivator (tTA) plasmid, and 1 μg of RBP (Cas + sgRNA). The spacer sequences used in the sgRNA for CUG targeting in the Cas13d system are listed in Table T. Cas protein and the corresponding sgRNA were expressed from the same plasmid. Cells were incubated overnight with 100 ng / ml doxycycline in Opti-MEM (containing 5% FBS), which is necessary to drive CUG-960 RNA expression. Cells were washed with PBS and further incubated for 24 hours in complete DMEM medium supplemented with 100 ng / ml doxycycline. Cells were harvested, RNA was extracted, and qRT-PCR was performed. CUG expression ΔΔCT was calculated and normalized to housekeeping genes to quantify CUG-960 knockdown relative to non-targeting (NT) sgRNA.

[0803] [Table 51]

[0804] Figure 1 demonstrates that the CUG-targeted Cas13d system using spacer sequences SEQ ID NOs: 457-459 eliminates >90% of the CUG target compared to the control.

[0805] Figure 2 demonstrates that the CUG-targeted Cas13d system eliminates >90% of CUG repeat RNA compared to controls, as analyzed by RNA fluorescence in situ hybridization (RNA-FISH).

[0806] Figure 3 shows the Cas13d system compared to the RCas9 system. The Cas13d system provides efficient cleavage, eliminating >90% of the CUG target compared to the control NT sgRNA. Cells treated with RCas9 showed approximately 80% knockdown of the targeted CUG repeats.

[0807] Example 2 The PUF system degrades DM1 toxic CUG repeats material Plasmid: pcDNA3.1 expressing CTG960 (960 CTG repeats), a Tet transactivator, and RBP

[0808] Transfection reagent: Lipofectamine 3000, opti-MEM, PBS, DMEM

[0809] RNA extraction kit: RNEASY PLUS (Qiagen)

[0810] qScript(TM) One-Step SYBR(R) Green qRT-PCR Kit, Quantabio method Transfection, RNA extraction, FISH, and qRT-PCR analysis

[0811] To assess knockdown of CUG repeat-containing RNAs, 5 × 10 4COSM6 cells were seeded in 24-well plates and transfected with 50 ng of DMPK-CTG960 plasmid (where CUG-960 expression is driven under the control of a tetracycline-regulatable promoter element (TRE)), 25 ng of Tet transactivator (tTA) plasmid, and 1 μg of RBP (PUF). Cells were incubated overnight with 100 ng / ml doxycycline in Opti-MEM (containing 5% FBS). Cells were washed with PBS and further incubated for 24 hours in complete DMEM medium supplemented with 100 ng / ml doxycycline. Cells were harvested, RNA extracted, and qRT-PCR was performed. CUG expression (ΔΔCT) was calculated and normalized to a housekeeping gene to quantify CUG960 RNA knockdown compared to the non-targeting (NT) control.

[0812] The PUF constructs (labeled CUG-f1 and CUG-f2 in Figure 1) targeted the toxic sequence UGCUGCUG (SEQ ID NO: 453).

[0813] FIG. 1 demonstrates that the CUG-targeted PUF-E17 fusion system abolishes >90% of the CUG target compared to the control.

[0814] FIG. 2 demonstrates that the PUF(CUG)-E17 fusion system eliminates >90% of CUG repeat RNA compared to the control, as analyzed by RNA fluorescence in situ hybridization (RNA-FISH).

[0815] Figure 3 shows the PUF(CUG) system compared to the RCas9 system. The PUF(CUG) system provides efficient cleavage, eliminating >90% of the CUG target compared to control NT. Cells treated with RCas9 showed approximately 80% knockdown of the targeted CUG repeats.

[0816] Example 3 Targeting expanded CUG repeats at the RNA level for the treatment of myotonic dystrophy type 1 (degradation and blocking mechanisms) The RNA targeting compositions disclosed herein, A01215 (Cas13d (CUG) for degradation), A01344 (PUF (CUG)-E17 for degradation), and A01686 (for blocking) were delivered by either systemic or intramuscular route using AAV-based approaches. For example, the PUF-targeting CUG constructs for AAV9-based delivery in the following art-recognized animal models of myotonic dystrophy are shown in Table 53. [Table 53]

[0817] To target the expanded CUG repeat associated with myotonic dystrophy, a vector carrying DNA encoding a CUG targeting composition was delivered by an AAV vector. Expression of PUF(CUG)-E17, Cas13d(CUG), or PUF(CUG) alone was driven by a promoter (Figures 4A-C and 12A-B). In some embodiments, a truncated CAG (tCAG) promoter (SEQ ID NO: 385) was used. In some embodiments, a short EF1-alpha (EFS) promoter (SEQ ID NO: 520) was used. In some embodiments, an EFS promoter with a UBB intron (SEQ ID NO: 609) was used.

[0818] AAV-9 preparations were produced according to standard techniques (triple transfection method) and purified by IDX density gradient ultracentrifugation. AAV titers were determined by qPCR and capsid ELISA. The above AAV9 versions were then injected intravenously (150 μL total volume, 1×10^12 vg) or into the tibialis anterior muscle of HSA-LR myotonic dystrophy type 1 mice (50 μL total volume, 2×10^10 vg, 1×10^11 vg), followed by daily clinical observation. Mice were sacrificed at 4 and 12 weeks post-injection. For RNA / protein assessment and gene expression changes, the tibialis anterior (injection site for IM injections), quadriceps, diaphragm, gastrocnemius, heart, spleen, liver (representative portion, i.e., lobe), intestine, and proximal half of the kidney were collected from each animal, placed individually (except for paired organs) in cryovials, and snap-frozen in liquid nitrogen. The remaining halves of all tissues were embedded in OCT and frozen. Muscle sections were cut transversely. Total RNA was prepared using the remaining half of the tissue.

[0819] Before sacrificing the mice at 4 and 12 weeks, electromyography was performed to assess the reversal of disease-associated myotonia (abnormal muscle relaxation) as a measure of the effectiveness of the RNA targeting composition in reversing the physiological phenotype of myotonic dystrophy type 1.

[0820] RNA isolation from frozen tissues was performed using RNAeasy columns (Qiagen) according to the manufacturer's protocol. RNA quality and concentration were estimated using a Nanodrop spectrophotometer. cDNA preparation was performed using Superscript III (Thermofisher) with random primers according to the manufacturer's protocol. qPCR and digital droplet PCR (ddPCR) were performed to assess the levels of the RNA targeting composition in tissues in the two mouse groups (RNA targeting composition, vehicle) and to evaluate the persistence of transgene expression.

[0821] RNA fluorescent in situ hybridization (FISH) was performed to measure the disappearance of RNA aggregates in muscle sections as a measure of the effectiveness of the RNA targeting composition in eliminating or blocking the expanded CUG repeat.

[0822] Immunofluorescence studies using antibodies against the chloride channels Clcn1 and Mbnl1 were performed as a measure of the efficacy of the RNA-targeting composition for treating the molecular pathology of myotonic dystrophy type 1. Reconstitution of Clcn1 and redistribution of Mbnl1 within the nucleus signifies reversal of the molecular pathology of myotonic dystrophy type 1.

[0823] cDNA was prepared from RNA isolated from muscle tissue, and RT-PCR was performed using primers flanking alternatively spliced ​​exon 22 of Atp2a1, exon 7 of Clcn1, and exon 11 of BIN1 to demonstrate restoration of myotonic dystrophy type 1-associated alternative splicing.

[0824] Example 4 Targeting expanded CUG repeats at the RNA level for the treatment of myotonic dystrophy type 1 with dCas13d and CUG-targeting guide RNAs A single transgene encoding a CUG-targeting guide RNA (gRNA) under the human U6 promoter and a nuclease-inactivated dCas13d linked to the endonuclease E17 (derived from the human ZC3H112A gene), or a nuclease-inactivated dCas13d (alone), is delivered by either viral or non-viral means, either systemically or intramuscularly. To target the expanded CUG repeat associated with myotonic dystrophy, a vector carrying a CUG-targeting gRNA and DNA encoding dCas13d (CUG) is delivered by an AAV vector. Cas13d (or dCas13d) expression is driven by a promoter (Figure 4B, Figure 4C, and Figure 12B). In some embodiments, a truncated CAG (tCAG) promoter (SEQ ID NO: 385) was used. In some embodiments, a short EF1-alpha (EFS) promoter (SEQ ID NO: 520) was used. In some embodiments, the EFS promoter with a UBB intron (SEQ ID NO: 609) was used.

[0825] AAV9 preparations were generated according to standard techniques (triple transfection method) and purified by IDX density gradient ultracentrifugation. AAV titers were determined by qPCR and capsid ELISA. The above AAV9 versions were then injected intravenously (150 μL total volume, 1×10^12 vg) or into the tibialis anterior muscle of HSA-LR myotonic dystrophy type 1 mice (50 μL total volume, 2×10^10 vg, 1×10^11 vg), followed by daily clinical observation. Mice were sacrificed at 4 and 12 weeks post-injection. For RNA / protein assessment and gene expression changes, the tibialis anterior muscle (injection site for IM injections), quadriceps muscle, diaphragm, gastrocnemius muscle, heart, spleen, liver (representative portion, i.e., lobe), intestine, and proximal half of the kidney were collected from each animal and individually (excluding paired organs) placed in cryovials and flash-frozen in liquid nitrogen. The other half of all tissues are embedded in OCT and frozen. Muscle sections are cut transversely. Total RNA is prepared using the other half of the tissue.

[0826] Electromyography (EMG) was performed before sacrificing mice at 4 and 12 weeks to assess the reversal of disease-associated myotonia (abnormal muscle relaxation) as a measure of the efficacy of dCas13d(CUG)-E17 by degradation or dCas13d(CUG) by blockade in restoring the physiological phenotype of myotonic dystrophy type 1. RNA isolation from frozen tissues was performed using RNAeasy columns (Qiagen) according to the manufacturer's protocol. A Nanodrop spectrophotometer was used to estimate RNA quality and concentration. cDNA preparation was performed using Superscript III (Thermofisher) with random primers according to the manufacturer's protocol. qPCR and digital droplet PCR (ddPCR) were performed to assess the levels of Cas13d (or dCas13d) and gRNA in tissues within the two mouse groups (Cas13d or dCas13d with CUG-targeting RNA, vehicle) to assess the persistence of transgene expression. RNA fluorescence in situ hybridization (FISH) was performed to measure the disappearance of RNA aggregates in muscle sections as a measure of the effectiveness of CUG-targeting gRNA+Cas13d (or dCas13d) in eliminating the expanded CUG repeat. Immunofluorescence using antibodies against the chloride channels Clcn1 and Mbnl1 was performed as a measure of the effectiveness of gRNA+Cas13d (or dCas13d) for treating myotonic dystrophy type 1 molecular pathology. Reconstitution of Clcn1 and redistribution of Mbnl1 in the nucleus indicate reversal of myotonic dystrophy type 1 molecular pathology. cDNA was prepared from RNA isolated from muscle tissue. RT-PCR was performed using primers flanking alternatively spliced ​​exon 22 of Atp2a1, exon 7 of Clcn1, and exon 11 of BIN1 to demonstrate restoration of myotonic dystrophy type 1-associated alternative splicing.

[0827] Example 5 CUG by degradation or blocking in patient muscle cells and HSA DM1 mice (above) exp Dose-dependent reduction of RNA Myotonic dystrophy type 1 (DM1) is a multisystemic autosomal dominant genetic disorder caused by a CUG microsatellite repeat expansion (MRE) in the 3' untranslated region (UTR) of DMPK mRNA. We previously demonstrated that CRISPR / Cas9-based RNA-targeted gene therapy has the potential to eliminate toxic RNAs expressed from the repeat tract in DM1 in primary patient cells and a DM1 mouse model. To further explore therapeutic MRE targeting strategies that are less tractable and more amenable to reducing or eliminating off-target effects, we engineered RNA targeting systems: 1) a novel CRISPR / Cas13d (A01215), 2) a PUF RNA-binding protein system derived from the naturally occurring human PUM1 protein (PUF-E17) coupled to an RNA endonuclease derived from human ZC3H112A (A01344), and 3) an endonuclease-free PUF RNA-binding protein system (A01686) to target expanded DM1-associated CUG repeats for either cleavage (1 and 2) or blocking. The engineered Cas13d and PUF-E17 packaged in AAvrh74 reduced nuclear CUG RNA aggregates in DM1 patient muscle cells in a dose-dependent manner. Furthermore, Cas13d, PUF-E17, and PUF(blockade) packaged in unitary AAV9 were separately administered by intramuscular (IM) and intravenous (IV) injection to adult (8-12 week old) mice. HSALR We report dose-dependent transgene expression, correction of DM1-associated alternative splicing, and reduction of muscle rigidity using electromyography (EMG) at 4 weeks after IM injection of all RNA targeting systems. As expected, reduction of RNA aggregates and improvement of splicing by Cas13d and PUF-E17 were accompanied by a reduction (>50%) in CUG RNA levels. In summary, we demonstrate that different mechanistic approaches (degradation and blockade) can effectively target MREs in DMPK and improve the molecular and clinical features of DM1. Figures 6-12.

[0828] Example 6 Tolerability and transgene expression in NHP studies To assess tolerability and transgene expression levels (biodistribution) in target tissues, non-human primate (NHP) studies are being conducted using AAV9 encoding the above-mentioned RNA targeting compositions (A01215, A01344, and A01686) under the control of muscle-specific promoters (skeletal, smooth, and cardiac). RNA targeting compositions. A vector carrying DNA encoding the CUG targeting composition was delivered by an AAV9 vector. Expression of PUF(CUG)-E17, Cas13d(CUG), or PUF(CUG) alone is driven by the promoter (Figures 4A-C and 12A-B). In some embodiments, the desmin promoter (full-length desmin SEQ ID NO: 568 or truncated desmin SEQ ID NO: 569) is used. Incorporation by Reference

[0829] All documents cited herein, including any cross-referenced or related patents or applications, are hereby incorporated by reference in their entirety, unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art to any invention disclosed or embodied herein, or that it alone, or in any combination with any other reference(s), teaches, suggests, or discloses any such invention. Furthermore, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall control. Other embodiments

[0830] While particular embodiments of the present disclosure have been illustrated and described, various other changes and modifications can be made without departing from the spirit and scope of the present disclosure, and the appended claims cover all such changes and modifications that fall within the scope of the present disclosure.

Claims

1. A composition comprising a nucleic acid sequence encoding an RNA-binding polypeptide, including an unguided RNA-binding polypeptide capable of binding to a toxic target CUG repeat RNA sequence.

2. The composition of claim 1, wherein the unguided RNA binding polypeptide is a PUF or PUMBY protein.

3. The composition described in claim 2, wherein the PUF protein comprises an amino acid sequence represented by any one of SEQ ID NOs: 444-451, 461, 570, or 638-649.

4. The composition of claim 2, wherein the PUF protein comprises an amino acid sequence as set forth in SEQ ID NO:

444.

5. The composition of claim 1, wherein the toxic target CUG RNA repeat sequence comprises any one of the nucleic acid sequences set forth in SEQ ID NOs: 453-456.

6. The composition of claim 1, wherein the toxic target CUG RNA repeat sequence comprises a nucleic acid sequence set forth in SEQ ID NO:

454.

7. The composition described in claim 2, wherein the PUF protein is encoded by a nucleic acid sequence shown in SEQ ID NO:

452.

8. A vector comprising the composition described in claim 4.

9. The vector of claim 8, wherein the vector is selected from the group consisting of adeno-associated virus (AAV), retrovirus, lentivirus, adenovirus, nanoparticles, micelles, liposomes, lipoplexes, polymersomes, polyplexes, and dendrimers.

10. The vector of claim 9 which is an AAV vector.

11. a first AAV ITR sequence; and A first promoter sequence; and a polynucleotide sequence encoding at least one CUG repeat RNA-binding polypeptide; A second AAV ITR sequence; An AAV vector comprising:

12. The AAV vector of claim 11, wherein the CUG repeat RNA-binding polypeptide comprises a PUF or PUMBY protein.

13. The AAV vector described in claim 12, wherein the PUF protein comprises an amino acid sequence represented by any one of SEQ ID NOs: 444-451, 461, 570 or 638-649.

14. The AAV vector described in claim 12, wherein the PUF protein comprises an amino acid sequence shown in SEQ ID NO:

444.

15. The AAV vector described in claim 12, wherein the PUF protein is encoded by a nucleic acid sequence shown in sequence number 452.

16. The AAV vector described in claim 14, wherein the first promoter is a tCAG promoter, an EFS / UBB promoter, a desmin promoter, a CK8e promoter or an EFS promoter.

17. The AAV vector of claim 12, wherein the first promoter sequence comprises a nucleic acid sequence set forth in SEQ ID NOs: 568, 569, 608, 609, 634-637.

18. The AAV vector of claim 14, wherein the first AAV ITR sequence comprises a nucleic acid sequence set forth in SEQ ID NO: 599 or 600.

19. The AAV vector of claim 14, wherein the second AAV ITR sequence comprises a nucleic acid sequence set forth in SEQ ID NO: 599 or 600.

20. The AAV vector of claim 14, wherein the vector further comprises a polyA sequence.

21. The AAV vector of claim 14, wherein the vector comprises at least one linker sequence.

22. The AAV vector of claim 14, wherein the vector comprises at least one nuclear localization sequence.

23. The AAV vector of claim 11, wherein the vector is encoded by a nucleic acid sequence set forth in any one of SEQ ID NOs: 574-582, 584-585, and 590-597.

24. a) an AAV vector according to claim 14; b) AAV capsid proteins; An AAV viral vector comprising:

25. 25. The AAV viral vector of claim 24, wherein the AAV capsid protein is an AAV1 capsid protein, an AAV2 capsid protein, an AAV4 capsid protein, an AAV5 capsid protein, an AAV6 capsid protein, an AAV7 capsid protein, an AAV8 capsid protein, an AAV9 capsid protein, an AAV10 capsid protein, an AAV11 capsid protein, an AAV12 capsid protein, an AAV13 capsid protein, an AAVPHP.B capsid protein, an AAVrh74 capsid protein, or an AAVrh.10 capsid protein.

26. 25. The AAV viral vector of claim 24, wherein the AAV capsid protein is an AAV9 capsid protein.

27. ​​A cell comprising the vector described in claim 14.

28. a) the AAV viral vector of claim 24; and b) at least one pharma- ceutically acceptable excipient and / or additive; 13. A pharmaceutical composition comprising:

29. The pharmaceutical composition of claim 28 for treating myotonic dystrophy type 1 (DM1).